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Our Mission
To protect and enhance public and animal health 
through the regulation of medicines, medical devices 
and healthcare products.
Our strategIc gOaLs and BaLanced scOrecard
STAKEHOLDERS 
Enhance healthcare product safety and patient outcomes by effective risk management 
and market surveillance.
Deliver clear, relevant and timely communications to patients, consumers and 
healthcare professionals.
PROCESSES 
Improve service delivery within a high quality, risk-based regulatory framework.
ORGANISATIONAL DEVELOPMENT 
Improve service delivery within a high quality, risk-based regulatory framework.
Influence legislation and policy development at European and international levels for 
the benefit of public and animal health.
HUMAN RESOURCES DEVELOPMENT 
Build future capabilities to meet evolving regulatory requirements, and scientific and 
technological advances.
FINANCIALS/VALUE FOR MONEY 
Build future capabilities to meet evolving regulatory requirements, and scientific and 
technological advances.
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CHAIRMAN’S 
STATEMENT
It is a great pleasure to present my first annual 
report as Chairman of the Irish Medicines Board 
(IMB). 
A number of things have impressed me greatly since 
taking up office. A positive ethos permeates all levels 
of the organisation as everyone strives for excellence 
in their work and decisions they make. There is also 
the quality of the IMB’s staff, people who demonstrate 
a vigour, passion and enthusiasm in their individual 
roles.  
The IMB has a very crucial function in national 
healthcare policy. It is charged with protecting 
public and animal health through regulating 
and monitoring medicines, medical devices and 
healthcare products. This demands excellence across 
all areas of its operations and a total commitment to 
ensuring the needs and best interests of our citizens 
and animals underpin everything we do. Together 
with an expanding remit, the IMB’s comprehensive 
level of activity and responsibility (outlined in some 
detail in this Annual Report) highlights the need 
for expertise in strategic management capabilities, 
robust quality management and technology systems. 
Good practice standards are also essential to support 
the organisation’s every work output. The fact 
that the IMB has secured an excellent reputation 
internationally as a highly effective and strong 
regulatory agency demonstrates that its structure, 
policies and work outputs are exemplary.
This report details the IMB’s activities over the past 
year and, as in previous years, it highlights significant 
developments and progress across all work areas. In 
the context of the current economic environment, 
which is bringing new challenges to every element of 
the public sector, this is a significant achievement. 
Our primary objective is to safeguard public and 
animal health by regulating the healthcare product 
sectors across the entire product lifecycle from 
clinical trials, through manufacturing, to marketing, 
distribution and end use by patients and animal 
owners. All our regulatory actions are grounded 
in legislative requirements and the application of 
scientific and regulatory expertise. Decisions are 
taken in the interests of public or animal health, 
based on the best available information at national 
and EU level, by experienced scientists and healthcare 
professionals. 
A core element of our role in protecting and 
enhancing public and animal health is achieved 
through robust monitoring of medicine and medical 
device safety. It is without doubt that medicines 
and medical devices bring significant health and 
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lifestyle benefits to the individuals that need them. 
These healthcare products, whilst bringing many 
advantages, also come with side effects and the 
potential risk of adverse incidents. The IMB and its 
partners at European level have to apply expert 
knowledge, ongoing review of adverse reactions 
and clinical data to ensure that people continue to 
have access to products where the benefit of using 
that product outweighs the inherent risks. In 2011 
there was, as in previous years, an intense focus on 
monitoring the safety of these products in use on the 
Irish market.  
Whilst assuming new responsibilities can often 
prove challenging to any organisation, the IMB has 
embraced an evolving expansion of its remit and 
absorbed new important consumer and patient 
protectorate functions seamlessly. 2011 was the first 
full year of the IMB’s new regulatory role in relation 
to cosmetics while 2012 and 2013 will see it adopt 
further additional functions. 
The year in review also saw the conclusion of a 
seven year transition period for herbal medicines. A 
substantial programme of stakeholder engagement 
and information communication was undertaken 
to assist the herbal sector to comply with the new 
EU regulations. Also, during 2011, a key focus for 
the organisation was highlighting an increase in 
the purchasing of medicinal products that were of 
doubtful origin via the internet and that could pose 
a threat to people’s health. The growth in new media 
and expanding access to the internet will mean this 
will now be a constant area of vigilance for the IMB. 
The pharmaceutical, medical device and life 
sciences sector in Ireland is a major contributor 
to our economy. The IMB’s robust regulatory role 
supports the sector’s continued success by ensuring 
the sector’s compliance with good manufacturing 
practices and adherence to legal requirements. A 
strong national regulator is a significant asset to 
Ireland’s reputation as a major world player in this 
specialist sector. 
The IMB plays a critical role at EU level where new 
legislation is developed. It continues to be an active 
contributor in this area with its objective being to 
ensure that a strong patient centric regulatory system 
for human and veterinary products is maintained and 
enhanced.
The IMB’s five year strategic plan for 2011-2015, which 
the Board is tasked with overseeing, sets out five 
high level strategic objectives and a clear roadmap 
to achieve these goals within the timeframe. To align 
with our plan’s implementation, this annual report 
now closely mirrors those goals in its layout and 
structure. 
On behalf of the Board, I thank the Minister for 
Health and the Minister for Agriculture, Food and the 
Marine as well as their executives and staff for their 
continued support of the IMB and its activities. 
I wish to recognise the effective chairmanship of my 
predecessor and his contribution to the IMB over a 
number of years. I have benefited greatly from the 
Board practices and standards already in place since 
my appointment in January 2011.
I would like to thank my fellow members of the new 
Board for the time, effort and expertise they have 
contributed during the past year. I would also like to 
express my appreciation to those members who chair 
IMB advisory committees and sub-committees. The 
role played by these committees is of immense value 
to the IMB and I wish to thank all the independent 
experts who contribute to them for their active 
participation and commitment.
Finally, I would like to thank the Chief Executive, 
management and all the staff and acknowledge their 
achievements during 2011. The IMB comprises expert 
professionals who are motivated by the fact that their 
individual contributions can make a difference to the 
health and quality of life of those who use healthcare 
products. I am proud to have been asked to chair this 
important and progressive organisation.
Michael D. Hayes
Chairman
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BOARD MEMBERS
The new Board of the IMB was appointed in January 
2011 by the then Minister for Health and Children 
in accordance with the powers conferred on her by 
subsection 2 of section 7 of the Irish Medicines Board 
Act, 1995.
Ms. Anne Horan
Chief Executive, Ryan Academy 
for Entrepreneurship, Dublin  
City University
Mr. Wilfred Higgins
Principal Engineering Advisor, 
Health Service Executive
Mr. Michael D. Hayes 
(Chairman)
Engineering Consultant
Professor Caitriona O’Driscoll
Professor of Pharmaceutics, 
University College Cork
Mr. Noel O’Donoghue
Veterinary Surgeon
Mr. Brendan McLaughlin
Farmer and Elected Board 
Director in the Management 
Committee of ICSA
Professor Mary Horgan* 
Associate Professor of Medicine, 
University College Cork
* Appointed to the Board by the 
Minister for Health in November 
2011 
Professor Brendan Buckley*
Honorary Clinical Professor 
in Pharmacology, University 
College Cork
* Resigned from the Board in 
September 2011
Mr. Pat Brangan
Senior Veterinary Inspector, 
Department of Agriculture, Food 
and the Marine
Ms. Maureen Windle*
Practitioner in Public Sector 
Healthcare Management
* Resigned from the Board in 
November 2011
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Mr. Pat O’Mahony
Chief  Executive
Mr. John Lynch 
Director of  Compliance
Dr. Gabriel Beechinor
Director of  Veterinary Medicines
Dr. J.M. Morris 
Director of  Scientific Affairs
Ms. Suzanne McDonald 
Director of IT and Change 
Management 
Ms. Ann O’Connor
Director of Human Products 
Authorisation and Registration 
Ms. Rita Purcell
Director of Finance  
and Corporate Affairs 
Dr. Joan Gilvarry 
Director of Human Products  
Monitoring
Ms. Frances Lynch
Director of  Human Resources
MANAGEMENT COMMITTEE
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CHIEF 
EXECUTIVE’S 
REPORT
I am pleased to report on the activities of the Irish 
Medicines Board (IMB) during 2011, a year that 
marked the 15th anniversary of the establishment 
of our organisation. While our remit has expanded 
significantly during this time, and will continue 
to so, our absolute commitment to the protection 
and enhancement of public and animal health 
remains constant. The effective and commendable 
programme of work delivered during this 12 
month period is evidence of another successful 
year in this regard.  
STRATEGIC PLAN 2011 – 2015 
2011 was particularly significant as it represented the 
first year of our new five year strategic plan. This plan 
sets out the IMB’s five high-level strategic goals for 
this time period. These goals were informed by our 
core remit of protecting public and animal health, the 
challenges identified in our operating environment 
and the strategies of our regulatory partners. The 
plan, which was approved by our Board in November 
2010 following a public consultation process, 
presents a clear roadmap to stakeholders and staff 
showing how our strategic goals will be achieved.
The five high-level strategic goals are:
1. Enhance healthcare product safety and patient 
outcomes by effective risk management and 
market surveillance.
2. Deliver clear, relevant and timely 
communications to patients, consumers and 
healthcare professionals.
3. Improve service delivery within a high quality, 
risk-based regulatory framework.
4. Influence legislation and policy development at 
European and international levels for the benefit 
of public and animal health.
5. Build future capabilities to meet evolving 
regulatory requirements, and scientific and 
technological advances.
The layout of the annual report for 2011 has been 
restructured to ensure that the main chapters are 
closely aligned with the goals set out above.
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AuThoRISATIoN, REGISTRATIoN ANd 
LICENSING ACTIvITIES  
The pre-market authorisation and registration of 
healthcare products, as well as the licensing of 
manufacturing, wholesaling and related activities, 
is one of the IMB’s primary public health functions. 
Essentially, these are the regulatory actions carried 
out by the IMB before a healthcare product can be 
marketed and supplied in Ireland. 
We are committed to providing an effective and 
efficient regulatory framework that is focused on 
timely availability of appropriate healthcare products. 
2011 was a busy and demanding year in this respect:
•	 In	2011,	68	new	clinical	trial	applications	were	
approved to commence in Ireland compared 
to 98 in the previous year. This decrease is 
consistent with a decline in clinical trial activity 
across Europe. An item of note during 2011 was 
the publication by the IMB of the findings of 
our investigation into the conduct of a clinical 
trial using rimcazole hemifumarate. It was 
concluded that this clinical trial, which took place 
at the Shandon Clinic in August 2010, was not 
conducted in full compliance with its approved 
protocol.
•	 In	respect	of	human	medicines,	the	number	of	
new product applications approved rose to 1,977, 
an increase of 10% compared to 2010. There were 
also 15,458 variations applications approved 
which was a slight reduction (4%) on the 2010 
figures. 
•	 With	regard	to	veterinary	medicines,	there	were	
110 new product applications assessed and 
approved while 1,231 variations to authorisations 
were granted through the national, mutual 
recognition or centralised procedures.
•	 The	IMB	continued	its	active	role	in	the	
European medicines licensing system. For 
human medicines, we completed 10 mutual 
recognition (MR) assessments and issued 16 new 
marketing authorisations via the decentralised 
(DC) procedure, with Ireland as the reference 
member state. In addition, the IMB was allocated 
27 applications for marketing authorisations to 
assess by the European Medicines Agency (EMA) 
and acted as rapporteur for 30 scientific advice 
procedures. For veterinary medicines, the IMB 
issued 25 new marketing authorisations through 
the MR procedure as the reference member state. 
During 2011, the IMB acted as the rapporteur 
or co-rapporteur for nine veterinary centralised 
procedures.
•	 The	IMB	maintains	a	medical	devices	registration	
system for Class I general, custom-made and 
in-vitro diagnostic devices. During 2011, the IMB 
registered 489 new medical devices within these 
categories.  
•	 In	2011,	the	IMB	received	9	applications	relating	
to clinical investigation of non-CE marked 
medical devices comprised of 5 new applications 
and 4 significant amendments to ongoing 
investigations.
•	 The	number	of	site	manufacturing	licences	in	
place at year end for human and veterinary 
medicines was 112. This figure has remained 
broadly stable in recent years. In addition, the 
IMB operates a register of new medical device 
organisations including manufacturers. The 
number of organisations registered during 2011 
was 34.
SAfETy ANd CoMPLIANCE MoNIToRING 
A core public health function of the IMB is to monitor 
the safety of medicines, medical devices and other 
healthcare products that have been licensed or 
registered for use in Ireland. This is known as post-
market surveillance. Quality issues related to how 
a product is manufactured, packaged, labelled, 
distributed or stored may also arise at the post-
market stage. If a healthcare product poses too great 
a risk to those who use it, we will take appropriate, 
timely and effective action. Our success in achieving 
this goal is as a result of the collective efforts of all our 
staff and our decisions are always based on the best 
available information regarding benefit and risk.  
•	 A	key	part	of	our	monitoring	efforts	is	the	
operation of a national pharmacovigilance 
scheme for adverse reactions, or side effects, 
associated with the use of human medicines. 
During 2011, the IMB received a total of 2,784 
suspected adverse reactions associated with 
the use of human medicines in Ireland. This 
figure represents a return to expected levels 
following the enhanced rates of reporting that 
resulted from the H1N1 national immunisation 
programme. 
•	 During	2011,	the	IMB	contributed	to	an	ongoing	
EU review of a potential association between the 
H1N1 vaccine Pandemrix and narcolepsy, a sleep 
disorder. Throughout the year, the IMB continued 
to review a small number of reports of suspected 
narcolepsy in Irish patients vaccinated with 
Pandemrix. Comprehensive follow-up with the 
healthcare professionals involved in each case 
was conducted. We also interacted with relevant 
national bodies focused on this issue. 
•	 During	2011,	the	total	output	for	periodic	safety	
update reports (PSURs) for human medicines was 
3,633. The IMB continues to actively participate 
in the Heads of Medicines Agencies (HMA) PSUR 
work-sharing project and is currently ranked in 
the top eight of national competent authorities 
in Europe in terms of lead member state 
assessment responsibilities.
•	 In	September	2011,	the	IMB	recommended	a	
number of new measures in relation to the use of 
over-the-counter cough and cold medicines for 
children.
•	 The	IMB	also	monitors	the	safety	and	
effectiveness of veterinary medicines on an 
ongoing basis. In 2011, we reviewed 228 reports 
of suspected adverse reactions associated with 
use of veterinary medicines, a 9% increase on the 
previous year. A total of 413 PSURs relating to 
veterinary medicines were also evaluated. 
•	 Post-market	surveillance	and	vigilance	is	a	
critical element in protecting the health and 
safety of those who use medical devices. During 
2011, 1,775 vigilance reports were received and 
assessed compared to 1,687 reports in 2010. This 
is the fourth year in succession that the reporting 
rate has increased. 
•	 In	2011,	882	compliance	cases	were	investigated	
in connection with medical devices. Similar to 
previous years, issues identified and investigated 
as part of these compliance cases included 
labelling problems, missing or incorrectly 
attached CE marking and classification issues.  
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Another key function of the IMB is to monitor and 
inspect industry compliance with legislation, policies 
and procedures. We are committed to ensuring that 
all healthcare products manufactured or distributed 
in Ireland meet essential quality standards and that 
they are advertised in an appropriate manner. 
•	 During	2011,	there	was	a	total	of	271	national	
inspections and audits performed compared to 
263 in 2010 and 238 in 2009. A further 29 foreign 
inspections and audits were performed in the 
past 12 months.
•	 A	total	of	917	quality	defects	were	reported	to,	or	
identified by, the IMB. This is the highest number 
of quality defect investigations in any one year 
since the introduction of the programme. 
•	 During	2011,	253	medicine	recalls	occurred.	Of	
these, 240 related to human medicines and 13 
to veterinary medicines. An incident of non-
adherence to cold chain requirements resulted in 
the recall of 65 products while a recall to primary 
and secondary wholesale level relating to a 
damaged product resulted in 48 products being 
recalled. 
•	 The	total	number	of	packs	of	exempt	medicinal	
products notified was 1,474,564, an increase of 
25% over 2010. The IMB continues to work with 
stakeholders in several areas to identify and 
develop solutions aimed at limiting the use of 
exempt products in Ireland.
•	 There	were	also	six	recalls	of	cosmetic	products	
in order to protect the health of consumers. Of 
these, four were related to high lead content in 
cosmetic products.
•	 The	nine	IMB-initiated	prosecutions	in	the	District	
Courts in relation to breaches of medicinal 
product regulations resulted in fines and/or 
suspended sentences. Our enforcement team 
also participated in Operation PANGEA IV. This 
was a global initiative to identify and act against 
illegal websites supplying counterfeit and illegal 
medicinal products. This operation led to the 
detention in Ireland of 51,621 tablets, capsules 
and creams.
LEGISLATIvE ANd REGuLAToRy 
dEvELoPMENTS
The remit and role of our organisation continues to 
change and expand due to changes in our operating 
environment, such as new national and European 
legislation, and in response to the addition of further 
competencies.
Legislative Changes
During the past year, representatives from across 
the IMB were heavily involved in implementing, 
or preparing for the implementation of, new and 
updated EU directives which will have a significant 
impact on the regulation of medicines and medical 
devices across Europe. 
•	 New	EU	pharmacovigilance	legislation,	adopted	
in December 2010, will begin to come into effect 
in July 2012. The new measures are intended 
to further promote and protect public health 
by strengthening the current European-wide 
system for monitoring the safety of medicines. 
Throughout 2011, the IMB worked with a wide 
range of stakeholders including the European 
Medicines Agency and other national regulators 
to prepare for the introduction of this new 
legislation. This included a very successful 
stakeholder information day that we held in 
Dublin in early December. 
•	 The	IMB	is	preparing	for	the	introduction	
of elements of new legislation on falsified 
medicines for human use, which are required 
to be transposed nationally by January 2013. 
The changes are intended to strengthen the 
protection of patients and consumers by 
preventing falsified medicines entering the legal 
supply chain.
•	 The	three	existing	European	directives	defining	
the requirements for medical devices are subject 
to an ongoing major revision by the European 
Commission. It is expected that during 2012, 
the Commission will adopt draft legislative 
proposals for discussion by the European Council 
and Parliament. This Commission initiative was 
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fully supported during 2011 by the IMB. An IMB 
proposal, made jointly with the Austrian Ministry 
for Health, to establish a recast working group 
of the Competent Authority for Medical Device 
(CAMD) network was endorsed. This group allows 
for detailed technical discussions on specific 
elements of the proposed revision to the medical 
devices legislation and for close co-operation 
between European regulators. 
Human Organs for Transplantation
It was agreed with the Department of Health during 
2011 that the IMB will assume the role of national 
Competent Authority for the directive on standards 
of quality and safety of human organs intended for 
transplantation. As a result, the IMB began a process 
of reviewing the requirements of the directive 
and developing an appropriate framework for 
implementation of the requirements which are due to 
come into effect in August 2012.
European and International Regulation
The products regulated by the IMB are part of a 
dynamic and developing global industry. Healthcare 
products manufactured here are used around the 
world while products manufactured elsewhere 
are used in the Irish healthcare system and by Irish 
patients and consumers. As a result, it is essential that 
the IMB plays an active role in the global regulatory 
network to ensure that we represent and protect the 
interests of Irish patients and consumers. 
During 2011, the IMB continued its very active role in 
the networked European regulatory model and, both 
formally and informally, worked closely with other 
relevant international organisations. 
•	 Our	participation	in	the	European	medicines	
regulatory system continued to be substantial 
with IMB scientific and technical staff 
contributing to a broad range of committees 
and working parties at the European Medicines 
Agency, the European Commission, HMA, and 
other fora. In addition to representing Ireland 
at relevant meetings and events, IMB delegates 
were also active in, and in many cases led, a 
series of European regulatory initiatives. For 
example, the Irish delegate (human medicines) 
to the European Medicines Agency’s Quality 
Working Party (QWP) was appointed as 
rapporteur for the revision of the QWP guideline 
on process validation while the Irish delegate 
to the Pharmacovigilance Working Party at the 
European Medicines Agency represented the EU 
at the ICH E2C (R2) Expert Working Group. 
•	 During	2011,	the	IMB	Pharmacovigilance	
Manager was invited to join the Board of the 
Uppsala Monitoring Centre (UMC) and the 
World Health Organization Collaborating Centre 
for International Drug Monitoring. This was 
international recognition of the prominent role 
played by the IMB in global pharmacovigilance 
practice.
•	 The	IMB	submitted	revised	maximum	residue	
limits (MRLs) applications for milk to the 
European Medicines Agency in August 2011 
following the rejection by the European 
Commission of the proposed MRLs for certain 
flukicidal veterinary medicines used in cattle. By 
year-end, positive opinions had been delivered 
to the European Commission for four separate 
substances.
•	 In	respect	of	medical	devices,	the	IMB	led	
discussions on the development of formal co-
operation between the existing HMA network 
and the medical devices networks represented 
by the Competent Authority for Medical Device 
(CAMD) and the Central Management Committee 
(CMC). The goal is to develop a larger, inclusive 
‘European Health Products Regulatory Network’ 
comprised of regulators from human medicines, 
veterinary medicines and medical device 
authorities. 
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•	 During	2011,	the	IMB	also	participated	in	
regulatory discussions focused on establishing 
a medical devices competent authority funding 
mechanism which is fair, transparent and 
sustainable.
•	 The	IMB	announced	the	signing	of	three	separate	
international co-operation arrangements with 
counterpart regulatory bodies in Japan, Mexico 
and Switzerland. The arrangements are designed 
to broaden existing contacts and to establish 
a co-operative framework of mutual support 
and information exchange. These co-operation 
arrangements were signed in October at the 6th 
Global Summit of Heads of Medicines Regulatory 
Agencies. This annual event provides an 
opportunity for medicines regulatory agencies 
from around the world to meet and discuss 
common challenges and concerns.
•	 In	June	of	2011,	the	IMB	and	the	Medical	Council	
signed a Memorandum of Understanding which 
will strengthen the co-operation between the 
two bodies, further promoting the highest 
standards of practice in medicines.
•	 The	IMB	continued	its	participation	in	the	
Benchmarking of European Medicines Agencies 
(BEMA) steering group of the HMA, which I 
co-chair. Proposals relating to the third cycle of 
inspections were developed and by year-end 
assessor training had been completed. Work also 
commenced on the visit schedule for 2012–2014.
STAkEhoLdER ENGAGEMENT ANd 
CoMMuNICATIoNS
As set out in our five year strategic plan, the IMB 
is committed to expanding and improving our 
communications activities and to ensuring that 
all our stakeholders have timely access to relevant 
safety and regulatory information. As well as our 
regular meetings and ongoing publication of safety 
and regulatory updates, newsletters and guidance 
documents, a number of significant communications 
initiatives were implemented during 2011. 
Consultative Panel on the Legal Classification of 
Medicines
The establishment at the end of 2011 of the 
Consultative Panel on the Legal Classification of 
medicines was a very important development for 
the IMB. Independently chaired and made up of 
external representatives drawn from a wide range of 
interested stakeholders including patients, healthcare 
professionals, the Department of Health and relevant 
public bodies, the panel will provide advice on 
external socioeconomic and policy issues that should 
be considered when determining the appropriate 
classification of a medicine. This advice will support 
the existing scientific assessment carried out by 
the IMB once we receive applications to reclassify a 
medicine. 
BT Young Scientist and Technology Exhibition 
2011
2011 marked the third year of IMB participation at 
this event and it was again a very positive experience 
for all involved. We welcomed thousands of students, 
teachers, parents and members of the general public 
from all over Ireland to the IMB’s exhibition stand. 
The content of the stand was focused on building 
awareness of the safe use of medicines and medical 
devices as well as the role the IMB plays in protecting 
public and animal health. 
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Consumer Research – Regulation of Herbal 
Medicines
The findings of consumer research, from a 
representative sample of the Irish population, were 
released in advance of the new regulatory system 
for traditional herbal medicines which came into 
effect across all EU member states on 1 May 2011. 
The results show significant support for this initiative 
with some 8 out of 10 consumers recognising 
the importance of regulating traditional herbal 
medicines.
IMB Leaflet – Automated External Defibrillators
In December 2011, the IMB published an information 
leaflet providing advice to people on how to correctly 
maintain an automated external defibrillator (AED). It 
was produced in light of the increased availability of 
AEDs in Ireland over the past number of years and a 
notable increase in the number of AED related issues 
reported to the IMB.
Website 
The IMB website continued to be updated with 
news, safety information and regulatory documents 
while further changes and improvements were 
made in response to stakeholder feedback. The 
veterinary medicines section of the IMB website was 
substantially revised early in 2011 to provide more 
relevant content while a new dedicated webpage 
was established for content relating to the new 
pharmacovigilance legislation. Almost 126,000 
unique visitors accessed the website during the past 
twelve months. 
dEvELoPING oRGANISATIoNAL 
CAPABILITy
It is essential that we continue to build our 
organisational capabilities in line with scientific, 
technological and regulatory advances and 
requirements. In 2011, as in each of the 15 years since 
the establishment of the IMB, there were further 
developments and changes both in the environment 
in which we operate and in the manner in which 
we deliver our services. Change is something that 
we have constantly embraced in this organisation 
and we are committed to ensuring that we have the 
requisite structures, systems and supports in place to 
deliver on our public health mission. 
Information Technology and Change 
Management
A new five year information and communication 
technology (ICT) strategy aligned to the 
organisation’s five year strategic plan was adopted 
by the Board in early 2011 and implementation 
commenced in the second half of the year. Key 
technologies for the organisation over the coming 
years will include improved data warehousing 
solutions, together with upgraded capacity 
management and case management systems. All 
information technology initiatives are undertaken 
in the context of providing new and/or improved 
services to stakeholders, enhancing decision-making 
and channelling scientific data to deliver on our 
public health remit.
The IMB has a long held commitment to continuous 
improvement. As part of our change management 
strategy, it was decided to develop a more structured 
approach to organisational project management. This 
resulted in the adoption of a project management 
office model for all relevant activities. Planning 
for the new office commenced in late 2011, with 
implementation scheduled for 2012. 
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Staff Developments
Ireland is recognised as an important global location 
for the life sciences sectors which are contributing 
significantly to our economy and playing a key role 
in driving export-led growth. The IMB supports this 
growth by indigenous and multinational companies 
through providing regulatory and technical advice 
and services, and by ensuring compliance with 
manufacturing standards. It is vitally important that 
we have the resources in place to deliver on these 
functions for the benefit of all our stakeholders.   
While recognising the constraints on public sector 
employment numbers, during 2011 we submitted 
a proposal as a predominantly self-funded agency 
on future staffing requirements to the Department 
of Health. This proposal focused on obligations 
arising from new responsibilities being assigned to 
the IMB by the Department as well as the impact of 
the introduction of a range of legislative changes 
between now and 2015.
Also during the year, we introduced a leadership 
development programme. This pilot programme is 
focused on enhancing the skills of mangers from 
across the organisation and it is hoped to expand and 
further develop the programme in the coming years. 
Financial Performance
The IMB is largely self-funded by a system of fees 
which are approved annually by the Minister 
for Health, following a public consultation. This 
approach is in line with the typical funding model of 
healthcare products regulation worldwide. The IMB is 
committed to the highest standards of independence 
and governance so as to ensure quality of service 
combined with value for money. We continued in 
2011 to successfully manage the affairs of the IMB in 
line with our statutory obligation that income at least 
meets costs.
THE FuTuRE
The IMB is focused on both the new challenges and 
the new opportunities that will no doubt arise during 
2012. 
The economic situation continues to present 
challenges across the public sector nationally, and for 
our regulatory colleagues globally. There is no doubt 
that resources will continue to be limited and this will 
pose substantial challenges to us as we continue to 
deliver on our public health remit and deliver services 
to stakeholders. Yet, it is clear also that the health 
products sectors we regulate have shown great 
resilience during the recent past and indeed have 
been drivers of growth.
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The overall workload for the organisation 
will continue to increase and diversify as we 
respond to the developments in respect of new 
European legislation and the addition of further 
national competencies. The former includes the 
implementation of new pharmacovigilance and 
falsified medicines legislation in addition to further 
progress in the revision of regulations for medical 
devices, while the latter involves the IMB assuming 
the role of national Competent Authority for the 
directive on standards of quality and safety of human 
organs intended for transplantation. 
Clearly, meeting these new demands will challenge 
everyone at the IMB to work in the most efficient 
and effective manner to ensure we meet the high 
standards we set for ourselves. As in previous years, 
we will continue to take a risk-based approach to our 
regulatory activities. We will adopt further necessary 
and beneficial change across the organisation and 
enhance further our performance management, 
quality management and ICT systems. There will 
be an ongoing review of our funding provision 
and management of our own cost base to ensure 
maximum use of resources.
We will also continue our active participation at a 
European level to ensure the best possible outcomes 
for Irish citizens. A wide range of legislative reform 
is foreseen across medical devices, veterinary 
medicines, clinical trials, cosmetics and precursor 
chemicals, which will directly affect our future work. 
There will also be initiatives in cross border healthcare 
and health technology assessment with which we will 
also have to engage. Proposals for an agreed Europe-
wide fee regimen for funding competent authority 
activities on medical devices will be developed and 
we will actively engage in these discussions. 
Also in 2012, we intend to develop further our 
communications and stakeholder engagement 
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programme. Of particular importance in the year 
ahead will be direct interaction and co-operation 
with patient representatives to build understanding 
of our role and to incorporate patient and public 
input. In addition, the consultative panel on the legal 
classification of medicines will examine the various 
policy positions of panel members and agree terms of 
reference. 
Our staff’s expertise and experience are critical to the 
success of our organisation. We will continue to make 
learning and development opportunities available so 
that we can maintain and enhance the skills that are 
required for our increasingly complex and expanding 
remit. 
ACkNoWLEdGEMENTS  
I wish to thank, on behalf of the IMB management 
team and staff, the Chairman and all members of the 
Board, as well as all the members of the IMB’s various 
advisory committees, for their valuable contributions 
during 2011. In total, over 100 people give of their 
time voluntarily to the work of the IMB through 
participation on the Board and these committees. 
Having access to this independent expertise and 
insight is of immense value to the workings of our 
organisation. 
The commitment and professionalism of the IMB 
staff members is critical to the successful delivery 
of our public health remit. I would like to express 
my personal appreciation to all colleagues for their 
valuable contribution to an ever-increasing workload 
during this past year. On the occasion of the 15th 
anniversary of the establishment of the IMB, I would 
also like to acknowledge the key role played by 
former staff to the development and progression of 
the IMB in the intervening period.  
Finally, I wish to thank and acknowledge the Ministers 
and staff of the Department of Health and of the 
Department of Agriculture, Food and the Marine for 
their continued support and co-operation during 
2011. 
During each of the past 15 years, the IMB has 
successfully adapted to and indeed embraced new 
challenges. I have no doubt that we will do so again 
in 2012 with renewed energy and conviction. Our 
five-year strategy sets out our high-level goals and, 
together with our annual business plans, sets out a 
clear roadmap for the future. As ever, an absolute 
focus on the protection and enhancement of public 
health will be our priority. 
Go raibh maith agaibh go léir.
Pat O’Mahony
Chief Executive
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AUTHORISATION, REGISTRATION 
AND LICENSING ACTIVITIES  
The authorisation and registration of healthcare products 
is a core public health function of the IMB. Often referred 
to as ‘pre market’ activities, these are the regulatory actions 
carried out by the IMB which happen before a healthcare 
product can be marketed and supplied in Ireland. Ensuring 
timely approval of new products applications in particular, 
following a positive assessment of their safety, quality and 
effectiveness, gives patients and users access to a range of 
appropriate treatments.
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The IMB is responsible for the authorisation of 
medicines and clinical trials and for the registration 
of medical devices and cosmetics. The IMB also 
licenses the manufacturers and wholesalers of 
human medicines, the manufacturers of veterinary 
medicines as well as blood and tissue establishments. 
In addition, the IMB is responsible for issuing export 
certificates and we provide a borderline product 
classification service.
The IMB also provides a service to stakeholders 
to assist in clarifying which products should be 
categorised as human medicinal products, veterinary 
medicinal products and medical devices. Such 
products fall under the remit of the IMB from a 
regulatory perspective and are distinct from other 
products which are outside the IMB’s remit.
HuMAN MEDICINES
BoRdERLINE PRoduCT CLASSIfICATIoN
Queries are routinely received in regard to the 
correct classification of human medicines, veterinary 
medicines and medical devices.
For products for human use, a classification service 
is operated for products which are on the borderline 
between human medicines and other products 
such as food supplements, cosmetics and medical 
devices. Requests for classification, whether external 
or internal, are presented to an internal, multi-
disciplinary, human medicinal product Classification 
Committee.
The Committee, which met 11 times in 2011, consists 
of appropriately experienced IMB staff from across 
the organisation and is chaired by the Director of 
Scientific Affairs. During the past 12 months, a total of 
153 new products were considered consisting of 132 
internal applications and 21 external applications. In 
addition, there were eight products revisited from 
pre-2011.
The Committee has a close working relationship with 
the Food Safety Authority of Ireland while it also 
engages in regular dialogue with the Department of 
Health and other national regulatory authorities.
CLINICAL TRIALS
Clinical trials are conducted to determine whether a 
new medicine is safe and effective when used to treat 
a disease or condition and whether it provides a real 
health benefit. Such clinical trials are necessary to 
establish whether a medicine should be authorised 
for use in the general population. 
The role of the IMB is to assess applications from 
sponsors permitting them to conduct clinical trials 
in Ireland. Sponsors typically include pharmaceutical 
companies and/or research institutions. The IMB 
approves the clinical trial protocols which describe 
the details of each trial and outline the steps that 
will be taken to protect the health of volunteers or 
patients.  
 Clinical Trials Approved 2007 - 2011
In 2011, 68 new clinical trial applications were 
approved to commence in Ireland. This was a 
decrease compared to previous years and is 
consistent with a decline in clinical trial activity across 
the EU. 
The IMB also reviewed and strengthened the 
process for authorisation of clinical trials. As part of 
this review, the Guide for Clinical Trial Applications 
has been extensively updated and requirements 
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for applicants clarified. The IMB met with potential 
sponsors and investigators seeking to carry out 
clinical trials in Ireland and responded to a large 
number of queries from them.
The clinical trials legislation is currently under 
review by the European Commission. The IMB has 
contributed to the consultation process and will 
continue to do so during 2012. The purpose of the 
review is to assess and improve the functioning of the 
clinical trials legislation.  
Premature Termination of Rimcazole Clinical Trial 
In October 2011, the IMB published the findings of 
its investigation into the conduct of a clinical trial 
using rimcazole hemifumarate at the Shandon Clinic 
in August 2010. The IMB concluded that this clinical 
trial was not conducted in full compliance with its 
approved protocol.
This investigation was initiated after three 
subjects participating in the trial experienced 
seizures. All three subjects recovered fully when 
the administration of the trial medication was 
discontinued.
NEW MARkETING AuThoRISATIoN 
APPLICATIoNS 
Before a new medicine can be placed on the Irish 
market, it must be firstly assessed and authorised, 
or licensed, by the IMB or the European Medicines 
Agency. When a company seeks approval of a new 
medicine from the IMB, it submits a dossier including 
all clinical trial data and analysis of the data, as well as 
information about how the medicine behaves in the 
body and how it is manufactured. An IMB assessment 
team of medical doctors, pharmacists and other 
scientists will review the company’s data and the 
proposed product information including the package 
leaflet and label. The IMB team assess the safety of the 
medicine and the evidence that it is effective for its 
intended use. If this assessment establishes that the 
medicine’s public health benefits outweigh its known 
risks, it will be granted a marketing authorisation.
While national applications are assessed solely by 
the IMB, companies may also choose the mutual 
recognition procedure (MRP) or the decentralised 
procedure (DCP). MRP and DCP applications involve a 
number of national European authorities. (Details of 
the IMB’s contribution to this process are outlined on 
page 21.)  
Total output for New Applications 2007 - 2011
 
During 2011, the number of new product applications 
assessed by the IMB was 1,977. This included 493 
new national applications and 806 new MRP and 
DCP applications. There were 233 new centralised 
applications and 394 transfer applications. The 
number of assessments completed rose 10% when 
compared to 2010. 
vARIATIoNS 
After a medicine has been authorised, the terms of 
the marketing authorisation may subsequently be 
varied. Examples of variations include the addition of 
a new indication or potential side effect, or updates 
to the company’s manufacturing or contact details. 
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Total output for variations 2007 - 2011 
 
During 2011, the IMB processed 15,458 variations to 
marketing authorisations for products authorised 
through the national or MR procedures. The reduction 
of 4% from the number in 2010 was due to the 
impact of the implementation of new variations 
regulations in that year. 
Norlevo – Change of Supply Status
In 2011, the IMB authorised the switch of Norlevo 
(levonorgesterl) emergency contraception from 
prescription to non-prescription supply. This followed 
receipt of an application from the marketing 
authorisation holder to change the supply status. This 
application was assessed by the IMB and Norlevo is 
now available over-the-counter (OTC) in pharmacies.
RENEWALS
Marketing authorisations are valid for five years from 
the date of first issue. For the authorisation to remain 
valid, it should be renewed at the end of this five year 
period.
In 2011, 757 renewals to marketing authorisations 
for products authorised through the national or 
MR procedures were processed. This was a 32% 
decrease compared to 2010. This can be explained 
by the change in legislation where only one renewal 
of a marketing authorisation is now required after 
five years instead of one every five years unless 
specifically requested by the IMB.
IMB AS REfERENCE MEMBER STATE
In certain circumstances, companies can apply for the 
simultaneous authorisation of a medicine in more 
than one EU country. Such applications require one 
country to be the reference member state (RMS) 
while the other countries involved are known as the 
concerned member states (CMS). 
The IMB continued to actively contribute to the 
European licensing system as a reference member 
state in both the MR and the DC procedures for 
generic medicines. The IMB completed 10 MRPs and 
issued 16 new marketing authorisations via DCP with 
Ireland as the reference member state. The numbers 
are consistent with our 2010 contribution.
IMB AS RAPPoRTEuR/Co-RAPPoRTEuR 
The IMB was allocated 27 applications for marketing 
authorisations to assess by the Committee for 
Medicinal Products for Human Use (CHMP) at the 
European Medicines Agency. These applications, 
referred to as centralised procedures, allow a 
successful applicant to market its product in all 
member states. The types of medicines included 
innovative treatments for diabetes, respiratory 
disease and radiopharmaceuticals. The assessments 
are complex and involve extensive discussion with 
EU colleagues. A total of 24 procedures were ongoing 
during 2011 while four were issued during the year.     
The IMB acted as rapporteur (lead assessor) for 30 
scientific advice procedures for medicines proposed 
for the treatment of respiratory, musculoskeletal, 
allergic and dermatological conditions, diabetes 
mellitus and infections.
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PARTICIPATIoN IN EuRoPEAN MEETINGS
The IMB is an active participant in the European 
regulatory network. During 2011, representatives 
of the IMB contributed to and, where appropriate, 
prepared papers for the following European 
committees and groups: 
•	 European	Medicines	Agency:
− Committee for Medicinal Products for 
Human Use (CHMP) and its associated 
Working Parties
− Committee for Orphan Medicinal Products 
(COMP)
− Paediatric Committee (PDCO)
− Herbal Committee (HMPC)
− Committee for Advanced Therapies (CAT)
•	 Heads	of	Medicines	Agencies:
− Co-ordination Group for the Mutual 
Recognition and Decentralised Procedures 
(CMDh)
− Clinical Trials Facilitation Group (CTFG) 
The IMB also participates at Council/Standing 
Committee meetings, as required. 
CMDh
The work of the CMDh is essential for the 
authorisation of over 90% of the medicines which 
are available in Europe. A large number of these 
authorisations are obtained by way of MR and DC 
procedures. The CMDh is responsible for referral 
procedures and also promotes harmonisation 
of product information for medicines. The IMB 
contributed significantly to the core activities of the 
CMDh in 2011, which included the implementation of 
new legislation such as the Variations Regulation and 
the pharmacovigilance legislation. 
TRAdITIoNAL hERBAL MEdICINAL 
PRoduCTS
To protect the health of consumers, the EU 
introduced the Traditional Herbal Medicinal Products 
Directive in 2004 to allow for the regulation of 
“traditional herbal medicinal products” (THMPs). 
This directive was transposed into Irish law on 23 
July 2007 and designates the IMB as the Competent 
Authority for the implementation of the legislation. 
On this basis, the IMB established the traditional 
herbal medicinal products registration scheme. 
Under this scheme, THMPs which meet certain criteria 
regarding traditional-use and safety and are suitable 
for use without the intervention of a doctor can apply 
for a certificate of traditional-use registration using 
the simplified registration procedure. 
The transition period for THMPs that were on the 
market when the 2007 Regulations came into force 
ended on 30 April 2011. A total of 57 applications had 
been received under this scheme by year-end and 
four products were registered in 2011. The number of 
applications received remains disappointingly low. 
In March 2011, the IMB held a second information 
session for stakeholders (the first was in 2008) to 
clarify the requirements, and also held meetings with 
individual applicants to assist them in the application 
process. A high volume of enquiries about the 
scheme was received by the IMB during 2011 and 
much emphasis has been placed on communication 
to facilitate successful implementation of the 
regulatory requirements. Guidance documents, 
questions and answers documents, and other 
relevant guidance on the scheme have been 
produced by the IMB and are available on our 
website. Market surveillance, to monitor adherence 
to the policy at wholesale and retail level, was carried 
out during the second half of the year.
The IMB is also advised in this regard by the Herbal 
Medicines Subcommittee of its Advisory Committee 
for Human Medicines.
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hoMEoPAThIC MEdICINES
Homeopathic medicines must be registered or 
authorised by the IMB before being placed on the 
Irish market. Registration is under the simplified 
registration scheme specifically for homeopathic 
medicinal products without indications that are 
administered orally or externally. Between 2008 and 
2011, 77 product applications were submitted to the 
IMB under this scheme. All 77 have been registered, 
including the 23 new applications received during 
2011. This represents another year-on-year increase 
in the number of products registered. In 2010, there 
were 22 products registered, 20 in 2009 and eight in 
2008. 
Authorisation of homeopathic medicines with 
indications has been facilitated by the introduction 
of national legislation (Medicinal Products (Control 
of Placing on the Market) Regulations, 2007 as 
amended) which establishes criteria for the licensing 
of homeopathic medicines under national rules 
as provided for under EU Directive 2001/83/EC, as 
amended. The national rules scheme, established 
by the IMB in May 2010, applies to homeopathic 
medicines with indications for mild self-limiting 
conditions. A number of applications have been 
received under this scheme and assessment of these 
was carried out during 2011. Together with the 
simplified registration scheme, this new national rules 
scheme will facilitate the licensing of all homeopathic 
medicines on the Irish market as well as new products 
entering the market.
CoNTRoLLEd dRuGS LICENSING 
Import, export and holding of controlled drugs (for 
legitimate purposes) are subject to licensing. The 
Department of Health is the licensing authority while 
the IMB handles the administrative aspects of the 
application and licensing process
During the past 12 months, activity levels increased 
slightly (5%) compared to the previous year. Details 
are provided in the following table.
Controlled drugs Licensing Activity 2007 2008 2009 2010 2011
Registration 19 23 20 28 26
Export and Import 964 1056 970 1270 1331
Annual – New 19 19 31 19 14
Annual – Renewal 171 243 221 172 170
Letter of no objection (LONO) 473 489 447 448 511
Pilgrims 14 14 11 12 10
Hemp 5 46 7 10 7
Total 1665 1890 1707 1959 2069
24 IMB ANNUAL REPORT 2011
VETERINARY MEDICINES
The IMB is committed to protecting the welfare of 
treated animals, including fish, poultry, bees and 
domestic animals, as well as ensuring the safety 
of foodstuffs obtained from animals treated with 
veterinary medicines. The assessment of products 
also includes an evaluation of any possible risks to the 
user as well as the elaboration of risk-management 
measures to control any risks. Finally, we also evaluate 
the safety of the veterinary medicines for the 
environment.
PRoduCT CLASSIfICATIoN REquESTS 
The IMB provides a service to stakeholders to assist 
in clarifying which products should be categorised 
as veterinary medicinal products. Such products 
fall under the remit of the IMB from a regulatory 
perspective and are distinct from other products 
which are outside the IMB’s remit. 
During 2011, 72 product classification queries were 
received in respect of veterinary medicines. There 
were 81 responses issued which related to queries 
received both during, and prior to, 2011. 
CLINICAL TRIALS
The IMB is regularly consulted by the Department of 
Agriculture, Food and the Marine prior to the granting 
of an approval for a clinical trial. The Department is 
the Competent Authority for licensing of clinical trials 
in animals. On receipt of a valid application from the 
Department, the IMB reviews the information based 
on an assessment of the expected risks to the animal, 
the user, the consumer and the environment. The IMB 
also considers the conduct of the proposed study.
During 2011, nine clinical trial applications were 
received by the IMB and issued to the Department. 
All were assessed and issued within clinical trial set 
timelines.
NEW APPLICATIoNS
Before a new veterinary medicine can be placed 
on the Irish market, it must be firstly assessed and 
authorised by the IMB or the European Medicines 
Agency. The decision on whether a medicine is 
authorised centrally in Europe or at a national level 
by the IMB, is generally dependent on the type of 
product in question. 
When a company seeks approval from the IMB for 
a new medicine, it submits a dossier that includes 
critical summary reports, details of the product 
information, such as the leaflet and label, as well as 
quality, safety and efficacy data. An IMB assessment 
team of veterinary surgeons, pharmacists and other 
scientists will then review the dossier to establish 
if the medicine’s animal and public health benefits 
outweigh its known risks.
During 2011, the number of new product applications 
received by the IMB was 115 of which 11 were 
national applications. We assessed and approved 110 
applications, including two new national licences. 
The number of MRP and DCP licenses issued was 108 
while 104 such applications were received. The MRP 
and DCP figures included both applications where 
Ireland was the reference member state and where 
it was a concerned member state. (See also ‘IMB as 
Reference Member State’ below). 
vARIATIoNS
After a medicine has been authorised, the terms of 
the marketing authorisation may subsequently be 
varied. Examples of variations include the addition of 
a new indication or potential side effect, or updates 
to the company’s manufacturing or contact details. 
During 2011, the IMB approved 1,231 variations to 
authorisations granted through the national, MR 
or centralised procedures while 1,274 variations 
applications were received.
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RENEWALS
Marketing authorisations are valid for five years from 
the date of first issue. For the authorisation to remain 
valid, it must be renewed at the end of this five-year 
period. Following this renewal, the authorisation 
remains valid for an indefinite period unless a further 
renewal is deemed necessary by the IMB on animal/
public safety grounds.
In 2011, 57 renewals to marketing authorisations for 
veterinary products authorised through the national 
or MR procedures were received while 129 were 
issued. 
IMB AS RAPPoRTEuR/Co-RAPPoRTEuR 
In the ‘centralised’ or ‘Community’ procedure, the 
Committee for Medicinal Products for Veterinary 
Use (CVMP) of the European Medicines Agency is 
responsible for conducting the initial assessment of 
veterinary medicines for which an EU-wide marketing 
authorisation is sought. Under this procedure, the 
CVMP appoints members from two different EU 
countries to assess the application and these are 
known as the rapporteur and co-rapporteur. 
During 2011, the IMB acted as the rapporteur or co-
rapporteur for nine centralised procedures (including 
extension applications). These assessments were 
complex and involved extensive discussion with EU 
colleagues. 
IMB AS REfERENCE MEMBER STATE
The IMB continued to actively contribute to the 
European veterinary licensing system and issued 
25 new marketing authorisations as the reference 
member state.
WoRk-IN-PRoGRESS APPLICATIoNS
The number of work-in-progress applications 
continued to decline from 645 units at December 
2009 to 596 units at December 2010 and 531 units at 
December 2011.
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MEDICAL DEVICES
CLASSIfICATIoN REquESTS
European legislation provides for the categorisation 
of medical devices into four different classes 
ranging from low risk to high risk. The class a 
particular medical device is assigned to depends on 
classification rules relating to the device’s duration of 
body contact, its degree of invasiveness, its use of an 
energy source, and the part of the body affected by 
its use. In addition, in certain cases, it may not be clear 
if a product falls under the medical device legislation 
or whether, for example, it should be classified as a 
medicine or a cosmetic product. 
In 2011, the IMB received 64 requests for formal 
advice on qualification and classification of products 
as medical devices. Of these requests, 59% came 
from other regulatory authorities in Europe seeking 
advice and consensus on the classification of medical 
devices and borderline products. Other external 
sources, such as medical devices manufacturers 
and the National Standards Authority of Ireland, 
accounted for 27% of the requests.
During 2011, the IMB was asked to act as an external 
expert on medical device classification for another 
European regulatory authority. In addition, we 
circulated two enquiries through the European 
Commission’s Classification and Borderline Working 
Group to seek consensus opinion on qualification of 
borderline products.
CLINICAL INvESTIGATIoN APPLICATIoNS
Medical devices intended for clinical investigations 
are typically required to comply with the requirement 
for clinical investigation specified in the medical 
devices directive and must be labelled that they are 
for clinical investigation.
When clinical investigations are to be carried out 
in Ireland, it is necessary to make an application to 
the IMB. Typically, applications are submitted to us 
by commercial sponsors such as medical device 
manufacturers. As part of this process, we encourage 
pre-submission meetings with potential sponsors of 
clinical investigations. 
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Applications to conduct clinical investigations are 
reviewed by an IMB assessment team prior to the 
investigation starting. We review the regulatory, 
technical and clinical aspects of the application. 
In 2011, the IMB received 9 applications relating 
to clinical investigation of non-CE marked medical 
devices comprised of 5 new applications and 4 
significant amendments to ongoing investigations. 
The average time for final opinion was 50 days, with 
completion of the IMB’s initial review at an average of 
32 days. 
Since the start of 2011, the European Commission 
medical device database system (EUDAMED) had 
added functionality to capture details of clinical 
investigations of medical devices. The database now 
provides for notification, traceability, monitoring 
and communication of review decisions between 
national competent authorities throughout Europe. 
Notification to this system became mandatory from 
May. The IMB began uploading details of clinical 
investigations of medical devices in Ireland at the 
start of 2011. 
dESIGNATIoN ANd MoNIToRING of IRISh 
NoTIfIEd BodIES 
Manufacturers of certain medical devices require a 
notified body to carry out a compliance assessment 
of those products before they can be placed on the 
market. In Ireland, the notified body is the National 
Standards Authority of Ireland (NSAI). It is the role 
of the IMB, as the national Competent Authority for 
medical devices, to monitor the performance of the 
NSAI as a notified body. This monitoring includes 
conformity assessment of medical devices and 
compliance with the Medical Device Directive, the 
Active Implantable Medical Device Directive and the 
In-vitro Diagnostic Device Directive.
(Details of the IMB audit programme at the NSAI are 
provided on page 53 of this report.) 
Various European working groups have been 
established to promote best practice and harmonise 
both the performance of medical device notified 
bodies and their oversight by competent authorities. 
During 2011, the IMB again participated in the peer 
review scheme operated by the Notified Bodies 
Operations Group (NBOG). This scheme seeks to 
ensure that regulatory authorities apply the same 
standards of oversight to notified bodies across 
Europe. The IMB peer reviewed the Medicines and 
Healthcare Products Regulatory Agency’s audit of one 
of the medical device notified bodies based in the UK.
PRoduCT REGISTRATIoNS
The IMB maintains a medical devices registration 
system for Class I general, custom-made and in-
vitro diagnostic devices. In 2011, the IMB registered 
489 new medical devices within these categories. 
Thirty-four new organisations based in Ireland also 
registered with the IMB as manufacturers of these 
types of medical devices. 
During 2011, the IMB further developed its 
online registration system for medical devices. 
Manufacturers utilise the system to register both their 
company details and details of the devices which 
they are placing on the market. Such registration 
is mandatory for Class I, custom-made, system and 
procedure pack, medical device sterilising services 
and in-vitro diagnostic manufacturers based in 
Ireland. The IMB system was upgraded to ensure 
effective interfacing with the European Commission’s 
new version of the European medical device database 
(EUDAMED), which became active in May 2011.
The IMB commenced a project during 2011 to 
validate and verify the information available on 
the register for medical devices to ensure that 
manufacturer and device details were up-to-date. 
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COSMETIC PRODuCTS
PRoduCT NoTIfICATIoNS
Manufacturers, importers and persons acting on their 
behalf who have responsibility for placing cosmetic 
products onto the market, are required to notify 
IMB of these activities. During 2011, 4,610 cosmetic 
product notifications were received from a total of 
64 companies. The three most common categories of 
product notifications were: 
1. Make-up products and make-up (23%);
2. Lip products (21%);
3. Creams, emulsions, lotions, gels and oils (17%).    
This was the first full year of notification to the IMB 
after we became the Competent Authority for this 
area in October 2010.
AuTHORISATION/LICENSING OF SITES 
AND FACILITIES
The IMB is responsible for the regulation of 
manufacturers of human and veterinary medicines 
and wholesalers of human medicines as well as blood 
and tissue establishments. We are also responsible for 
the approval of contract laboratories.   
Such sites and facilities are required to be authorised 
by the IMB for the activities which they carry out. The 
IMB will grant an authorisation based on application 
for an authorisation/licence and adherence to 
relevant European legislation and guidelines. 
Compliance with these requirements is based on 
satisfactory outcomes of IMB inspections (see also 
the Safety Monitoring and Surveillance section of this 
report).
The total number of licences/authorisations in place 
at year end for the past five years is presented below 
by category. The figures show that overall the number 
of manufacturer’s authorisations over this period 
has remained quite stable while the total number of 
wholesaler’s authorisations has increased during the 
past two years. This latter trend has been influenced 
by parallel exporting.
Total Number of Licences/Authorisations (Sites) 2007 2008 2009 2010 2011
Manufacturers of Medicines for Human Use 81 86 85 86 88
Manufacturers of Veterinary Medicines 29 26 25 27 24
Investigational Medicinal Products for Human Use 12 45 50 51 50
Wholesalers of Medicines for Human use 141 214 209 220 243
Blood Establishments 0 6 5 4 4
Tissue Establishments 0 6 13 16 17
Laboratory Approvals 0 11 13 16 16
Total 263 394 400 420 442
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EXPORT CERTIFICATES 
Export certificates are required by health authorities 
in many third country markets as an indication that a 
product registered/authorised and/or manufactured 
in the country of origin is of appropriate quality. As 
Ireland is a large exporter of medicines and medical 
devices, companies exporting from here request a 
large number of certificates. Export certificates are 
also required in many third countries to facilitate the 
registration of cosmetic products. The inspection and 
authorisation/registration programmes operated 
by the IMB form the basis on which certificates 
are issued. Where possible, certificate formats, as 
published by the World Health Organization, are 
used.
There were 4,146 export certificates issued during 
2011, a total broadly consistent with the previous 
year. 
Product Certification Activity  2007 2008 2009 2010 2011
Certification of Documents 316 266 235 234 239
Certificates of Free Sale - Medicinal Products 52 22 22 13 34
Certificates of Good Manufacturing Practice       
for Finished Product Manufacturers 200 212 230 224 233
Certificates of Good Manufacturing Practice       
for Active  Substance Manufacturers 62 42 39 31 39
Certificate of a Pharmaceutical Product  1046 1273 942 1187 1382
Medical Device Free Sale Certificates 432 434 977 2142 1780
Cosmetic Products Free Sale Certificates N/A N/A N/A 174* 388
Other 82 61 56 28 51
Total 2190 2310 2501 4033 4146
*2011 was the first full year that the IMB was responsible for issuing certificates for cosmetics.
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SAFETY AND COMPLIANCE  
MONITORING 
Monitoring the safety of medicines, medical devices and 
other healthcare products that have been authorised, 
licensed or registered for use in Ireland is known as post-
market surveillance. It is a primary function of the IMB. 
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Assessing reports of suspected adverse events/
incidents and reactions (also known as side effects), 
conducting scheduled safety reviews, monitoring 
field safety corrective actions to medical devices 
and evaluating new and emerging data from trials 
and studies are among the tools used to monitor 
the safety of healthcare products on an ongoing 
basis. Quality issues concerning how a product is 
manufactured, packaged, labelled or distributed and 
stored may also arise at the post-market stage.
In a small number of cases, where it is established 
that the risks of a particular product outweigh the 
benefits for those using it, the manufacturer and/
or the IMB may decide that it is necessary to remove 
or recall that product from the market. In such 
circumstances, we will work with all stakeholders 
impacted to ensure such recalls are managed in a 
timely and effective manner.
HuMAN MEDICINES
PhARMACovIGILANCE 
Pharmacovigilance is defined as the science and 
activities relating to the detection, assessment, 
understanding and prevention of adverse reactions, or 
side effects, associated with the use of medicines. Key 
to its effectiveness is an active reporting culture. The 
majority of adverse reaction reports are notified to the 
IMB by the pharmaceutical companies marketing the 
medicines, also known as the marketing authorisation 
holder. Most of these reports will have been initiated 
by doctors, pharmacists and other healthcare 
professionals who may also report directly to the IMB. 
We also receive reports of adverse reactions directly 
from patients and members of the public.
The IMB monitors adverse reaction reports to look 
for new types, or increased numbers, of adverse 
reactions. In co-operation with pharmacovigilance 
professionals in Europe and further afield, we focus 
especially on serious and potentially life-threatening 
risks. If there appears to be a new and serious 
risk, the issue must be assessed to determine the 
impact on the overall benefit/risk profile of the 
medicine concerned and consideration is given as 
to how any new risks should best be managed and 
communicated to healthcare professionals and 
patients.
2011 Reports
During 2011, the IMB received a total of 2,784 
suspected adverse reactions associated with the use 
of human medicines in Ireland. While this represents 
a decrease of some 14% in reporting rates compared 
with 2009/2010, it reflects a return to expected 
levels following the enhanced rates of reporting 
that resulted from the H1N1 national immunisation 
programme. The 2011 figures show a small increase 
in reporting compared to 2008. A percentage 
breakdown of adverse reaction reports received by 
source is provided in the accompanying table. 
Individual case reports were followed up by the IMB 
and follow-up information was provided to reporters 
where appropriate. Serious, suspected cases notified 
directly to the IMB by healthcare professionals were 
appropriately forwarded to relevant stakeholders, 
including the European Medicines Agency (EMA) and 
marketing authorisation holders within the agreed 
timeframes and formats.  
Source of Suspected Adverse   
Reaction Reports %
Marketing Authorisation Holder 63
Community Care Doctor 9
General Practitioner 6
Hospital Doctor 5
Community Nurse 4
Hospital Pharmacist 4
Community Pharmacist  3
Hospital Nurse 3
Member of Public 1
Health Sector - Other 2
In addition, the IMB received and processed some 
3,350 follow up reports during 2011.
Online Reporting 
The IMB’s online reporting system, available 
to healthcare professionals, patients and other 
members of the public accounted for 12% (345) of 
all reports received during 2011. This was a slight 
increase on the previous year. Access to the online 
reporting system is available through the homepage 
of the IMB website www.imb.ie.
In relation to industry, 288 companies were 
operational with electronic reporting to the IMB by 
the end of the year. This was an increase of some 
25% over the number of companies reporting 
electronically in 2010.
During 2011, the IMB continued to report all 
suspected serious adverse reactions occurring in 
Ireland electronically via EudraVigilance to the EMA.
Monitoring Compliance with Pharmacovigilance 
Obligations
Company/sponsor compliance with 
pharmacovigilance obligations is continuously 
monitored through:
•	 review	of	the	timeliness	and	quality	of	individual	
adverse reaction reports;
•	 evaluation	of	the	follow-up	information	provided	
for individual reports;
•	 assessment	of	the	quality	and	
comprehensiveness of cumulative information 
such as periodic safety update reports (PSURs) 
and Annual Safety Reports (ASRs); and 
•	 review	of	responses	to	IMB	requests	for	
pharmacovigilance data. 
Throughout 2011, issues identified in relation to the 
compliance areas above were followed up with the 
companies concerned through correspondence, 
meetings and teleconferences. The IMB also reviewed 
and gave feedback on corrective action plans 
developed to address the issues raised. 
The pharmacovigilance inspection programme 
continued in 2011, jointly carried out by IMB 
pharmacovigilance and compliance colleagues. 
The pharmacovigilance team participated in three 
inspections during the year.
At a European level, the IMB participated in the 
Pharmacovigilance Inspectors Working Group 
workshop which examined the impact of the new 
pharmacovigilance legislation. In addition, we 
participated in the development of Good Vigilance 
Practice (GVP) guidance for pharmacovigilance 
systems requirements and inspections.
Pharmacovigilance Assessment Activities
A new product application submitted to the IMB 
for authorisation must include a document known 
as a ‘detailed description of pharmacovigilance 
systems’. An updated version of this document may 
also be required for certain variation applications. 
This part of the product file or dossier is reviewed 
by our pharmacovigilance assessors. The following 
table outlines the number of detailed descriptions of 
pharmacovigilance systems assessed during 2011:
New Product Assessments  updates Assessed as part of variations
New National procedures 41 National Variations 3
New Outgoing MR/DCP  8 Outgoing MR Variations 10
New Outgoing CAP 13 Outgoing CAP Variations 1
  Incoming MRP/DCP/CAP Variations 16
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There were also 241 Type 1AIN variations reviewed 
for updates to the details of the Qualified Person 
Responsible for Pharmacovigilance. Type 1AIN 
(immediate notification) variations are those 
submitted after implementation.
Gardasil               
The IMB continued to monitor national experience 
with Gardasil, the human papillomavirus (HPV) 
vaccine, used through the HSE school immunisation 
programme during 2011. As part of this monitoring 
programme, two updates outlining the number and 
nature of suspected adverse reactions associated 
with the use of Gardasil that were reported to the 
IMB relating to national monitoring were published 
on our website. The final update was published in 
July 2011 following completion of the first full year 
of the school programme. This update outlined the 
consistency between national reporting experience 
and the known safety profile of the vaccine, with no 
new risks identified in association with use of Gardasil 
in Ireland.
The IMB continued to address numerous queries and 
requests for information regarding the safety profile 
of Gardasil throughout 2011. These were received 
from members of the public, the media, healthcare 
professionals and interest groups. 
Pandemrix – Investigation into Association with 
Narcolepsy
A potential association between the H1NI vaccine 
Pandemrix and narcolepsy, a sleep disorder, was first 
highlighted in August 2010. This followed an increase 
in the number of narcolepsy cases reported among 
children and adolescents who received this vaccine 
in Finland and Sweden. A detailed review of the issue 
was announced at EU level and this was ongoing at 
the end of 2011. The IMB is contributing to this review 
through its participation at the European Medicines 
Agency and will continue to do so during 2012.  
In late 2010, the IMB received preliminary information 
regarding a small number of reports of suspected 
narcolepsy in Irish patients vaccinated with 
Pandemrix. Additional information and confirmation 
of a diagnosis of narcolepsy was received for some of 
these cases early in 2011. Throughout the remainder 
of the year, additional reports of suspected 
narcolepsy were received by the IMB in addition to 
many queries from members of the public, healthcare 
professionals and the media. Comprehensive follow-
up with the healthcare professionals involved in each 
case was conducted. We interacted with relevant 
national bodies, including the Department of Health 
and the Health Protection Surveillance Centre 
(HPSC) in the context of the investigation. The IMB 
was also represented on the HSE Serious Incident 
Management Team which was co-ordinating the 
overall national review.
VIGILANCE ASSESSMENT
For the purposes of lifecycle benefit-risk 
management, it is necessary to continue to evaluate 
the risks and benefits of a medicine in everyday 
medical practice and long term use in the post-
market phase. This is to ensure that the benefits of 
the medicine continue to outweigh the risks and that 
risk minimisation measures are implemented where 
needed. 
Vigilance assessment activities include evaluation 
of periodic safety update reports (PSURs), risk 
management plans and post authorisation safety 
studies, pharmacovigilance-related referrals, and 
the assessment and approval of Direct Healthcare 
Professional Communications issued by companies 
and risk minimisation plans to be implemented in 
Ireland. 
During 2011, a new signal management system was 
implemented. This system determines whether, 
based on an examination of individual case safety 
reports, aggregated data from active surveillance 
systems or studies, literature information or other 
data sources, there are new risks associated with an 
active substance or medicine or whether risks have 
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P-RMS allocation
changed. The signal management process covers 
all steps from detection of signals, through their 
validation and confirmation, analysis, prioritisation 
and assessment to recommendations for action. 
Periodic Safety update Reports
Periodic safety update reports (PSURs) are a 
pharmacovigilance tool to monitor the ongoing 
safety of medicines post marketing. They are 
submitted by the MAH in respect of each authorised 
medicine, at defined intervals following the initial 
authorisation of the product. A PSUR is intended 
to provide an update of the worldwide safety 
experience of the medicine. PSURs are evaluated 
either by the IMB or by other EU medicines agencies 
operating a work-sharing system.
During 2011, the total output for PSURs was 3633. 
This includes PSURs for national authorisations, MR, 
centralised and PSUR work-sharing procedures. 
The IMB continues to actively participate in the 
HMA PSUR work-sharing project and is currently 
ranked in the top eight of national competent 
authorities in Europe in terms of lead MS assessment 
responsibilities (see corresponding graph below). 
The IMB contributed to the implementation 
planning for the new pharmacovigilance legislation 
which introduces substantial changes for PSURs by 
providing the member state co-lead for the joint 
member state/EMA project team. In the future, 
requirements for PSURs will be risk-based and the 
scope of the evaluation will be extended to integrate 
cumulative information on both benefits and risks. 
The link to risk management will be strengthened. 
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Risk Management Plans 
In certain cases, a dedicated risk management 
plan (RMP) may be required as part of a medicine’s 
approval process and for maintenance of approval. 
An RMP is a risk mitigation tool for managing a 
known or potential serious risk associated with a 
medicine.
The total number of RMPs assessed during 2011 was 
629 (76 outgoing and 553 incoming applications). 
There were also 87 follow-up measures assessed 
including results of post authorisation safety 
studies. Some 44 Direct Healthcare Professional 
Communications providing new safety information or 
risk minimisation advice were approved. In addition, 
39 risk minimisation plans were assessed including 
risk minimisation tools for healthcare professionals 
and patients to support the safe and effective use of 
the medicine. 
Pharmacovigilance Working Party Assessments
The IMB provides active representation to the 
Committee for Medicinal Products for Human Use 
(CHMP) Pharmacovigilance Working Party and its 
drafting groups at the European Medicines Agency. 
During 2011, the working party provided advice 
to the CHMP and also the CMDh (the HMA’s co-
ordination group for MRPs and DCPs) for centrally-
authorised and nationally-authorised products 
respectively. 
The following assessments for nationally authorised 
products were concluded in 2011 leading to 
variations of national marketing authorisations:
•	 Antipsychotics	(conventional	and	atypical)	and	
use during the third trimester of pregnancy and 
risk of abnormal muscle movements and/or 
withdrawal symptoms in newborns;
•	 Beta-blocking	agents	for	ophthalmic	use	and	
systemic adverse drug reactions after ophthalmic 
administration;
•	 Citalopram	and	risk	of	QT-interval	prolongation;
•	 Domperidone	and	risk	of	QTc	prolongation,	
serious ventricular arrhythmias and sudden 
cardiac death;
•	 Escitalopram	and	risk	of	QT-interval	prolongation;
•	 Fluoroquinolones	and	risk	of	QT-interval	
prolongation;
•	 Use	of	Hydrochlorothiazide	during	lactation,	
and consolidated wording for the summary of 
product characteristics and package leaflet of 
ACE-inhibitors used alone or in combination with 
hydrochlorothiazide in pregnancy and lactation; 
•	 Insulin	products	and	risk	of	cardiac	failure	with	
concomitant use of pioglitazone;
•	 Key	elements	for	warnings	for	summary	of	
product characteristics and package leaflet 
regarding Stevens-Johnson syndrome) and toxic 
epidermal necrolysis for 14 ‘high risk’ substances 
(for systemic use);
•	 Powder	formulations	of	Plantago	ovata	seeds	and	
allergic reactions after prolonged occupational 
exposure;
•	 Risk	of	psychiatric	adverse	drug	reactions	to	
inhaled and intranasal corticosteroids and risk of 
non-psychiatric systemic adverse drugs reactions 
to intranasal corticosteroids.
New Advice for use of Cough and Cold Medicines 
in Children
In September 2011, the IMB recommended a number 
of new measures in relation to the use of over-the-
counter cough and cold medicines for children. 
Following a review of the safety and effectiveness of 
cough and cold medicines, we advised that over-the-
counter cough and cold medicines should not be 
used in children under the age of six years. For six to 
twelve year olds, the advice was that these medicines 
could continue to be used but care should be 
taken to ensure that the maximum daily dose is not 
exceeded and that no other cough or cold medicine 
is taken at the same time. The product information 
for these medicines was updated to reflect this 
advice.  
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BLOOD, TISSuES AND CELLS
hAEMovIGILANCE
The IMB is the Competent Authority for legislation 
concerning blood and blood components.
Haemovigilance refers to a set of organised 
surveillance procedures relating to serious adverse 
or unexpected events or reactions in donors or 
recipients and the epidemiological follow-up of 
donors.
The IMB continued its interaction with the National 
Haemovigilance Office (NHO) during 2011 and 
discussed issues of mutual interest and concern at 
regular meetings throughout the year. Key items 
discussed at these meetings included: 
•	 Review	and	discussion	of	national	experience	
with haemovigilance reactions and events; 
•	 Updates	to	guidance	on	haemovigilance	
reporting; 
•	 Review	of	systems	to	facilitate	simultaneous,	dual	
submission of mandatory reports to the NHO and 
the IMB;
•	 Further	developments	to	support	monitoring	
activities and ensure compliance with EU and 
national legislative provisions.
Following collaboration with the NHO, the IMB 
submitted an annual report on serious adverse 
reactions and events to the European Commission 
during 2011. The report reflected information 
received from January to December 2010 and 
included information on 151 serious adverse 
reactions and 122 serious adverse events which met 
the mandatory legislative reporting requirements. 
These figures represent substantial increases in 
reporting over the previous year. There was an 
increase of almost 50 % in serious adverse reaction 
reports and of almost 170% in serious adverse 
event reports. The increase in the number of 
serious adverse events in this year’s report relates 
to a change in reporting policy as the criteria 
were expanded to include reports from blood 
establishments and near miss reporting, in line with 
the legislative requirements. In addition, information 
on some 396 non-mandatory donor-related reactions 
provided on a voluntary basis was included in the 
report as requested by the Commission. 
The European Commission continued to progress 
harmonisation initiatives to develop a common 
approach to the provision of data by member states 
through a Working Group on Haemovigilance 
convened in 2007. During 2011, the IMB attended a 
meeting of this group and has actively contributed to 
the development of an updated guidance document, 
in collaboration with colleagues from the NHO. 
Further updates to this guidance are expected in 
2012. 
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TISSuE ANd CELL vIGILANCE
The IMB is the Competent Authority in Ireland for the 
purposes of the EU tissues and cells legislation. The 
legislation focuses on standards of quality and safety 
for donations, procurement, testing, processing, 
preservation, storage and distribution of human 
tissue and cells.
Tissue and cell vigilance activities progressed 
throughout the year in review and included the 
three-year project co-funded by the EU Public Health 
group on Substances of Human Origin Vigilance and 
Surveillance (SoHOV&S). The project’s primary aim is 
to support the establishment of effective vigilance 
and surveillance systems for tissues and cells used 
in transplantation and in assisted reproduction. The 
IMB continued its participation as a partner in the 
various working groups of this project and in its role 
as the lead partner for one of the work packages, 
with responsibility for organising training courses, 
including e-learning modules on the investigation 
and management of vigilance and surveillance for 
tissues and cells.
In line with the legislative requirements, the IMB 
submitted an annual report on serious adverse 
reactions and events associated with tissues and 
cells to the European Commission during 2011. The 
report reflected information received from January 
to December 2010 and consisted of some 32 reports 
associated with use of tissues and cells, 27 of which 
met the legislative reporting requirements, including 
three serious adverse reactions and 24 serious 
adverse events. The remaining five donor reaction 
reports, while not fulfilling the mandatory reporting 
requirements, were included on a voluntary basis as 
requested by the Commission.   
Following submission of the annual report to the 
European Commission, an overview of the national 
data was compiled for distribution to stakeholders 
to provide some feedback on the national reporting 
experience for the period. 
The European Commission also continued to 
progress harmonisation initiatives to develop a 
common approach to the provision of data by 
member states through a working group on tissues 
and cells vigilance. During 2011, the IMB continued 
to participate in the development of guidance for 
reporting. 
VETERINARY MEDICINES
PhARMACovIGILANCE
Effective reporting is central to a successful and 
robust pharmacovigilance scheme. During 2011, there 
were 228 reports of suspected adverse reactions 
associated with the use of veterinary medicinal 
products received by the IMB. This represents an 
increase of 9% over the number of reports received 
in 2010. 
The breakdown of the 228 reports is as follow:
•	 121	related	to	suspected	adverse	reactions	in	the	
treated animals
•	 94	related	to	suspected	lack	of	expected	efficacy
•	 10	involved	suspected	adverse	reactions	
in individual users following exposure to a 
veterinary medicinal product 
Three reports related to violations of approved 
residue limits in foodstuffs of animal origin. On 
investigation, it was determined that residue 
standards being applied were more stringent than 
those defined by EU residue legislation. 
Periodic Safety update Reports
PSURs are intended to provide an update of the 
worldwide safety experience of a medicine. In 2011, a 
total of 413 PSURs were assessed which compares to 
396 for 2010.
Significant Product Suspensions or Variations
The marketing authorisation for Hiprabovis Pneumos 
Emulsion for injection for cattle was suspended 
in 2011. This action followed a decision by the 
European Commission that the benefit/risk profile 
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had changed due to an increase in the incidence of 
anaphylactic-type adverse events associated with 
use of the vaccine, some of which were fatal. The 
underlying cause of the adverse reactions observed 
was undetermined and as a result no specific risk-
management measures could be devised.
Inspections of Pharmacovigilance Systems
The IMB conducted one inspection of a 
pharmacovigilance system at a marketing 
authorisation holder’s premises during 2011. In 
addition, we participated in two inspections in other 
EU member states in respect of centrally-authorised 
products for which the IMB was the rapporteur. 
uSE of vETERINARy ANTIMICRoBIALS IN 
IRELANd
In accordance with EU policy to help underpin 
effective strategies to control the spread of 
antimicrobial resistance in animals and in humans, 
the IMB gathered information on the usage of 
veterinary antimicrobials in Ireland. The total 
consumption in 2011 was 93 tonnes, a slight increase 
of 2% in usage compared to the previous year. 
MARKET COMPLIANCE – HuMAN AND 
VETERINARY MEDICINES
The IMB is responsible for a number of risk-based 
market surveillance programmes. These include 
proactive activities such as the sampling and 
analysis programme and the advertising compliance 
programme, and reactive activities such as the 
quality defect and recall programme. 
The IMB also operates an exempt medicinal products 
notification scheme designed to monitor the 
importation and supply of unauthorised medicinal 
products. In addition, we carry out a programme of 
regulatory compliance inspections at the premises 
of marketing authorisation holders. The latter is 
designed to assess the level of compliance against 
national legislation relating to the placing on the 
market and advertising of medicines.
SAMPLING ANd ANALySIS PRoGRAMME
The IMB’s sampling and analysis programme for 
medicines for human and veterinary use contributes 
to our monitoring of the quality, safety and efficacy 
of medicinal products on the Irish marketplace.
This is done through the analytical testing and/
or examination of packaging and labelling of 
active substances, medicinal products, borderline 
medicinal/non-medicinal products and enforcement-
related samples. A risk-based approach is taken when 
carrying out sampling and analysis work and this 
determines the degree of analytical work carried out 
on the sampled products.    
A total of 529 product samples were sent for 
examination and/or analytical testing in 2011.
Examination of Packaging and Labelling 
The packaging and labelling of 246 medicinal and 
other products were examined. Of these, 68% 
were subjected to general packaging and labelling 
examinations, with a particular emphasis on the 
adequacy of the required safety and warning 
information on package leaflets. A further 27% of 
products were subjected to Braille compliance checks.  
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Analytical Testing 
There were 284 medicines and other product 
samples tested of which 281 were obtained from 
the Irish marketplace. Three samples originated 
from other EU marketplaces as part of the IMB’s 
involvement in EU-wide work-sharing surveillance 
programmes.
Approximately 49% of the analytical work related 
to enforcement and borderline medicinal/non-
medicinal product samples. In addition, 33% related 
to authorised medicinal products. Of the remainder, 
5% concerned active substances while 9% of the 
programme was taken up by microbiological analysis 
work.  
description of products examined Number of samples examined
Medicinal products subjected to general compliance monitoring for   
packaging and labelling attributes 167
Medicinal products subjected to Braille compliance checks 67
Product usability checks 4
Samples arising from monitoring of advertising 4
Work arising from notification of exempt medicinal products  3
Borderline Medicinal/Non-medicinal products associated with IMB   
Classification Committee work 1
Total 246
Product categories selected for Analytical Testing in 2011 Number of samples analysed
Physico-chemical Analysis/Biological Analysis
Enforcement-related products 138
Nationally authorised medicinal products 30
MRP/DCP authorised medicinal products  30
Centrally authorised medicinal products  25
Active substances 13
Human medicinal products manufactured for export 12
Borderline Medicinal/Non-Medicinal products 5
Exempt medicinal products 2
MRP/DCP authorised biological products 1
PPA and DPR medicinal products 1
Veterinary nationally authorised biological medicinal product 1
Microbiological Analysis
Nationally authorised medicinal products 20
MRP/DCP authorised medicinal products 6
Total 284
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Participation in Eu Co-ordinated Market 
Surveillance Activities
The IMB is an active participant in EU programmes 
that involve the sampling and analysis of medicinal 
products. This is achieved via our participation in 
the Official Medicines Control Laboratories (OMCL) 
Network. 
We participated in the sampling and/or analysis of 25 
centrally-authorised medicinal products. Of these, 21 
were sampled from the Irish marketplace for testing 
at OMCLs in other countries and 4 were analysed in 
Ireland on behalf of the European Medicines Agency. 
The IMB also actively participated in the surveillance 
programme for MRP/DCP medicinal products  
co-ordinated by the European Directorate for Quality 
of Medicines (EDQM). As part of work-sharing and in 
an effort to make the best use of available laboratory 
resources, the IMB sampled 21 medicinal products 
from the Irish marketplace for analysis at other 
member state OMCLs. There were four borderline 
medicinal/non-medicinal products analysed by 
the UK’s OMCL and one further such product was 
analysed at the Public Analyst’s Laboratory in Galway. 
Other work-sharing activities carried out included 
analysis of 20 Irish market samples by the UK OMCL 
as part of an anti-counterfeiting project while 26 
samples were microbiologically analysed at the 
Finnish and Czech OMCLs.
Analysis findings
Laboratory analysis Five out-of-specification results associated with the analytical testing of two authorised   
 human medicinal products were identified. Four of these related to non-compliances with  
 product appearance specifications and one product was out-of-specification for assay. 
Packaging and  26 non-compliances were identified in the packaging and labelling of authorised   
labelling medicinal products. Nine of these related to the Braille that was applied to the product   
 packaging. Other non-compliances related to SPCs and package leaflets containing   
 incorrect information and to the inappropriate overlabelling of parallel imported packs.   
Unauthorised Three unauthorised medicinal products were identified on the Irish marketplace via  
medicinal products  this programme. The products concerned were found to be prescription-only medicines   
 and appropriate follow-up actions were taken.
Principal Findings
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All non-compliances were followed-up with the 
relevant companies until the issues could be closed. 
Follow-up is dependent on the type of non-
compliance and can involve:
•	 initiating	company	re-testing;	
•	 reviewing	stability	data;
•	 reviewing	packaging	and	labelling	controls	
(including Braille); and 
•	 recommending	amendments	to	company	
methods.
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quALITy dEfECTS ANd RECALLS
The quality defects and recalls programme 
investigates, on the basis of risk to public and animal 
health, reports of suspected quality defects in both 
human and veterinary medicines and in their related 
active substances. It also co-ordinates all recall 
actions on the Irish market.
Number and Type of Quality Defects 
A total of 917 quality defects were reported to, or 
identified by, the IMB. This is the highest number of 
quality defect investigations in any one year since the 
introduction of the programme and represents a 22% 
increase over 2010.
A number of factors contributed to this increase. 
These included awareness-raising work carried out 
by the IMB among manufacturers in relation to what 
should be reported as a quality defect as well as a 
significant increase in the number of rapid alerts 
issued by other national competent authorities. Such 
alerts enable the immediate sharing of quality defect 
information across Europe.   
Medicines for human use accounted for 847 quality 
defect reports (92 %) with 70 reports concerning 
veterinary medicines. The accompanying table 
illustrates how the various quality defect issues were 
classified in 2011. For comparison, the corresponding 
figures for the previous three years are also 
presented.
Of the total number of defects, 715 (78%) were 
determined to affect Ireland. In these cases, the 
defective batch or batches were either on the Irish 
market and/or were manufactured in Ireland. 
Type of defect  2008 2009 2010 2011
Minor Quality Defects  105 147 241 314
Major Quality Defects  299 345 332 364
Critical Quality Defects  127 105 173 231
Number of Quality Defect Reports Not Justified  23 17 5 8
Total Number of Quality Defects   554 614 751 917
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Critical quality defects, which are those defects 
defined as potentially life-threatening or a serious 
risk to health, accounted for 231 of the total reports 
received. Of these, 100 (11% of the total for the year) 
were determined to affect Ireland. All related to 
medicines for human use. One further critical report 
related to tampering with packs of Nurofen Plus in 
the UK. While market action were taken in Ireland 
to check all packs at wholesale and pharmacy level, 
there was no evidence that the Irish market was 
affected by the issue.
The 100 critical quality defect reports included eight 
reports of falsified medicines from other competent 
authorities where the genuine product was 
manufactured in Ireland. In none of those cases was 
the falsified pack identified on the Irish market. 
The issues of concern in the remaining 92 critical 
quality defect cases were:
•	 Non-adherence	to	cold	chain	by	wholesalers	and	
manufacturers (57)
•	 Product	contamination	(17)
•	 Product	mix-up	(11)
•	 Undeclared	active	ingredient	identified	in	
products (5)
•	 An	unfavourable	shift	in	the	benefit/risk	profile	of	
a product as a result of newly acquired safety-
related information (1)
•	 Lack	of	therapeutic	efficacy	(1)
The type and number of all quality defects received is 
provided in the accompanying table.
Types of quality defects human quality defects veterinary quality defects
Contamination Issue 102 1
SPC/Carton/Label/Leaflet 97 2
Other Packaging Component 89 8
Stability 73 14
Cold Chain Issue 69 9
Non-Compliance with MA 62 5
Product Mix-Up 55 0
Damaged Product 55 8
Non-Compliance with Spec 51 3
Product Preparation/Administration 43 0
Unauthorised Product 34 2
Undeclared Active 31 0
Other 18 0
Lack of Sterility Assurance 17 0
Adverse Reaction/Change in Risk/Benefit 16 1
Erroneous Distribution 13 0
Counterfeit Issue 9 0
Non-compliance with GMP 7 17
Lack of Efficacy 6 0
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When compared with the quality defect data from 
2010:
•	 Contamination	issues	increased	by	52%	during	
2011. Part of this increase was attributable to the 
40 rapid alerts received from other competent 
authorities (compared to 11 the previous year);
•	 Product	mix-ups	increased	by	162%	with	
several products implicated in some cases. In 
particular, three individual incidents, which 
occurred at manufacturing facilities outside 
Ireland, accounted for 35 (64%) of the 55 product 
mix-ups. However, there were less individual 
occurrences of product mix-up than in 2010. 
•	 Damaged	product	cases	increased	by	75%	to	63.	
However, 38 of those cases related to a single 
incident at an Irish wholesaler.
(Stability issues decreased by 21 primarily due to re-
categorisation of the data.)
Sources of Quality Defects 
As in previous years, pharmaceutical companies 
accounted for the majority of reports of human 
medicine quality defects received (63%). While the 
total number increased from 429 in 2010 to 533 in 
2011, the percentage of the total remained similar. 
There was a 6% increase in the number of human 
medicine quality defects reported by other 
competent authorities compared to 2010.
Source – human Medicine Reports Number
Companies (Manufacturers, Distributors   
and/or MA Holders) 533
Other Competent Authorities 196
IMB Staff Members 51
Community Pharmacists 28
Hospital Pharmacists 27
Patients and/or Members of the Public 6
Physicians and Nurses 2
Other 2
In respect of veterinary medicines, other competent 
authorities again accounted for the majority of 
quality defect reports (63% in 2011, up from 53% the 
previous year).
Source – veterinary Medicine Reports Number
Other Competent Authorities 44
Companies (Manufacturers, Distributors   
and/or VPA Holders) 25
Department of Agriculture, Food and the Marine 1
Recalls of Human and Veterinary Medicinal 
Products 
In order to protect the health and safety of patients, 
it is deemed necessary in certain cases to withdraw, 
or recall, products from the Irish market. During the 
year in review, 253 medicine recalls occurred. Of 
these, 240 (95%) related to human medicines and 13 
to veterinary medicines. 
The recall from the Irish marketplace of a batch 
or a number of batches of a medicinal product 
occurred in approximately 28% of all quality defect 
cases investigated. This was an increase of 6% on 
2010. However, in a number of cases, these recall 
actions related to multiple products. The most 
significant example of this was a single instance 
of non-adherence to cold chain requirements that 
resulted in the recall of 65 products from the Irish 
market, accounting for 27% of all recalls in the year. 
Similarly, a recall to primary and secondary wholesale 
level relating to a damaged product resulted in 48 
human medicinal products being recalled, and this 
comprised 20% of all recalls. 
As shown in the accompanying table, product 
contamination issues, non-compliance with 
specifications and errors in printed packaging 
materials were some of the other issues that resulted 
in the recall of human medicines from the Irish 
market. 
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Type of quality defect – human Medicines 2010 2011
Non-adherence to Cold Chain 9 67
Damaged Product 12 38
Non-compliance with Specifications 5 28
Particulate or other Contamination 4 24
SPC/Carton/Label/Leaflet Issues *See note 2 below 17
Stability 9 13
Product Preparation/Administration Issue #See note 1 below 9
Unauthorised Product on the Irish Market 44 8
Lack of Sterility Assurance 3 7
Products Containing Undeclared Active Ingredients 6 5
Other Packaging Component issues *See note 2 below 5
Adverse Event/Change in Benefit/Risk Ratio 17 4
Erroneous Distribution 1 3
Non-compliance with MA 2 2
Product Mix-Up 4 2
Lack of Therapeutic Efficacy 0 2
Product Usage Issues 0 #See note 1 below
Packaging and/or Labelling 32 *See note 2 below
Other 10 6
Total Number 158 240
#Note 1: ‘Product Usage’ category is no longer in use and has been replaced by ‘Product preparation/administration  
 issue’.
*Note 2: This category has been sub-divided into: ‘SPC/Carton/Label/Leaflet issues’ and ‘Other Packaging Components  
 issue’.
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In respect of veterinary medicines, the above table 
shows that damaged product accounted for 8 of the 
13 product recalls.
Other findings from the recall programme include 
the following:
•	 Exempt	medicinal	products	distributed	on	the	
Irish market accounted for 23 (9%) of the human 
product recalls in 2011.
•	 Compounded	products	for	human	use	accounted	
for 24 recalls (10%). This related to one main 
issue.
•	 Of	the	products	recalled	from	the	Irish	market,	
59 (25%) were manufactured at an Irish 
manufacturing facility.  
•	 There	was	an	increase	in	the	number	of	recalls	to	
wholesale and patient level. This is in line with an 
increase in the number of both minor and critical 
quality defect issues that were reported and 
investigated. 
RETAIL SALES MoNIToRING 
Exempt Medicinal Products Programme
Medicines placed on the Irish market must be 
authorised by the IMB or, in the case of centrally 
authorised products, by the European Commission. 
However, European regulations do provide for an 
exemption to this rule. In this case, registered doctors 
and dentists are permitted to prescribe unauthorised 
medicines for individual patients under their direct 
responsibility in order to fulfil the special needs of 
those patients. Such products are defined as ‘exempt 
medicinal products’.
In accordance with the Medicinal Products 
Regulations 2007-2010, wholesalers and 
manufacturers of medicinal products are obliged 
to provide certain information to the IMB in relation 
to any exempt (unauthorised) products that they 
source. The main purpose of our receiving such 
information is to facilitate, when needed, the 
effective recall of any defective exempt medicines 
from the Irish market. 
Type of quality defect – veterinary Medicines 2010 2011
Damaged Product  0 8
Non-adherence to Cold Chain  0 3
Stability  3 1
Unauthorised Product on the Irish Market 3 1
Adverse Event/Change in Benefit/Risk Ratio 2 0
SPC/Carton/Label/Leaflet Issues *See note 1 below 0
Other Packaging Component Issues *See note 1 below 0
Packaging and/or Labelling  1 *See note 1 below
Other  1 0
Total Number 10 13
*Note 1: This category has been sub-divided into: ‘SPC/Carton/Label/Leaflet issues’ and ‘Other Packaging Components  
 Issue’.
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The total number of packs of exempt medicinal 
products notified was 1,474,564, an increase of 25% 
when compared with 2010. The IMB continues to 
work with stakeholders in several areas to identify 
and develop solutions in relation to reducing the use 
of exempt products in Ireland.
A number of significant non-compliances were 
identified with the supply of exempt products. 
As a result, three of the companies involved were 
required to perform a retrospective review of their 
notifications to the IMB. Corrections to the IMB 
database were subsequently required and these 
contributed to the increase in the notification figures 
for the year.  
General Retail Sale Investigations
There were 13 cases relating to non-compliance 
with requirements governing general retail sale 
of medicines investigated. These originated from 
complaints received by the IMB and from direct 
surveillance. The majority of cases investigated 
related to the sale of medicines not authorised on 
the Irish market. The number of cases investigated 
was considerably reduced relative to 2009 (43 cases) 
and 2010 (72 cases). The reduction in the level of 
non-compliances in this area is considered to be 
attributable to an increased awareness within this 
sector of the legislative requirements.
Regulatory Compliance Inspections 
These inspections are carried out at the premises 
of marketing authorisation holders and are fully 
risk-based. The programme of inspections enables 
the IMB to inspect compliance with a number of the 
legal requirements pertaining to the marketing and 
advertising of medicines in Ireland. Areas of activity 
that have a high potential to impact the quality 
and safe use of medicines are the main focus of the 
inspections carried out. These areas include the 
following:
•	 implementation	of	safety-related	changes	to	
product information and product labelling  of 
medicines placed on the market;
•	 management	and	communication	of	regulatory	
commitments and changes;
•	 management	of	approved	product	information;
•	 provision	of	a	medical	information	service	for	
healthcare professionals;
•	 presence	of	a	quality	management	system	to	
facilitate regulatory compliance;
•	 medicinal	product	advertising.
Five such inspections were carried out, including one 
that was performed jointly with the UK’s Medicines 
and Healthcare products Regulatory Agency 
(MHRA). The programme of regulatory compliance 
inspections has also enabled the IMB to inspect 
key areas of activity concerning the marketing and 
advertising of medicines by companies in Ireland. 
See the following section of this report for related 
information.
Human Medicines Advertising Compliance 
Programme
It is important that in the interests of public health, 
the benefits, uses and effects of medicines are 
promoted responsibly. It is the role of the IMB to 
monitor and review advertising and promotion 
activities by the industry for compliance with the 
requirements of the Medicinal Products (Control of 
Advertising) Regulations, 2007.
Overall, 471 individual advertisements were reviewed 
for compliance during 2011 through the IMB’s 
advertising compliance programme. This programme 
has four main components:  
•	 Proactive	Monitoring
− There were 299 advertisements across 
several different media reviewed. Of these, 
62% were reviewed as part of risk based pre-
planned proactive surveillance projects while 
38% were selected on a random basis. 
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− The proactive activity identified 40 individual 
advertisements that were non-compliant 
while 60 individual advertisements were 
found to be non-compliant during random 
surveillance work. 
•	 Inspection	of	Company	Advertising	Programmes
− Five regulatory compliance inspections 
were carried out at offices of marketing 
authorisation holders. In three of these cases, 
advertising programmes and activities were 
reviewed in detail.  
− A number of deficiencies were identified and 
the IMB oversaw the implementation of the 
necessary corrective and/or preventative 
actions.
•	 Advertising-related	Complaints
− A total of 17 advertising-related complaints 
were received from healthcare professionals, 
pharmaceutical companies, the general 
public, IMB staff and others. As part of 
the investigation of those complaints, 90 
advertisements were reviewed. 
− Of the complaints received, nine 
were deemed to be valid. These nine 
cases concerned 29 non-compliant 
advertisements. 
•	 Advertising-related	Queries
− Queries were received from a range of 
interested parties. These resulted in the 
review of 82 advertisements. Of those, 15 
were considered to be non-compliant.  
 Total Advertisements Non-Compliances   
  Reviewed Identified
Proactive Monitoring: Pre-planned Projects 10 185* 40 individual advertisements were  
   non-compliant
Proactive Monitoring: Randomly 14 114* 60 individual advertisements were 
Selected Projects    non-compliant
MAH Inspections Performed 5 Not quantified Several major and other deficiencies  
   identified
Complaints Received 17 90* 29 advertisements were found to be  
   non-compliant
Queries Received 62 82* 15 advertisements were found to be  
   non-compliant
*Note: Some of these figures include website advertisements, and each page of a website is counted as one   
 advertisement, because multiple pages can have multiple advertisements.  
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A breakdown of the advertisements reviewed based 
on the type of product promoted is provided in the 
accompanying graph. Of the 205 advertisements 
promoting prescription-only products, 44 (21%) 
were found to be non-compliant. In respect of 
advertisements promoting over-the-counter 
medicines, 63 (35%) were deemed non-compliant.
 
In all cases of non-compliance identified by the 
different elements of the programme, the IMB 
supervised the adoption of the necessary corrective 
and/or preventative actions by the marketing 
authorisation holder.   
Types of Product Advertising Reviewed in 2011
48 IMB ANNUAL REPORT 2011
Borderline Food
Borderline Medical Device
Exempt Medicinal Product
Unauthorised Medicinal Product
Borderline Food Supplement
Borderline Cosmetic
OTC Medicinal Product
POM Medicinal Product
0
181
205
50 100 150 200 250
1
4
5
11
21
43
MEDICAL DEVICES
vIGILANCE 
Post-market surveillance and vigilance is a key 
element in protecting the health and safety of those 
who use medical devices and it is a core function of 
the IMB.
The European medical devices directives (93/42/
EEC, 90/385/EEC and 98/79/EC) include requirements 
for medical devices manufacturers to report certain 
types of incidents to the national Competent 
Authority (IMB). The directives also outline the 
obligations on competent authorities to share details 
of certain incidents reported to them, between 
each other and with the European Commission. The 
vigilance system is the name given to the process of 
notification and evaluation of these incidents.
The IMB’s reporting system for incidents associated 
with medical devices is intended to protect the 
health and safety of patients, users and others by 
reducing the likelihood of the same type of incident 
being repeated across Europe and to correct product 
problems.
2011 Reports
A total of 1,775 medical device vigilance reports were 
received and assessed, which is an increase on 2010. 
As can be seen from the accompanying graph, since 
the IMB assumed the role of Competent Authority for 
medical devices, there has been a consistent upward 
trend in the number of vigilance cases received. 
Manufacturers accounted for 50% of all vigilance 
reports received in 2011 while 42% were received 
from competent authorities. Of the vigilance reports 
received, 33% were as a result of an incident on the 
Irish market. During the past year, the IMB issued 108 
competent authority vigilance reports. 
Of the vigilance reports received, 65% resulted in 
an action being taken. There were 227 product 
removals conducted in Ireland in 2011 and this was 
the most common action taken. The publication of 
a manufacturer’s field safety notice, which informs 
users of safety issues relating to medical devices, was 
the next most common action. Safety information 
was also highlighted to the public through IMB 
safety notices. There were 34 such notices sent to the 
relevant interest groups and published on the IMB 
website during 2011.  
2011 Report by Product Type
Orthopaedic implants, surgical equipment, infusion 
and transfusion devices accounted for a large 
proportion of vigilance reports. 
The continued reporting of revision procedures 
associated with the ASRTM Articular Surface 
Replacement and ASRTM XL Actabular system 
manufactured by DePuy contributed to the majority 
of the orthopaedic implant reports. In addition, 
vigilance reports following the explantation of breast 
implants manufactured by Poly Implant Prothese 
following global recall in 2010 continued to be 
submitted to the IMB. 
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The increasing trend in reports relating to diagnostic 
and radiotherapy software and equipment noted in 
2010 also continued throughout 2011.
  
In the area of in-vitro diagnostic (IVD) devices, the 
largest number of vigilance reports received related 
to clinical biochemistry. Field safety corrective 
actions relating to clinical chemistry analysers 
continued to have a high impact on the number of 
IVD vigilance cases.
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CoMPLIANCE
Medical device compliance activities are focused 
on protecting the health and safety of those 
who use medical devices. All potential safety and 
non-compliance issues identified are subject to 
investigation and non-compliant devices may be 
removed from the Irish market. 
In 2011, 882 compliance cases were investigated 
which was a 42% increase on the previous year 
and continues a broadly upward trend since 2004. 
Contributing to this increase was the fact that a 
significant amount of proactive compliance work 
was focused in the area of Class I and custom made 
devices, devices for sale in discount stores and 
pregnancy tests which are sold widely in Ireland.  
Similar to previous years, issues identified in 2011 and 
investigated as part of compliance cases included 
labelling problems, missing or incorrectly attached 
CE marking and classification issues.  
Of the total cases notified to the IMB, 71% were from 
other competent authorities and mainly related to 
notified body certificate withdrawals. A number 
of these reports related to certification changes 
resulting from the requirements outlined in European 
Directive 2007/47/EC.
MARKET COMPLIANCE OF COSMETICS
MARkET SuRvEILLANCE
Post market surveillance activity relating to cosmetics 
involves close co-operation between the IMB and 
the HSE. The HSE Environmental Health Service 
and the three Public Analysts’ Laboratories based 
in Cork, Dublin and Galway were involved in the 
preparation of the market surveillance schedule and 
the subsequent sampling and analysis of cosmetic 
products on the Irish market. 
Reactive surveillance included investigation of quality 
related complaints (compliance cases) and reports of 
undesirable effects relating to the use of cosmetics 
(vigilance cases). There were 106 compliance cases 
initiated during 2011 and these accounted for 
the vast majority of investigations. In addition, 22 
vigilance cases were investigated. 
There were also six recalls of cosmetic products in 
order to protect the health of consumers. Of these, 
four were related to high lead content in cosmetic 
products.
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RAPEX Alerts
Reactive surveillance of cosmetic products also 
includes investigation of in-coming RAPEX Alerts 
(EU safety alerts for cosmetic and other consumer 
products). The National Consumer Agency (NCA) 
is the national contact point for the receipt and 
circulation of these alerts. In conjunction with the 
HSE, the IMB investigated these alerts on the basis 
of risk and market action was taken as appropriate. 
Where the product in question was found on the Irish 
market, a reaction report was submitted to the NCA 
outlining the market actions taken. The IMB received 
114 such alerts. In the case of seven, the products 
were found to be on the Irish market. 
INSPECTIONS AND AuDITS 
As part of our regulatory role, the IMB is focused 
on ensuring industry compliance with relevant 
standards and legislation. Our inspections and audits 
work programme includes:
•	 Regular	inspections	of	manufacturers	and	
wholesalers of medicines to check for compliance 
to EU guidelines on Good Manufacturing Practice 
(GMP) and Good Distribution Practice (GDP), 
respectively. 
•	 Inspection	of	clinical	trial	sites	for	compliance	
with EU and International Conference on 
Harmonisation (ICH) guidelines on Good Clinical 
Practice (GCP). The GCP inspection programme 
includes inspection of sponsor companies, 
investigators, contract research organisations and 
laboratories and applies to clinical trials approved 
in Ireland and those performed in support of 
national and EU marketing authorisations.
•	 Inspection	for	compliance	with	Good	
Pharmacovigilance Practice of the systems put 
in place by marketing authorisation holders 
for dealing with reports of adverse reactions to 
medicines.
•	 Regular	audit	of	the	NSAI,	the	notified	body	for	
medical devices that is designated by the IMB. 
•	 Proactive	audit	of	manufacturers	of	Class	I	
devices and ‘for cause’ audits as required, for 
example, as part of the follow-up to a defect.
•	 Inspection	of	blood	and	tissue	establishments	
for compliance with applicable EU guidelines on 
the quality and safety of blood, blood products, 
tissues and cells. 
•	 Inspection,	often	in	conjunction	with	the	
National Drugs Unit of An Garda Síochána, of 
manufacturers and wholesalers of medicines 
containing controlled drugs (CD) and of 
precursors (chemicals that can be used in 
the preparation of illicit drugs) to check for 
compliance with security and record-keeping 
requirements for these controlled substances. 
ovERvIEW of ThE 2011 INSPECTIoN 
PRoGRAMME
During 2011, there was a total of 271 national 
inspections and audits performed compared to 
263 in 2010 and 238 in 2009. A further 29 foreign 
inspections and audits were performed in the past 12 
months, a figure broadly similar to the past two years. 
The average number of days required to close-out 
the inspections and audits was 79. 
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Performance Results and Statistics   2007  2008    2009    2010    2011
No. of national inspections and audits performed    239 228 238 293 271   
No. of foreign inspections and audits performed    13    27    28    30    29   
% inspections and audits closed on time (≤ 90 days)    79    67    58    62    66   
Average time for close-out (days)    139    89    112    194    79  
Total 263 394 400 420 442
In the past year, there were:
•	 76	GMP	inspections	performed.	These	included	
18 foreign inspections, 6 of which were carried 
out at the request of the European Medicines 
Agency for centrally-authorised products.
•	 114	inspections	performed	to	assess	
compliance with GDP and controlled drugs (CD) 
requirements. 
•	 18	GCP	inspections	completed.	Of	these,	13	were	
carried out at investigator sites in Ireland with 
two being GCP system inspections. In addition, 
three inspections were conducted outside of 
Ireland at the request of the European Medicines 
Agency.
•	 6	pharmacovigilance	inspections.	This	included	
three at Irish based marketing authorisation 
holders’ facilities and three inspections for 
centrally-authorised products that were 
conducted at the request of the European 
Medicines Agency.
•	 40	audits	of	Irish	medical	device	manufacturers	
(5 proactive and 7 reactive audits) conducted 
while 22 audits were performed of manufacturers 
of custom made medical devices. Audits of 
medical device manufacturers included proactive 
surveillance audits and ‘for cause’ reactive audits 
resulting from vigilance/market issues.  
•	 3	surveillance	audits	and	two	observed	audits	
of the National Standards Authority of Ireland 
(NSAI), the notified body for medical devices 
in Ireland, were carried out. As the Competent 
Authority, the IMB is responsible for the 
continued monitoring of the NSAI. In carrying out 
this role, we conducted surveillance audits at the 
NSAI’s offices and observed NSAI staff performing 
audits at device manufacturers’ premises. The IMB 
also performed one peer review audit of another 
EU Medical Device Competent Authority.
•	 4	blood	establishment	inspections	were	
completed. This included two inspections 
of facilities maintained by the Irish Blood 
Transfusion Service (IBTS).
•	 13	tissue	establishment	inspections	were	carried	
out. The majority of these inspections were 
routine compliance inspections at authorised 
tissue establishments.
In late 2010, the presence of pyrogens (bacterial 
fragments capable of causing elevated temperatures 
and other complications in patients) was detected in 
some products manufactured at an Irish site. This led 
to the suspension of manufacturing of the products 
concerned and the eventual recall of unused packs 
once sufficient replacement stocks were available. 
Investigation and follow up of these issues required 
considerable resources across the IMB as these are 
vital products and the site is a major supplier to 
the EU and other markets. Following a significant 
refurbishment programme and intensive inspections, 
the IMB approved the resumption of manufacture 
of the products concerned in October 2011. Close 
monitoring of the manufacturing site and of the 
usage of the products from there will continue in 
2012.
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ENFORCEMENT 
Illegal activity involving the manufacture, supply 
and sale of medicines or medical devices can 
potentially have consequences for public health. 
It is the role of the IMB to investigate potential 
breaches of human medicinal product and medical 
device legislation. Where necessary, we will take the 
appropriate corrective action including possible legal 
proceedings.
ENfoRCEMENT CASES
In 2011, a total of 4,549 enforcement cases were 
initiated internally by the IMB, compared to 3,936 
for 2010. This represents a year-on-year increase of 
16%. There were 4,475 cases closed during the past 
year, the majority of which were mail order/internet 
importations of prescription-only medicines.
dETAINEd MEdICINES
A total of 762,641 dosage units of medicinal products 
were detained. This represents a decrease of 7% 
compared to 2010. This 2011 figure includes 251,883 
dosage units detained which relate to weight-
loss products containing the active substance 
sibutramine. In addition, 63,270 dosage units 
detained related to erectile dysfunction products. 
Other products contained diazepam, zopiclone, 
flurazepam, Tribulus terrestris and anabolic steroids. 
The majority of these unauthorised medicinal 
products supplied into Ireland originated from China 
and India.
Medicinal products destroyed during the year, in 
compliance with the Waste Management Acts 1996 
to 2003, amounted to 4,519 kilograms.
A summary of the IMB enforcement data is provided 
in the accompanying table.
year 2007 2008 2009 2010 2011
Product detained 188,784 393,067 494,502 822,484 762,641 
 Dosage Units Dosage Units Dosage Units Dosage Units Dosage Units
Cases opened 1,397 3,037 3,729 3,936 4,549
Prosecutions 10 2 2 5 9
Product destroyed -- 1,902kg 2,601kg 1,400kg 4,519kg
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INTER-AGENCy Co-oPERATIoN ANd 
PANGEA Iv
The IMB liaises with other enforcement agencies, 
both nationally and internationally, to stem the 
unauthorised flow of illegal medicinal products, 
medical devices and cosmetic products into and out 
of the State. During the year, officers from the IMB, 
Revenue’s Customs Service and An Garda Síochána 
carried out a number of joint operations. These 
included joint activities under Operation Pangea 
IV in September 2011. This was a global initiative to 
identify and act against illegal websites supplying 
counterfeit and illegal medicinal products and it 
involved 83 countries worldwide. This operation led 
to the detention in Ireland of 51,621 tablets, capsules 
and creams with an estimated value in excess of 
€150,000. 
dISTRICT CouRT PRoSECuTIoNS
The IMB initiated nine prosecutions in the District 
Courts during the course of 2011:
•	 On	10	January	2011,	at	Richmond	District	Court	
in Dublin, Judge Bridget Reilly convicted Ms. 
Fang (Susan) Huang, trading as Rong Zing 
Supermarket, Parnell Street, Dublin 1, on a total 
of 10 charges. The charges related to the breach 
of manufacture regulations, prescription and 
control regulations, and packaging and labelling 
regulations. Judge Reilly imposed a fine of €500 
per charge and awarded costs of €5,550 to the 
IMB. Mr. Ji Rong Zheng, who owns the business 
and manages the finances, gave a commitment 
before the Court that he or his business 
would not engage in any unlawful activity in 
contravention of the Irish Medicines Board Acts. 
This undertaking was summarised in writing 
and was lodged with the conviction. A forfeiture 
order was issued by the Court for the 70 products 
detained during the investigation. 
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•	 On	11	January	2011,	at	Athy	District	Court,	
Judge Desmond Zaidan sentenced Ms. Mojisola 
Olubukola Soleye trading as Bimtom Ventures, 
Athy. Ms. Soleye had pleaded guilty to 11 
charges on 14 December 2010. The charges 
included importing unauthorised prescription-
only medicinal products from Nigeria and 
retailing prescription-only medicinal products 
from her shop in Athy. Judge Zaidan imposed a 
12-month sentence on each of two charges to 
run consecutively and suspended the custodial 
sentence provided that she did not come to the 
attention of the IMB or commit any offences 
within the next two years. Judge Zaidan also 
fined her €500 on each of six charges with the 
remaining five charges taken into account. 
Costs of €9,865 were awarded to the IMB and 
a forfeiture order was issued by the Court for 
the destruction of the 3,414 medicinal products 
detained during the investigation.  
•	 On	7	February	2011,	at	Richmond	District	Court	
in Dublin, Judge Bridget Reilly convicted Mr. 
Mike Ryan and his company Eustace Street 
Holdings Ltd, trading as Basic Instincts (an adult 
retail store), on 14 charges. The charges (seven 
for each party) were in relation to the supply of 
three prescription-only medicinal products by 
retail sale without a prescription and by mail 
order through the company website. In addition, 
convictions also included charges of having 
no product authorisation and advertisement 
offences. Judge Reilly fined both parties a total of 
€7,000 and awarded costs to the IMB of €3,752. A 
forfeiture order was also granted for all medicinal 
product detained during the case. 
•	 Mr.	Shaoib	Abbasi	was	convicted	on	seven	
charges at Clonmel District Court by Judge 
Terence Finn on 1 March 2011. Mr Abbasi 
was supplying medicinal products without a 
prescription, a manufacturer’s authorisation (for 
importation), a wholesaler’s authorisation or a 
marketing authorisation. He was also engaged 
in mail order of medicines. Judge Finn handed 
down a 10-month custodial sentence on each 
of five charges (concurrent) to be suspended for 
three years on a bond for good behaviour and 
fines of €3,000 on the two remaining charges. 
The Court heard evidence that two products 
in question were counterfeit and that €65,000 
was transacted through Mr. Abbasi’s account 
with €43,000 being sent on to Pakistan and 
Hong Kong. Costs of €2,000 were awarded to 
the IMB and a forfeiture order was issued for the 
destruction of all medicinal products detained 
throughout the investigation. 
•	 On	17	May	2011,	Judge	McMahon,	at	Navan	
District Court, convicted Mr. Patrick Joseph 
Delaney and his company The Natter Stores 
Limited which was trading as Day Brake, The 
Natter Stores, Clonee, Co. Meath. Mr. Delaney 
was found guilty on a total of three charges for 
supplying pharmacy-only medicinal products 
and for retailing packs of paracetamol tablets 
containing more than the permitted maximum 
of twelve tablets. Mr. Delaney was fined a total 
of €500 and The Natter Stores Limited was fined 
a total of €1,000 (€500 per charge) with costs of 
€1,000 awarded to the IMB. 
•	 On	23	May	2011,	at	Richmond	District	Court	in	
Dublin, Judge Blake convicted Mr. P. J. Delaney 
on eight charges. Mr Delaney was charged 
in connection with retail sale of pharmacy-
only medicinal products, for retailing packs of 
paracetamol tablets containing more than the 
permitted maximum of twelve tablets and for 
not possessing a marketing authorisation. Judge 
Blake fined Mr. Delaney a total of €6,950, and 
awarded costs totalling €4,550. The Judge also 
stated that Mr. Delaney showed no remorse for 
his actions and if Mr. Delaney appeared in his 
Court again on similar charges he would get a 
custodial sentence.  
•	 Mr.	George	Buckley	appeared	before	Judge	
Patrick McMahon at Navan District Court on 
6 July 2011. Mr. Buckley was convicted on 
nine charges of supply without a wholesaler’s 
authorisation, two charges of supplying 
pharmacy-only medicinal products and two 
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charges of supplying medicinal products without 
a marketing authorisation. Judge McMahon fined 
Mr. Buckley a total of €2,600 with six months to 
pay. In addition, costs of €3,750 were awarded to 
the IMB and a forfeiture order was issued for all 
products detained during the investigation.
•	 At	Carrickmacross	District	Court	on	20	July	2011,	
Judge Sean McBride convicted Mr. Michael 
Quinn and Cloughvalley Stores Limited on 
ten charges each. The charges concerned the 
retail sale of pharmacy-only and unauthorised 
medicinal products, and the retail sale of packs 
of paracetamol tablets containing more than the 
permitted maximum of twelve tablets. Judge 
McBride fined Cloughvalley Stores Limited a total 
of €8,000 and Mr. Quinn €6,000. The judge also 
awarded costs of €6,500 to the IMB. A forfeiture 
order for destruction of all medicinal products 
detained during the investigation was also 
issued. 
•	 On	15	December	2011,	Judge	Gráinne	Malone	
at Balbriggan District Court convicted Mr. Gou 
Hui Li (aka Tim Li) on thirteen charges. The 
charges resulted from the supply by retail sale of 
prescription-only medicinal products, supply by 
wholesale without a wholesaler’s authorisation 
and for not possessing a marketing authorisation. 
The products concerned were indicated for 
erectile dysfunction. Mr. Li made a charitable 
donation of €7,500 to Ruhama, a Dublin-based 
non-governmental organisation, and paid costs 
awarded to the IMB of €7,500. Judge Malone held 
over sentencing to 6 February 2012 at Swords 
District Court and fined Mr. Li €100 per charge, 
totalling of €1,300. 
The Director of Scientific Affairs provides scientific 
advice on an ongoing basis in respect of enforcement 
activities. This advice includes preparation of 
statements on various products to support 
enforcement actions on the products concerned. 
During 2011, 7 such expert statements were 
prepared.
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LEGISLATIVE AND REGULATORY 
DEVELOPMENTS
The legislative and regulatory environment in which the 
IMB operates is changing constantly and this has been the 
case since the establishment of the IMB as the national 
regulator in 1996. As a result, the remit and role of our 
organisation continues to change and expand in line with 
national and European legislative changes and in response 
to the addition of further competencies such as cosmetics in 
October 2010. 
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This section of our annual report outlines the most 
significant legislative and regulatory developments 
during 2011 for each of the healthcare products we 
regulate, how these changes influenced the work of 
the IMB and, where relevant, the associated impact 
on stakeholders.
HuMAN MEDICINES
PREPARING foR NEW Eu 
PhARMACovIGILANCE LEGISLATIoN
New EU pharmacovigilance legislation, adopted in 
December 2010, will begin to come into effect in 
July 2012. The new measures are intended to further 
promote and protect public health by strengthening 
the current European-wide system for monitoring the 
safety of medicines. Amending existing provisions, 
the new legislation is focused on improving the 
pharmacovigilance system in the EU, making the 
reporting of adverse reactions (or side effects) 
easier and the introduction of special provisions 
for medicines that need additional monitoring. The 
legislation also aims to ensure that members of the 
public become better informed about the benefits 
and risks of taking medicines.
Throughout 2011, the IMB worked with a wide range 
of stakeholders including the European Medicines 
Agency and other national regulators to prepare for 
the introduction of this new legislation. As part of 
this process, a public stakeholder day was organised 
in early December (details of which are included in 
the “Stakeholder Engagement and Communications” 
section of this report). Additionally, the IMB 
interacted with Irish and EU citizens impacted by the 
legislative changes through participation in European 
Medicines Agency stakeholder days. IMB staff also 
delivered presentations at these events. 
The IMB is committed to continuing our engagement 
with Irish and EU stakeholders including patient 
organisations, healthcare professional organisations 
and the pharmaceutical industry to ensure that the 
new legislation delivers on its objective of promoting 
and protecting public health while at the same time 
making best use of all available resources.
A designated section of the website www.imb.ie has 
been developed where additional information and 
guidance will continue to be made available in 2012.
oNGoING IMPLEMENTATIoN of ThE 2010 
vARIATIoNS REGuLATIoN
The IMB continued to apply the new Variations 
Regulation (Commission Regulation 1234/2008) for all 
variations to marketing authorisations submitted to 
the IMB in 2011. The new regulation came into force 
on 1 January 2010. In parallel, the IMB reviewed its 
internal procedures for the processing of variations 
in order to streamline and maximise the efficiency of 
those procedures while maintaining a high quality 
standard in the review process. One of the main 
outcomes of this review was a change in the approval 
process for variations.
oNGoING IMPLEMENTATIoN of ThE 
TRAdITIoNAL hERBAL MEdICINAL 
PRoduCTS dIRECTIvE
As outlined earlier in this report, the transitional 
period for traditional herbal medicinal products 
ended on 30 April 2011. A meeting was held with 
interested parties at the end of March and guidance 
on IMB policy was issued in advance of the April 
deadline. A question and answer document and 
other guidance were also published on our website 
including updated policy information at the end of 
December. Market surveillance, to monitor adherence 
to the policy, was carried out during the second half 
of the year.
fALSIfIEd MEdICINES dIRECTIvE
In July 2011, the EU adopted new legislation (Directive 
2011/62/EU, amending Directive 2001/83/EC) on 
falsified medicines for human use. The directive 
aims to strengthen the protection of patients and 
consumers by preventing falsified medicines entering 
the legal supply chain. The IMB is preparing for the 
introduction of elements of this directive which are 
required to be transposed nationally by January 
2013. The remaining measures will be transposed at 
defined times thereafter.
dECENTRALISEd PRoCEduRES WINdoW 
The IMB actively participates in this European 
approval system and a ‘window’ for requests for 
Ireland to act as RMS for DCP applications was first 
introduced in 2010. This window was opened once in 
2011 for the period January 2012 to December 2012 
inclusive. All requests were considered and successful 
applicants were allocated a dedicated slot for 
assessment. Detailed information on the process for 
submitting requests is available on www.imb.ie.   
uSER TESTING ANd BRAILLE 
In the interests of patient safety, it is critical that 
those who use medicines can access and understand 
the information included on packaging and the 
accompanying leaflet.
The Medicinal Products (Control of Placing on the 
Market) Regulations 2007 transposed European 
legislation requiring user testing of package leaflets 
into national law. These regulations, which came into 
force in July 2007, require all marketing authorisation 
holders (MAH) to submit user test reports carried out 
on the package leaflet and to introduce Braille to the 
outer packaging of all marketed products in Ireland 
by way of variation. The deadline for submission 
of reports was 30 October 2010. Assessment of 
these applications continued throughout 2011. 
By year end, more than 90% of these applications 
had commenced. Completion of these variations is 
expected in 2012.
PARALLEL IMPoRTS
In July 2011, the IMB published revised guidance in 
relation to parallel importation of medicines from an 
EU Member State or a country within the European 
Economic Area (EEA) which are already authorised 
on the Irish market. In order to legally distribute such 
products, a company must apply to the IMB for a 
parallel import licence. 
The IMB guide was updated following consultation 
with interested parties. In addition, an information 
meeting was held with parallel importers to present 
and discuss the revised document and changes to 
the IMB’s procedures for reviewing parallel import 
applications. The classification of variations for 
parallel product authorisations was also revised 
during 2011. 
CoNTRIBuTING To ThE EuRoPEAN ANd 
GLoBAL REGuLAToRy NETWoRk
Europe
Our participation in the European medicines 
regulatory system continued to be substantial during 
2011. IMB scientific and technical staff contributed 
to a broad range of committees and working parties 
at the European Medicines Agency, the European 
Commission, HMA, and other fora. This broad and 
significant involvement of IMB staff at European 
meetings is outlined in Appendix 4.
In addition to our regular participation at a European 
level, highlights from 2011 included the following: 
•	 The	Irish	delegate	(human	medicines)	to	the	
European Medicines Agency’s Quality Working 
Party (QWP) was appointed as rapporteur for 
the revision of the QWP guideline on process 
validation. It is anticipated that the guideline will 
be adopted by QWP for public consultation in 
early 2012. 
•	 During	2011	IMB	experts	were	heavily	
involved in a joint member state/European 
Medicines Agency project team to support 
the implementation of the new EU 
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pharmacovigilance legislation. The IMB was 
represented in the project teams, in the project 
co-ordination group and at project oversight 
level as a member of the HMA European Risk 
Management Strategy Facilitation Group. Key 
deliverables were contributions to the drafting 
of the technical contribution on the European 
Commission’s Implementing Measures and the 
first wave of Good Vigilance Practice Modules. 
•	 The	Irish	delegate	to	the	Pharmacovigilance	
Working Party at the European Medicines 
Agency represented the EU at the ICH E2C (R2) 
Expert Working Group. The ICH concept paper 
highlights the fact that the technology and 
science of pharmacovigilance has progressed 
significantly while the associated documentation 
has not kept pace. Revision of the E2C guideline 
will address this and ensure that regulatory and 
industry resources are more productively linked 
to public health protection and promotion.
•	 The	public	consultation	on	the	updated	
Commission Guidelines on Good Distribution 
Practice of Medicinal Products for Human Use 
closed on 31 December. A representative from 
the IMB oversaw the production of a section of 
this document as a member of the GDP drafting 
group.  
•	 Group	12	(Pharmaceutical	Dosage	Forms)	of	
the European Pharmacopoeia Commission met 
twice in 2011 under the chairmanship of the 
IMB’s Director of Scientific Affairs. A monograph 
on multi-dose veterinary oral pastes was 
developed by the Group while the monograph 
on oromucosal preparations and the dissolution 
test for medicated chewing gums were updated.
World Health Organization
The IMB Pharmacovigilance Manager was invited 
to join the Board of the Uppsala Monitoring 
Centre (UMC) and the World Health Organization 
(WHO) Collaborating Centre for International Drug 
Monitoring as one of the WHO’s representatives to 
this foundation for a three year period to December 
2013. This was a welcome endorsement of the 
contribution made by the IMB to pharmacovigilance 
practice at a global level and recognition in 
particular of the prominent role played by our 
Pharmacovigilance Manager, Ms. Niamh Arthur. 
IMB staff participated at the annual meeting 
of national centres participating in the WHO 
international drug monitoring programme and 
continued to provide details of reports received 
nationally to the WHO for inclusion on its 
international database. The volume of adverse 
reaction reports from Ireland continued to fall 
within the highest reporting rates among the 104 
participating countries in the programme (as of April 
2011). As can be seen from the accompanying graph, 
Ireland ranked as the sixth highest reporter in 2011 
(per million inhabitants). 
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Pharmaceutical Inspection Co-operation Scheme 
(PIC/S)
•	 The	Inspection	Manager	was	appointed	to	the	
Executive Bureau (management group) of the 
PIC/S and was due to take up the appointment 
on 1 January 2012.
•	 Two	week-long	training	seminars	for	new	
inspectors were hosted by the IMB in January and 
August under the auspices of the Pharmaceutical 
Inspection Co-Operation Scheme (PIC/S). These 
were designed to provide a thorough grounding 
to new inspectors on the conduct of inspections 
of manufacturers of medicines and were a further 
contribution to the harmonisation of global 
inspection standards.
CoNTRIBuTING To NATIoNAL hEALTh 
INITIATIvES
The IMB also contributes at various levels to national 
cross-agency initiatives. In 2011, these included:
•	 The	Research	Ethics	Advisory	Group	established	
by the Health Information and Quality Authority 
(HIQA) to draft standards for research ethics 
committees.    
•	 The	National	Rare	Diseases	Strategy	Steering	
Group established by the Department of Health.
•	 The	Ethics	Working	Group	of	the	Irish	Medical	
Council in relation to updating its guidance for 
doctors on interactions with pharmaceutical and 
medical device companies.
AdvISoRy CoMMITTEE foR huMAN 
MEdICINES
A new Advisory Committee for Human Medicines 
was appointed by the Minister for Health and 
Children in early 2011. The committee, which includes 
both newly appointed and a number of reappointed 
members, met three times during 2011. Among the 
topics discussed during those meetings were new 
applications for medicines, safety issues and updates 
on new legislation.  
VETERINARY MEDICINES
CoNTRIBuTING To ThE EuRoPEAN 
REGuLAToRy NETWoRk
Maximum Residue Limits for certain Flukicidal 
Medicines
Following the rejection by the European Commission 
of the proposed maximum residue limits (MRLs) for 
certain flukicidal veterinary medicines used in cattle 
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on the basis that the legal basis was incorrect, the 
IMB submitted revised MRL applications for milk 
to the EMA in August 2011. By year-end, positive 
opinions had been delivered to the European 
Commission for the substances clorsulon, closantel, 
nitroxynil and triclabendazole. The establishment of 
MRLs is expected to improve consumer confidence 
in the safety of milk and milk products and to 
remove uncertainty regarding the conditions of use 
of such products in dry-cows within the European 
Community. 
WoRk-ShARING INITIATIvES WITh ThE uk’S 
vETERINARy MEdICINES dIRECToRATE
In the interests of improving the availability of 
veterinary medicines in Ireland, the IMB expanded 
its work-sharing initiatives with the UK’s Veterinary 
Medicines Directorate (VMD) during 2011. A primary 
objective of these initiatives was to facilitate 
companies in having common packaging for more 
than one market, thereby allowing the production of 
more economical batch sizes. An existing agreement 
between the IMB and the VMD on work-sharing in 
respect of the assessment of variations to products 
marketed in both countries was expanded during 
the year to include applications in Belgium and the 
Netherlands. This development is also expected to 
reduce the overall regulatory costs in all participating 
countries, thereby helping to reduce the regulatory 
burden on companies. The IMB and the VMD also 
published a joint product literature standard to 
facilitate applicants in the production of common 
labels for Ireland and the UK.
CoNTRIBuTING To NATIoNAL hEALTh 
INITIATIvES
The IMB participated in an initiative undertaken 
under the aegis of the Department of Agriculture, 
Food and the Marine to help minimise the 
development of anthelmintic resistance in Irish 
sheep. This initiative will see the introduction of new 
symbols on certain anthelmintics which will allow for 
more effective use of the medicines concerned. 
AdvISoRy CoMMITTEE foR vETERINARy 
MEdICINES 
A new Advisory Committee for Veterinary Medicines, 
including both existing and new members, was 
appointed by the Minister for Health and Children 
in consultation with the Minister for Agriculture, 
Fisheries and Food in early 2011. The Committee 
has a general statutory role in providing advice to 
IMB staff in relation to scientific matters concerning 
veterinary medicines brought to its attention. It has a 
specific statutory role in providing advice to the IMB’s 
Board when it proposes to refuse an application for 
authorisation of a medicine or a manufacturer. The 
committee met three times during the year. 
MEDICAL DEVICES
REvISIoN of EuRoPEAN MEdICAL dEvICES 
dIRECTIvES
The three existing European directives defining the 
regulations for medical devices are subject to an 
ongoing major revision by the European Commission. 
It is expected that during 2012, the Commission will 
adopt draft legislative proposals for discussion by 
the European Council and Parliament. This initiative 
was fully supported during 2011 by the IMB. It is 
expected to be under active discussion during the 
Irish Presidency of the European Council in the first 
half of 2013.
CoNTRIBuTING To ThE EuRoPEAN 
REGuLAToRy NETWoRk
Medical Devices Directives
A proposal made jointly by the IMB and the Austrian 
Ministry for Health to establish a recast working 
group of the Competent Authority for Medical 
Device (CAMD) network was endorsed at the 27th 
CAMD meeting in February in Budapest. This group 
allows for detailed technical discussions on specific 
elements of the proposed revision to the medical 
devices legislation and for close co-operation 
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between European competent authorities, health 
ministries and the European Commission. During 
December 2011, we hosted the sixth meeting of the 
working group at the IMB offices in Dublin.
Resourcing the European Medical Devices 
Regulatory Network
During 2011, we held a series of meetings in close 
co-operation with colleagues from the UK’s MHRA, 
with the European Commission, the medical device 
industry, notified bodies for medical devices and 
other interested stakeholders. The meetings were 
held to discuss the proposed development of new 
structures and mechanisms to optimise resourcing of 
the medical devices regulatory network and to create 
a funding mechanism which is fair, transparent and 
easy to use.
In March 2011, as part of this process, the IMB 
Chief Executive was invited by the European 
Commission to make a presentation on optimising 
resources and co-ordination of the medical devices 
regulatory framework to the Commission’s High-
level Conference ‘Exploring Innovative Healthcare 
– the role of Medical Technology Innovation and 
Regulation’.
European Commission Guidance Documents
During 2011, the IMB also contributed significantly 
to MEDDEV guidance documents compiled by 
subgroups of the European Commission’s Clinical 
Investigation and Evaluation Working Group.
Developing a European Health Products 
Regulatory Network
In 2011, the IMB also led on discussions to seek 
development of formal co-operation between the 
existing Heads of Medicines Agency (HMA) network 
and the medical devices networks represented by 
the Competent Authority for Medical Device (CAMD) 
and the Central Management Committee (CMC). Our 
objective is to develop a larger, inclusive ‘European 
Health Products Regulatory Network’ comprised 
of regulators from human medicines, veterinary 
medicines and medical device authorities. The aim 
is to promote mutual co-operation, exchange of 
experience and best practice, and shared decision 
making while optimising resources available to the 
network. 
Through the IMB-led initiative to enhance co-
operation between the HMA and CAMD/CMC 
networks, an initiative to examine the regulation 
of different types of drug-device and combination 
products throughout Europe was also launched 
during 2011.
Notified Body Oversight
The IMB is leading work items on notified body 
oversight for the recently established Central 
Management Committee (CMC) for medical devices. 
During 2011, the committee decision to endorse, 
implement and audit against best practice guidance 
from the Notified Body Oversight Group (NBOG) was 
created and proposed by the IMB. In addition, the 
IMB was appointed to lead on new work items to 
develop CMC proposals, in close co-operation with 
experts from NBOG, on:
•	 New	process	for	designation	and	ongoing	
monitoring of notified bodies for medical devices 
with enhanced co-operation on these activities 
across Europe;
•	 New	criteria	and	requirements	for	notified	
bodies defining general, organisational, quality, 
procedural and resource requirements to operate 
as a notified body for medical devices.
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AdvISoRy CoMMITTEE foR MEdICAL 
dEvICES 
A new Advisory Committee for Medical Devices, 
including both existing and new members, was 
appointed by the Minister for Health and Children 
in 2011. The committee met three times during the 
year and considered topics such as key post-market 
surveillance/safety issues, updates on monitoring 
of medical device notified bodies and the ongoing 
revision of the medical devices regulatory framework.
ADVANCED THERAPIES
Applications for marketing authorisations for 
advanced therapy medicinal products (ATMPs) 
proceed via the EU centralised procedure as laid 
down in Regulation 726/2004/EC. The Regulation 
provided for the establishment of a specialised 
Committee on Advanced Therapies within the 
European Medicines Agency. The Committee has 
one member and one alternate member from each 
Member State with Ireland represented by the IMB.
The IMB internal group on biological products and 
ATMPs continued to meet during 2011 as a forum for 
internal exchange of information on ATMPs, tissue 
and blood and biological products generally. Also 
during the past year, the IMB collaborated with the 
Parenteral Drug Association, Ireland Chapter, to 
prepare an international conference on gene and 
cell therapy to be held in Dublin during July 2012 in 
conjunction with Dublin City of Science.
HuMAN ORGANS FOR 
TRANSPLANTATION
The Minister for Health appointed the IMB to the role 
of national Competent Authority for the directive 
on standards of quality and safety of human organs 
intended for transplantation (2010/53/EU). An 
internal multidisciplinary group was established to 
facilitate review of the requirements of the directive 
and to develop an appropriate framework for 
implementation of the requirements which are due 
to come into effect in August 2012. The IMB was also 
represented on an implementation steering group 
convened by the Department of Health.
COSMETICS
TEETh WhITENING PRoduCTS dIRECTIvE
Directive 2011/84/EU concerning the use of hydrogen 
peroxide in teeth-whitening/oral care products 
was adopted in September 2011. According to 
the new directive, products with less than 0.1% 
hydrogen peroxide may be made available directly 
to consumers. However, products having between 
0.1% to 6% hydrogen peroxide content may only 
be supplied to and administered by dentists. All 
other tooth-whitening products with more than 6% 
hydrogen peroxide will no longer be available in the 
European Union. 
The directive, which is being introduced to ensure the 
safety of European consumers, will come into force 
in October 2012. The IMB commenced preparations 
for its introduction during 2011 in co-operation with 
other relevant authorities.
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STAKEHOLDER ENGAGEMENT 
AND COMMUNICATIONS 
The IMB is committed to expanding and improving our 
communications activities and to ensuring that all our 
stakeholders have timely access to relevant safety, licensing 
and regulatory information. This commitment is one of our 
core strategic goals and will continue to be an area of focus 
and development for the IMB over the coming years.
A number of significant communications programmes and 
initiatives took place during 2011.
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STAkEhoLdER ENGAGEMENT
Consultative Panel on the Legal Classification of 
Medicines
The Consultative Panel on the Legal Classification of 
medicines held its first meeting in December 2011. 
The Panel is independently chaired and consists 
of external representatives drawn from a wide 
range of interested stakeholders including patients, 
healthcare professionals, the Department of Health 
and relevant government agencies. The aim of the 
Panel is to support the existing scientific assessment 
within the IMB of applications for reclassification of 
medicines. The panel will provide advice on external 
socioeconomic and policy issues that should be 
considered when determining the appropriate 
classification of medicines. Quarterly meetings are 
planned to consider the outcome of the public 
consultation process on the legal supply classification 
of medicines which was held during 2011. 
Meetings with Stakeholders – Human Medicines
Two joint meetings were held with the Association 
of Pharmaceutical Manufacturers in Ireland (APMI) 
and the Irish Pharmaceutical Healthcare Association 
(IPHA). At these bi-annual meetings, key regulatory 
issues of mutual concern are discussed. In 2011, these 
issues included assessment outputs, labelling and 
electronic submissions. 
In March 2011, IMB staff held a meeting with the 
Irish Association of Health Stores (IAHS), the Irish 
Health Trade Association (IHTA) and herbal medicines 
companies and distributors. This meeting focused 
on the imminent 30 April 2011 deadline for the 
registration of traditional herbal medicines. 
A parallel product authorisation information session 
was held at the IMB in April 2011. It was attended 
by most of the applicant companies. The updated 
Guide to Parallel Imports was presented and issued 
for consultation. Details on how the IMB will handle 
new source country variation applications which 
have been submitted with out-of-date product 
information was raised with a follow up letter 
subsequently sent to licence holders.
Three half-day information seminars were held in 
June for general sale wholesale distributors. The 
sessions were held in Portlaoise and Sligo and topics 
included supplier approval, the receipt of medicinal 
products and the storage of medicinal products 
including management of temperature excursions.
A meeting of an Advertising Compliance Technical 
Group including representatives from the IMB, the 
APMI and the IPHA was held in April. Issues of mutual 
interest were discussed including clarification of 
the IMB’s interpretation of a number of aspects 
of the Medicinal Products (Control of Advertising) 
Regulations 2007 and anonymised feedback 
on findings from our advertising compliance 
programme.
Meetings with Stakeholders – Veterinary 
Medicines
The IMB hosted a number of pre-application 
meetings during 2011 for interested parties. Such 
meetings provide applicants intending to use the 
IMB as reference member state in future European 
application procedures with an opportunity to 
outline their proposed applications and to seek 
clarification on regulatory matters. Two meetings 
were also held with the Department of Agriculture, 
Food and the Marine to discuss matters of mutual 
interest. Additionally, we also met with the Irish 
Pharmacy Union.
Meetings with Stakeholders - Manufacturers of 
Medicines
A joint meeting was held with the Animal and 
Plant Health Association (APHA), the Association of 
Pharmaceutical Manufacturers in Ireland (APMI) and 
Pharmachemical Ireland (PCI). At this annual meeting, 
key manufacturing issues of mutual concern are 
discussed. In 2011, these issues included revisions 
to the EU Guide to Good Manufacturing Practice, 
the Falsified Medicines Directive (2011/62/EU), and 
obligations of authorised/licensed manufacturers. 
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Meetings with Stakeholders – Medical Devices 
During 2011, four meetings were held with the 
Department of Health to discuss medical device 
issues. These useful meetings allowed for discussion, 
advice and exchange of information in respect of:
•	 Developments,	revision,	policy	and	interpretation	
of medical devices legislation.
•	 Updates	on	specific	post-market	surveillance	
issues such as IMB safety notices, field safety 
corrective actions and recalls of medical devices.
•	 Oversight	and	ongoing	monitoring	of	notified	
bodies at national level and in Europe.
•	 Clinical	investigation	and	research	activities	in	
Ireland.
Meetings were held during 2011 with the Irish 
Medical Devices Association (IMDA) to discuss 
regulatory issues affecting the medical device 
industry in Ireland. These issues included the 
ongoing revision of the medical devices legislation, 
clinical investigations and oversight of notified 
bodies for medical devices. 
Regular meetings were also held with the National 
Standards Authority of Ireland (NSAI), the notified 
body for medical devices in Ireland. These meetings 
focused on new legislation, regulatory guidance, 
requirements and policies. Discussions were also 
held in respect of audit findings and follow-up and 
regarding issues identified by NSAI during the course 
of their certification activities.
Throughout 2011, many additional meetings with 
medical device stakeholders were held by the IMB 
to discuss the major revisions to the medical devices 
legislation expected during 2012. The focus of these 
meetings was the impact of the possible changes on 
the many different stakeholder groups involved. In 
addition, IMB contributions to the development of 
the European regulatory network were discussed. 
These included the development of proposals to 
optimise the utilisation of resources and funding 
as well as efforts to further develop co-operation 
between the medicines and medical devices 
networks.
The IMB also held a range of meetings throughout 
2011 with academics, clinicians, innovators and 
established medical device manufacturers to discuss 
the further development of different types of medical 
technologies. Regulatory requirements, clinical 
investigation of devices in Ireland and post-market 
requirements were among the topics considered. 
Information Days
IMB information days provide regulatory guidance 
and updates to a range of stakeholders. As well as 
presentations from IMB staff and, where appropriate, 
external contributors, the events enable all attendees 
to submit questions, seek clarifications and network 
with colleagues. Two information days were held 
during 2011:
•	 A	veterinary	medicines	information	day	was	
held on 6 October. The event was focused on 
updating stakeholders on current regulatory 
topics and ongoing IMB activities and initiatives. 
Part of the session also examined the expected 
changes in the EU legislation governing the 
authorisation and monitoring of veterinary 
medicines. External subject matter experts, 
including a representative from the Department 
of Agriculture, Food and the Marine, joined the 
IMB in delivering presentations.
•	 An	information	day	addressing	the	
implementation of the new European 
Pharmacovigilance legislation was held on 2 
December. This event was attended by over 250 
participants including patient representatives, 
healthcare professionals, academic institutions, 
professional bodies and the pharmaceutical 
industry. The agenda for the day included a 
review of the amendments and a discussion on 
the relevant implications for pharmacovigilance 
processes, marketing authorisations and public 
participation. There was a particular focus on the 
impact the new legislation will have on patients, 
healthcare professionals, the pharmaceutical 
sector and the IMB. Representatives from the 
Department of Health, the European Medicines 
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Agency, the UK’s Medicines and Healthcare 
products Regulatory Agency and the European 
Organisation for Rare Diseases joined the IMB 
in delivering presentations. Feedback from 
delegates confirmed the success of the meeting 
in terms of raising awareness of the requirements 
of the new legislation and promoting exchange 
of ideas, concerns and opinions.  
Presentations to Stakeholders
Throughout 2011, the IMB invested significant time 
in delivering a programme of presentations and 
talks at a range of external stakeholder events such 
as meetings, seminars, conferences and training 
courses. In addition, a programme of presentations 
was delivered to undergraduate and post graduate 
students studying courses related to the role of the 
IMB.
Such presentations contribute to the IMB goal of 
providing stakeholders including patients, healthcare 
professionals and regulatory professionals with 
access to relevant, up-to-date information. The 
presentations are delivered by IMB staff from across 
the organisation and cover all products and functions 
under our remit. While some are general in nature 
and primarily focused on explaining the role of 
the IMB, others were more specific and dealt with 
specialist areas and/or new regulatory developments. 
A full list of all presentations delivered during 2011 is 
provided in Appendix 2.
PuBLICATIoNS
Guidance Documents
IMB guidance documents provide stakeholders, 
primarily from the industry sectors we regulate, 
with advice and direction in respect of legislation 
and regulatory requirements. New and updated IMB 
guidance documents are published regularly on our 
website with alerts issued to website subscribers. 
During 2011, six new guidance documents were 
published while a number of existing documents 
were updated. A full list of these documents is 
provided in Appendix 3. 
Also in 2011, the IMB and the Department of 
Agriculture, Food and the Marine collaborated on 
drafting a guidance document addressing cosmetic-
biocide borderline products. The guidance was 
issued for public consultation in October.
In addition, a frequently asked questions (FAQ) 
document relating to advertising compliance for 
human medicines was published on the IMB website.
Newsletters
Medicinal Products Newsletter
This newsletter provides regulatory updates for those 
working in the pharmaceutical and cosmetics sectors 
on Irish and European legislation, new/revised IMB 
regulatory publications and stakeholder events such 
as information days. 
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Three Medicinal Product Newsletters were published 
during 2011. Topics covered included:
•	 Details	regarding	changes	to	the	submission	of	
product information to the IMB
•	 Homeopathic	medicines	update
•	 Experience	to	date	with	the	new	Variations	
Regulation
The newsletter is published on the IMB website 
and issued to those who subscribe to the IMB alerts 
system via our website. 
Drug Safety Newsletter
This newsletter is published on a regular basis and 
aims to provide healthcare professionals with up-to-
date information and clinical advice regarding the 
safe use of medicines. 
Six issues of the IMB’s Drug Safety Newsletter 
(including one edition with a special insert on 
intravenous paracetamol) were distributed to 
doctors, dentists and pharmacists during 2011. The 
publication is circulated by a combination of post 
and email and is available to download from the IMB 
website. Topics covered in the past year included 
a wide range of safety issues a full list of which is 
provided in Appendix 3.  
Medical Devices Newsletter 
This newsletter provides regulatory and safety 
updates for those working in the medical devices 
sector and professionals working in the health area 
who regularly use or purchase medical devices. It 
provides updates on Irish and European legislation, 
on safety issues as well as details of IMB medical 
devices publications and stakeholder events. The 
newsletter includes articles from both IMB and 
external contributors. 
During 2011, the IMB published three Medical Devices 
Newsletters. Topics included:  
•	 Safety	information	for	users	of	medical	devices.	
A full list of such articles from the past year is 
included on in Appendix 3.
•	 Manufacturer	and	notified	body	information	
such as regulatory updates, regulatory guidance 
on the legal term ‘placing on the market’ and new 
requirements for the European medical device 
database (EUDAMED).
•	 Scientific	articles	on	tissue	engineering	and	
neural engineering.
External Articles
Pharmacovigilance
There were 15 IMB articles published in MIMS Ireland. 
One article was published each month while the 
remaining three were part of special supplements. 
MIMS (Monthly Index of Medical Specialities) is an 
independently edited publication designed as a 
prescribing guide for general practitioners. Two 
further articles were published in the Irish Medicines 
Formulary (IMF). The IMB also provided an article 
for inclusion in the Journal of the Irish Dental 
Association. The full list of topics covered in these 
articles in included in Appendix 3. All articles were 
also published on the IMB website.
Veterinary Medicines
Consistent with our objective to improve stakeholder 
knowledge on the use of veterinary medicines, we 
contributed several articles to the veterinary/trade 
publications (1) Veterinary Ireland Journal and (2) It’s 
Your Field.
The topics covered in these articles are listed in 
Appendix 3.
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Safety Warning and Notices 
Throughout 2011, the IMB published various warning 
statements and notices on safety issues or benefit/
risk evaluations of human medicines. There were 
44 Direct Healthcare Professional Communications 
concerning human medicines published on the 
IMB website and issued to subscribers. Separately, 
34 medical devices safety notices were sent to the 
relevant stakeholder groups and published online.
IMB Advice on Automated External Defibrillators
In December 2011, the IMB published an information 
leaflet providing advice to people on how to correctly 
maintain an automated external defibrillator (AED) so 
that it works effectively in the event it is needed in an 
emergency. 
AEDs can improve a person’s survival chances 
following sudden cardiac arrest when used in an 
emergency situation. The leaflet highlights the critical 
importance of maintaining, storing and servicing the 
AED correctly to ensure it is always in good working 
order. It was produced in light of the increased 
availability of AEDs in Ireland over the past number 
of years and a notable increase in the number of AED 
related issues reported to the IMB.
The AED leaflet is available for download from the 
IMB website. Printed copies can also be requested by 
calling the IMB directly.
MEdIA CoMMuNICATIoNS
Throughout 2011, we continued our media 
communications programme to proactively 
communicate important safety messages and to 
build awareness of the role of the IMB. We issued 
37 press releases concerning safety and regulatory 
issues to ensure consumers, healthcare professional 
and other stakeholders received timely and accurate 
information and advice. In a number of instances, 
these communications resulted in national and 
regional media interviews with an IMB spokesperson. 
Among the issues highlighted by IMB press releases 
during the past year were:
•	 The	dangers	of	mail	order	and	illegal	prescription	
medicines 
•	 Rise	of	66%	in	illegal	medicines	detained	in	2010
•	 The	risk	of	high	levels	of	lead	in	certain	children’s	
face paints 
•	 New	advice	for	use	of	cough	and	cold	medicines	
in children
•	 Operation	Pangea	IV	targeting	the	online	sale	of	
counterfeit and illegal medicines 
In addition, we responded to 438 queries from 
national, local and specialist media during the year. 
Providing responses to such queries involves subject 
matter experts from across the organisation. 
72 IMB ANNUAL REPORT 2011
PuBLIC CoNSuLTATIoNS
Public consultations enable the IMB to identify the 
needs and expectations of stakeholders so that we 
may incorporate their views into the way our services 
are planned and delivered.
During 2011, the IMB completed public consultations 
on:
•	 Fees	for	2012	
•	 Legal	supply	classification	of	medicinal	products	
•	 Herbal	substances	classification
The IMB also makes submissions to third party 
consultations where the topic is related to or impacts 
our regulatory functions and the broader public 
health agenda. During 2011, we participated in the 
following consultations: 
•	 Crisis	pregnancy	strategy	(HSE	Crisis	Pregnancy	
Programme) 
•	 Accreditation	standards	(Pharmaceutical	Society	
of Ireland) 
•	 Nurse	prescribing	(Department	of	
Health) 
•	 Core	competency	framework	(Pharmaceutical	
Society of Ireland) 
•	 Risk	Review	Group	examination	of	vaccine	under-
dosing (Pharmaceutical Society of Ireland)
 
WEBSITE
The website www.imb.ie is a key component of 
our communications programme. The site outlines 
the primary functions and activities of the IMB and 
facilitates the dissemination of information to a 
wide variety of audiences including patients and 
consumers, healthcare professionals and industry 
personnel. As new content is regularly added 
to the website, we are focused on its continued 
development and enhancement to ensure it remains 
an attractive and user-friendly resource.
2011 Statistics
•	 Almost	126,000	unique	visitors	accessed	the	
website during the past twelve months resulting 
in close to 345,000 visits in total. 
•	 Over	60%	of	visits	to	the	website	originated	from	
Ireland, 11% from the UK and 6% from the US.
•	 Of	the	unique	visitors,	34%	were	new	or	first	time	
users of the site. 
•	 Among	the	most	popular	sections	of	the	website	
were the human and veterinary medicines 
listings and publications.
 
Veterinary Medicines
The veterinary medicines section of the IMB 
website was substantially revised early in 2011 to 
provide more relevant content. A specific veterinary 
medicines page was created with a link included 
on the homepage. In addition, an online reporting 
form for the notification of suspected adverse events 
was introduced. Further improvements include 
a monthly listing of newly authorised products 
as well as information on licensing procedures 
and reporting of adverse reactions. New content 
concerning medicines availability and safety advisory 
notices relating to veterinary medicines were also 
incorporated.  
Pharmacovigilance
A dedicated webpage on the new pharmacovigilance 
legislation was developed. Additional information 
and guidance will continue to be published on this 
webpage.
BT youNG SCIENTIST ANd TEChNoLoGy 
ExhIBITIoN 2011
Thousands of students as well as teachers, parents 
and members of the general public from all over 
Ireland visited the IMB’s exhibition stand at the BT 
Young Scientist Exhibition 2011. The exhibition took 
place in mid-January in the RDS and it was the second 
year in succession the IMB was involved. 
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Our stand focused on building awareness of the 
significant role the IMB plays in protecting public 
and animal health. In particular, the important 
issue of medicines and medical devices safety was 
highlighted. The stand also focused on the many 
interesting science related career opportunities that 
are available in the healthcare products industry.
fREEdoM of INfoRMATIoN
The IMB is subject to the Freedom of Information Acts 
1997 and 2003. The Acts assert the right of members 
of the public to obtain access to official information 
to the greatest extent possible consistent with public 
interest and the right to privacy of individuals. During 
2011, the IMB received seven Freedom of Information 
requests consisting of six non-personal requests and 
once personal request. While none of these requests 
were appealed to the Information Commissioner, 
three appeals to the Information Commissioner from 
2010 were finalised and closed.
PARLIAMENTARy quESTIoNS 
During 2011, the IMB received and responded to 34 
parliamentary questions, and four representations. 
Over half of the queries related to human medicines 
and the majority of the remainder related to staff, 
payroll and expenditure. A number of other queries 
from our parent department, the Department of 
Health, were received and responded to.
CuSToMER SERvICES
In 2011, the customer services team responded 
to 3,078 queries from industry representatives, 
healthcare professionals and members of the public. 
Queries were received primarily via email and by 
phone. Over 2,000 of these queries concerned human 
medicines with many relating to product variations as 
well as product information and packaging. 
In addition to the queries managed by customer 
services staff, a range of stakeholder queries are 
addressed by specialist staff across the organisation. 
Many of these queries come from healthcare 
professionals requesting information about specific 
medicines.
Also during 2011, 466 queries were received that 
related specifically to medical devices.
RESEARCh
Attitudes Towards Direct Healthcare Professional 
Communications
In collaboration with the School of Pharmacy, Trinity 
College Dublin, an initial pilot research project was 
undertaken to evaluate healthcare professional 
awareness and attitudes towards Direct Healthcare 
Professional Communications. Results will be 
published during 2012.
Consumer Attitudes towards the Regulation of 
Herbal Medicines
Research carried out by the IMB during 2011 revealed 
that some 8 out of 10 consumers think it is important 
that traditional herbal medicines should be 
regulated. The same number believe it is necessary to 
inform their doctor when taking a herbal medicine. 
The survey findings were released in advance of 
the new regulatory system for traditional herbal 
medicines which came into effect across all EU 
member states on 1 May 2011.
Industry Experience of National Procedures for 
Veterinary Medicines
The IMB surveyed applicant companies on their 
experiences with national procedures in place to 
improve medicines availability. Results of the survey 
were used to introduce changes to procedures to 
facilitate applicant companies and improve the 
efficiency of the procedures. 
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ORGANISATIONAL MANAGEMENT 
AND DEVELOPMENT
It is essential that the IMB has in place the requisite 
corporate functions, systems and supports to ensure we 
deliver on our public health mission. We must be flexible 
and proactive as an organisation to respond to regulatory 
and other external developments, and to adopt necessary 
changes in how we deliver our services. We must also 
ensure that the highest levels of corporate governance are 
developed and maintained. 
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huMAN RESouRCES 
The IMB’s people management practices and policies 
are developed to contribute to the achievement 
of our strategic goals and to attract and retain the 
relevant skills to maintain organisation capability. 
While adapting our structures and work practices to 
enable us to manage our human resources within 
the constraints of the public sector environment, 
the following projects were delivered or progressed 
during 2011:
•	 Arising	from	our	2010	Learning	and	
Development strategy was the requirement 
for further development of leadership skills 
across the organisation. As a consequence, 
a programme for managers was launched in 
September 2011. Ten managers from across the 
organisation at various levels are participating 
in this initiative which will run throughout 2012. 
The objectives of the programme are:     
− To support the development of managers 
within the IMB, to evaluate the skills they 
have and how they are applying them now 
and for the future;
− To develop skills and behaviours in line with 
the IMB’s Leadership Capability Framework; 
− To foster collaboration across different 
functions and promote an understanding of 
cross functional roles and projects.
•	 While	recognising	the	constraints	on	public	
sector employment numbers, in the context of 
the IMB status as predominantly a self-funded 
agency, we submitted a proposal on future 
staffing requirements to the Department of 
Health. This proposal focused on obligations 
arising from new responsibilities being assigned 
to the IMB by the Department as well as 
the impact of the introduction of a range of 
legislative changes between now and 2015. It is 
vitally important that the IMB has the resources 
in place to fulfil our statutory obligations and 
to serve the related requirements of all our 
stakeholders.  
•	 A	risk-based	approach	to	the	assessment	of	
a range of application types was adopted 
across the IMB thus targeting resource time to 
areas of greatest priority. While this approach 
will continue to be rolled out it will require 
ongoing monitoring in the context of increasing 
workloads and application complexity.
•	 We	have	maintained	our	focus	on	empowering	
line managers by providing proactive support 
to assist them with staff management. This 
contributes to improved performance in an 
environment which requires flexibility and a 
timely response to changing structures and 
processes.  
•	 In	line	with	our	commitment	to	staff	continuous	
learning and development, a number of 
organisational awareness sessions were held to 
facilitate cross-departmental engagement.
•	 Initial	planning	took	place	in	relation	to	the	
consolidation and restructuring of current 
human resources tools with a view to ensuring 
improved performance.    
•	 An	annual	performance	management	
programme has been in place in the IMB since 
2004 and was again implemented during 
2011. The business plans for each internal 
department provide the framework for the 
scheme, which is known as the Performance 
Development Programme (PDP). The programme 
incorporates the objectives, tasks and key 
performance indicators against which individuals 
are evaluated. In addition, the organisational 
and personal competencies expected of all 
our staff are identified as are individual plans 
identifying training and development needs for 
the year ahead. This process recognises good 
performance as well as addressing any under-
performance and/or training needs.  
2011 Statistics
•	 The	organisation	continues	to	be	in	compliance	
with the 3% target set by the Disability Act 2005.
•	 Absence	management	practices	are	in	place	and	
attendance statistics are included in monthly 
management and bi-monthly Board reports. The 
overall absence rate for 2011 was 2.4%. This rate 
is well below industry norms of 3.5% - 4%.
•	 Average	spend	per	employee	in	relation	
to training was just under €900 with 9% of 
employees participating in further education and 
development programmes.
INfoRMATIoN TEChNoLoGy ANd ChANGE 
MANAGEMENT 
The Information Technology and Change 
Management department delivers specialist 
business analysis, information technology and 
telecommunications services throughout the 
organisation. Change management and business 
process improvement initiatives are also co-ordinated 
by the department, reflecting the IMB’s commitment 
to the agenda of transformation in the public sector.
Information Technology 
Technology plays a key role both in supporting the 
efficient operations of the IMB and in providing a 
range of services to our stakeholders. A broad range 
of applications are available to the public, healthcare 
professionals and industry. These services include 
online reporting systems for potential safety and 
quality issues relating to medicines, medical devices, 
tissues and cells as well as a range of extranet 
solutions. The latter includes registration and licence 
application systems and close to 1,000 users are 
registered to avail of these services. During 2011, 
there was a 15% increase in user take-up of our 
extranet solutions when compared with the previous 
12-month period. 
During 2010, we commenced a review of our 
information technology usage with a view to 
developing a new five-year strategy aligned to the 
organisation’s new five-year strategic plan. This 
information technology strategy was adopted by the 
Board in early 2011 and implementation commenced 
in the second half of the year. Key technologies for 
the organisation over the coming years will include 
improved data warehousing and mining solutions, 
together with upgraded capacity management and 
case management systems. Other developments 
over the life of the strategy include the design of a 
new IMB website, together with the introduction 
of relevant knowledge management solutions. All 
information technology initiatives are undertaken in 
the context of providing new and improved services 
to stakeholders, enhancing decision-making and 
channelling scientific data to deliver on our public 
health remit.
The IMB is also part of the wider European regulatory 
network working on a broad and co-ordinated 
EU Telematics Programme. During 2011, we were 
active in six significant projects as part of this 
work programme which is designed to support 
licensing and safety related activities across the EU. 
Of note, the IMB had specific responsibility for a 
project to support electronic submissions from the 
pharmaceutical industry. This initiative, known as the 
Common European Submission Portal (CESP), has 
received a positive response from industry and will 
move into phase II of its development in 2012.
In 2011, the IMB also provided support to other 
government agencies in Ireland through the 
provision of both technology hosting and advisory 
services. We continued to work with health bodies to 
enhance communication and data sharing across the 
regulatory and health network. International interest 
in our technology solutions, particularly our workflow 
management systems, remained high with several 
visits from foreign delegations throughout 2011 and 
more scheduled for 2012.
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Change Management
The IMB has a long held commitment to continuous 
improvement and first implemented change 
management strategies as far back as 2003. In the 
interim, the organisation has implemented significant 
departmental restructuring, taken on a range of new 
activities and also developed new and innovative 
approaches to service delivery. While efficiency is 
a key goal in such initiatives, legislative changes, 
improved flexibility and the requirement to respond 
to stakeholder needs are also key drivers for change. 
All process improvement initiatives take account of 
the organisation’s mission to protect and enhance 
public health.
In 2011, it was considered timely to develop a more 
structured approach to organisational project 
management. This resulted in the adoption of a 
Project Management Office model for all relevant 
activities. This office is tasked with supporting 
the planning process, ensuring alignment with 
organisational objectives and developing consistent 
management and control mechanisms. Planning for 
the new Project Management Office commenced in 
late 2011, with implementation scheduled for 2012.    
 
Additional change management initiatives in 2011 
included the commencement of work on a new IMB 
enforcement strategy. There has been significant 
growth in enforcement related activities at both 
national and international level in respect of medical 
products over the past five years. Our enforcement 
strategy must take account of this growth and also 
the evolution of activities in this area. The new 
strategy will incorporate mechanisms to focus on the 
areas of highest vulnerability while taking account 
of the organisational capacity. The strategy will be 
available for public consultation in mid 2012.
An impact analysis of the new pharmacovigilance 
legislation also started in December 2011 with 
proposals and recommendations due in early 
2012. The requirements of the new legislation will 
necessitate changes to existing work practices. 
Work also commenced on a review of the IMB’s 
customer service model and the future needs of the 
organisation in this regard.   
The IMB acknowledges the assistance of various 
partner organisations, both nationally and 
internationally, in developing new strategies for 
organisational improvement.
Project
Management 
Office
Skills & 
Support
Pragmatic
Processes & 
Controls
Governance
& Strategic
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ChIEf ExECuTIvE’S offICE
The Chief Executive’s Office is responsible for 
communication, for strategy and planning, for quality 
management and a number of information functions 
for external stakeholders. It also provides the 
secretariat for the benchmarking programme across 
EU medicines agencies. 
BEMA
The Benchmarking of European Medicines Agencies 
(BEMA) programme provides assurance to the heads 
of the EU medicines agency network (HMA) with 
respect to the quality of the systems and practices 
in place in agencies and a resource for sharing of 
best practices. The chief executive is co-chair of 
the BEMA steering group with the head of the Paul 
Ehrlich institute in Germany. During 2011, the IMB 
continued its participation in the steering group, as 
it developed proposals for the third cycle of BEMA 
assessments and brought them to the heads of 
the medicines agencies for approval. By year-end, 
assessors had been trained in the new questionnaire 
and methodology, and the IMB, which also provides 
secretariat resources to the steering group, was 
preparing the visit schedule for 2012 – 2014.
Provision of Information 
During 2011, the IMB received and responded to 34 
parliamentary questions, and 4 representations (as 
outlined on page 73).
We provided comments with respect to five 
consultations (as outlined on page 72).
CoRPoRATE AffAIRS
Corporate Affairs is responsible for the delivery of 
a number of key service areas to the organisation. 
These include building and accommodation 
management as well as the provision of reception, 
canteen, travel, library and event management 
services. The section also manages legal issues 
and Freedom of Information requests. In addition, 
it provides secretarial support to the Board and 
Committees ensuring adherence to best practice in 
the area of corporate governance. Across all these 
functions, 2011 was another busy and productive 
year.
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Event Management
The IMB held six events in 2011 all of which were 
organised and managed in-house. This approach 
ensures cost effective delivery of events while also 
allowing IMB staff to deal directly with stakeholders. 
This has resulted in very positive feedback from 
attendees via event questionnaires. 
The six events consisted of two information days and 
four training seminars. The information days, which 
typically provide regulatory guidance and updates 
to interested parties, were focused on (1) veterinary 
medicines and (2) the implementation of the new 
pharmacovigilance legislation. Close to 500 delegates 
in total attended both these events.
The training seminars which the IMB provided 
included three grocery wholesale training half 
day seminars and two week long Pharmaceutical 
Inspection Co-Operation Scheme (PIC/S) seminars for 
new inspectors.  
Freedom of Information
During 2011, the IMB received six non-personal and 
one personal Freedom of Information requests (as 
outlined on page 73). 
Board and Committees
The Corporate Services section provides secretarial 
support to the Board and Committees of the IMB 
and ensures adherence to best practice in the area of 
corporate governance.
•	 The	Board	of	the	Irish	Medicines	Board	met	
seven times in 2011 and considered a number 
of strategic matters including corporate policy, 
planning and finance matters. The latter included 
monthly management accounts, annual budgets 
and the financial statements for 2010. The Board 
also reviewed update reports from the Statutory 
Advisory Committees and the Audit Committee. 
In addition, it reviewed the licences for all 
medicinal healthcare products as approved by 
the Management Committee.
The number of meetings attended by each Board 
member during 2011 is as follows:
•	 The	Audit	Committee,	a	subcommittee	to	the	
Board, met four times in 2011. Further details are 
provided in the financial statements.
•	 The	Advisory	Committee	for	Human	Medicines	
assists and advises the Board in relation to any 
matters pertaining to the safety, quality or 
efficacy of medicinal products for human use 
as are referred to it by the Board. It also reviews 
the licenses for human medicinal products as 
approved by the Management Committee. The 
Committee met four times in 2011.
•	 The	Advisory	Committee	for	Veterinary	Medicines	
assists and advises the Board in relation to any 
matters pertaining to the safety, quality or 
efficacy of medicinal products for animal use 
as are referred to it by the Board. It also reviews 
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Board Member Number  Number 
 of meetings of meetings 
 held during  attended during 
 the period  the period  
 the member the member 
 was on was on
 the Board the Board 
Mr. Michael Hayes (Chair) 7 7
Mr. Pat Brangan  7 7
Prof. Brendan Buckley  4 3
Mr. Wilf Higgins  7 7
Ms. Ann Horan  7 7
Prof. Mary Horgan 2 2
Mr. Brendan McLaughlin 7 6
Mr. Noel O’Donoghue 7 5
Prof. Caitriona O’Driscoll 7 7
Ms. Maureen Windle 5 5
the licenses for veterinary medicinal products as 
approved by the Management Committee. The 
Committee met three times in 2011.  
•	 The	Advisory	Committee	for	Medical	Devices	met	
twice in 2011. It assists and advises the Board in 
relation to any matters pertaining to the safety, 
quality or efficacy of medical devices for human 
use as are referred to it by the Board.  
•	 The	Herbal	Medicines	Committee,	a	
subcommittee to the Advisory Committee for 
Human Medicines, met five times in 2011. The 
Committee considered a number of matters 
including the Traditional Herbal Medicinal 
Products Registration Scheme and updates from 
the Committee on Herbal Medicinal Products of 
the European Medicines Agency. 
•	 The	Clinical	Trials	Committee,	a	subcommittee	to	
the Advisory Committee for Human Medicines, 
met twelve times in 2011. The Committee 
considers the suitability of trials submitted for 
approval under the European Communities 
(Clinical Trials on Medicinal Products for Human 
Use) Regulations 2004, (S.I. No. 190 of 2004). 
fINANCE
It is the role of the finance section to manage and 
safeguard the finances of the IMB. It must ensure that 
the IMB fulfils its legislative requirements and applies 
best practice to the governance of its affairs. All 
procedures are carried out using standard operating 
procedures under the quality management system. 
The 2011 financial statements presented in 
conjunction with this report were prepared by 
the finance section and submitted for audit to 
the Comptroller and Auditor General. All financial 
transactions during the period under review are 
reflected and reported upon in these statements 
as is our commitment to the highest standards of 
corporate governance. 
ovERvIEW of ENERGy uSAGE IN 2011
With effect from 1 January 2011, the IMB, as a public 
sector body, has been required to report annually 
on its energy usage and actions taken to reduce 
consumption in accordance with S.I. No. 542 of 2009. 
These regulations transpose the Energy End Use 
Efficiency and Energy Services Directive (2006/32/EC) 
into Irish law. 
The IMB uses electricity for lighting, air conditioning 
as required and the provision of hot water. Natural 
gas is used for central heating. 
In 2011, the IMB consumed 759 MWh of energy, 
consisting of:
•	 507	MWh	of	electricity;	
•	 0	MWh	of	fossil	fuels;	
•	 252	MWh	of	renewable	fuels	
Actions undertaken in 2011
In 2011, the IMB further improved energy 
performance by entering into framework agreements 
for the supply of both electricity and natural 
gas. Both of these framework agreements were 
established by the National Procurement Service 
for the supply of electricity and natural gas to the 
Irish public sector. Cost savings were in the region 
of 12% for electricity and 5% for gas. Energy savings 
amounted to 10 MWh. Please note that the National 
Procurement Service contract rates were fixed until 
the end of 2011.
Total Energy Savings
In total, initiatives undertaken prior to 2010 and the 
measures outlined above are saving the IMB 117 MWh 
annually.
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Actions Planned for 2012
In 2012, the IMB intends to maintain energy 
performance by continuing its participation in newly 
contracted framework agreements for the supply of 
both electricity and natural gas established by the 
National Procurement Service. It is not anticipated 
that there will be energy savings, but the cost savings 
maintained since 2010 will be in the region of 5% 
for gas. With regard to electricity, there will be cost 
savings of 6% over 2011. These contract rates are 
fixed until the end of 2012 except for an increase to 
the carbon tax charge from 1 May 2012 as advised in 
the Budget of the 6 December 2011.
The IMB also intends to replace its single glazed 
windows on the upper floors to more energy efficient 
double glazed windows.  
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BoARd MEMBERS ANd oThER INfoRMATIoN
Board Members: Mr. Michael Hayes (Chairman) (until 31/12/2015)
 Prof. Brendan Buckley (resigned 14/09/2011)
 Ms. Ann Horan (until 31/12/2015)
 Prof. Mary Horgan (until 31/12/2015) *
 Mr. Noel O’Donoghue (until 31/12/2015)
 Prof. Caitriona O’Driscoll (until 31/12/2015)
 Mr. Pat Brangan (until 31/12/2013)
 Mr. Brendan McLaughlin (until 31/12/2013)
 Mr. Wilfred Higgins (until 31/12/2013)
 Ms. Maureen Windle (resigned 08/11/2011)
 The above Board was appointed by the Minister for Health on   
 18/01/2011 until the specified dates.
 *Professor Mary Horgan was appointed on 08/11/2011.
 
Bankers: Allied Irish Bank
 Lower Baggot Street
 Dublin 2
 Bank of Ireland Corporate
 Lower Baggot Street
 Dublin 2
Solicitors: Eugene F. Collins
 Temple Chambers
 3, Burlington Road
 Dublin 4
Head Office: Kevin O’Malley House
 Earlsfort Centre
 Earlsfort Terrace
 Dublin 2
Auditors: Comptroller and Auditor General
 Dublin Castle
 Dublin 2 
CORPORATE GOVERNANCE
The Irish Medicines Board (the IMB) was established under the terms of the Irish Medicines Board 
Act, 1995, and is governed by a Board which was appointed by the Minister for Health. The Board of 
the IMB (the Board) consists of a chairman and eight unremunerated non executive members.
The IMB is committed to the highest standards of Corporate Governance and has implemented the 
Department of Finance “Code of Practice for the Governance of State Bodies”. This Code of Practice, 
which was issued to the IMB in January 2002, incorporates many of the principles under which the 
IMB operates, taking account of the size and legal nature of the organisation. 
An updated Code of Practice was published by the Minister for Finance in June 2009, to take account 
of administrative and legislative developments in the corporate governance framework since 2001. 
The IMB has carried out a detailed review of this updated Code, to ensure that its provisions are still 
reflected in the principles under which the IMB operates.
The IMB has in place an extensive Code of Conduct and conflicts of interest policy for all staff, 
committees and Board members. The IMB applies the highest standards of disclosure and 
transparency in respect of interests held by staff, committees and Board members.
AudIT CoMMITTEE
The IMB has an audit committee comprising three Board members, which met on 4 occasions 
during 2011. This committee is responsible for reviewing internal control matters, together with any 
other issues raised by the external auditors, the Board or management. The external auditor meets 
annually with the audit committee to brief them on the outcome of the external audit. In 2010 the 
IMB re-appointed Crowleys DFK as internal auditor to the Board under a three-year contract. During 
2011 the internal auditors reviewed the areas of income, corporate governance and electronic 
banking and reported their findings to the audit committee. The audit committee has also been 
involved with the review of the quality systems as described below.
quALITy SySTEMS
During 2011, the finance section of the IMB continued the process of implementing and reviewing 
standard operating procedures (SOPs) under the quality management system. This process 
involved a critical review and analysis of internal controls and processes throughout the section 
with particular emphasis on risk management. This system now underpins the internal control 
environment and feeds into the internal audit process and ultimately into the audit committee.
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REMuNERATIoN PoLICy - BoARd MEMBERS ANd ExECuTIvE dIRECToRS
Remuneration and travel expenses paid to Board members are disclosed in note 17 to the 
financial statements. The Chairman receives remuneration as directed by the Minister for Health in 
accordance with the Irish Medicines Board Act, 1995. Other Board members receive travel expenses 
in accordance with circulars issued by the Department of Health. The Chief Executive is remunerated 
in accordance with guidelines issued from Government and other Executive Directors are paid in 
accordance with Department of Health pay scales. 
REMuNERATIoN CoMMITTEE
The IMB has established a remuneration committee as a sub-committee of the Board to review the 
remuneration of the Chief Executive, in accordance with guidelines issued by the Department of 
Finance and the Department of Health. The Chief Executive’s remuneration is disclosed in note 18 to 
the Financial Statements.
INTERNAL CoNTRoL
The Board is responsible for the IMB’s systems of internal control. Such systems can only provide 
reasonable and not absolute assurance against material misstatement or loss. The systems of internal 
controls in use in the IMB are described more fully in the Chairman’s report on the following page.
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REPORT OF THE CHAIRMAN OF THE IRISH MEDICINES BOARD 
REGARdING ThE ASSESSMENT of INTERNAL fINANCIAL CoNTRoLS of A STATE 
Body foR ThE yEAR ENdEd 31 dECEMBER 2011
1. I, as Chairman, acknowledge that the Board is responsible for the body’s system of internal 
financial control.
2. The IMB system of internal control can provide only reasonable and not absolute assurance 
against material error, misstatement or loss.
3. The Board confirms that there is an ongoing process for identifying, evaluating and managing 
the significant risks faced by the IMB. This process is regularly reviewed by the Board via the 
report of the Chief Executive.
 Management are responsible for the identification and evaluation of significant risks applicable 
to their areas of business together with the design and operation of suitable internal controls. 
These risks are assessed on a continuing basis and may be associated with a variety of internal 
or external sources including control breakdowns, disruption in information systems, natural 
catastrophe and regulatory requirements.
 Management reports fortnightly on operational issues and risks and how they are managed 
to the Management Committee. The Management Committee’s role in this regard is to review 
on behalf of the Board the key risks inherent in the affairs of the IMB and the system of actions 
necessary to manage such risks and to present their findings on significant matters via the Chief 
Executive to the Board.
 The Chief Executive reports to the Board on behalf of the executive management on significant 
changes in the work of the IMB and on the external environment, which affects significant 
risks. The Director of Finance and Corporate Affairs provides the Board with monthly financial 
information, which includes key performance indicators. Where areas for improvement in the 
system are identified, the Board considers the recommendations made by the Management 
Committee.
 An appropriate control framework is in place with clearly defined matters which are reserved 
for Board approval only or, as delegated by the Board, for appropriate Management Committee 
approval. The Board has delegated the day-to-day management of the IMB and established 
appropriate limits for expenditure authorisation to the Management Committee. The Chief 
Executive is responsible for implementation of internal controls, including internal financial 
control.
 The system of internal financial control is monitored in general by the processes outlined above. 
In addition, the Audit Committee of the Board reviews specific areas of internal control as part of 
their terms of reference.
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4. The Audit Committee of the Board has satisfactorily reviewed the effectiveness of the system 
of internal control on behalf of the Board. The Audit Committee of the Board carried out a 
formal review of these systems in respect of 2011 at its meeting on 27 March 2012. The internal 
control work carried out by the Audit Committee was reviewed and approved by the Board at its 
meeting on 28 March 2012.
Mr. Michael Hayes 
Chairman to the Board
87IMB ANNUAL REPORT 2011
STATEMENT OF BOARD MEMBERS’ RESPONSIBILITIES
The Board is required by the Irish Medicines Board Act, 1995 to prepare financial statements for each 
financial year which give a true and fair view of the state of affairs of the IMB and of its surplus or 
deficit for that period.
In preparing those statements the Board is required to:
•	 select	suitable	accounting	policies	and	apply	them	consistently
•	 make	judgements	and	estimates	that	are	reasonable	and	prudent
•	 disclose	and	explain	any	material	departures	from	applicable	accounting	standards,	and
•	 prepare	the	financial	statements	on	a	going	concern	basis	unless	it	is	inappropriate	to	presume	
that the IMB will continue in existence.
 
The Board is responsible for keeping proper accounting records which disclose with reasonable 
accuracy at any time the financial position of the IMB and which enable it to ensure that the financial 
statements comply with the IMB Act and with accounting standards generally accepted in Ireland.  It 
is also responsible for safeguarding the assets of the IMB and hence for taking reasonable steps for 
the prevention and detection of fraud and other irregularities.
 
  
On behalf of the Board
Chairman Board Member
Mr. Michael Hayes Ms. Ann Horan    
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REPORT OF THE COMPTROLLER AND AuDITOR GENERAL 
FOR PRESENTATION TO THE HOuSES OF THE OIREACHTAS
I have audited the financial statements of the Irish Medicines Board for the year ended 31 December 
2011 under the Irish Medicines Board Act, 1995.
The financial statements, which have been prepared under the accounting policies set out therein, 
comprise the Accounting Policies, the Statement of Income and Expenditure, the Balance Sheet, the 
Cash Flow Statement and the related notes.
The financial reporting framework that has been applied in their preparation is applicable law and 
Generally Accepted Accounting Practice in Ireland as modified by the directions of the Minister for 
Health in relation to accounting for superannuation costs.
RESPoNSIBILITIES of ThE BoARd
The Board is responsible for the preparation of the financial statements, for ensuring that they give 
a true and fair view of the state of the Board’s affairs and of its income and expenditure, and for 
ensuring the regularity of transactions.
RESPoNSIBILITIES of ThE CoMPTRoLLER ANd AudIToR GENERAL 
My responsibility is to audit the financial statements and report on them in accordance with 
applicable law.
My audit is conducted by reference to the special considerations which attach to State bodies in 
relation to their management and operation.
My audit is carried out in accordance with the International Standards on Auditing (UK and Ireland) 
and in compliance with the Auditing Practices Board’s Ethical Standards for Auditors.
SCoPE of AudIT of ThE fINANCIAL STATEMENTS
An audit involves obtaining evidence about the amounts and disclosures in the financial statements, 
sufficient to give reasonable assurance that the financial statements are free from material 
misstatement, whether caused by fraud or error. This includes an assessment of
•	 whether	the	accounting	policies	are	appropriate	to	the	Irish	Medicines	Board’s	circumstances,	
and have been consistently applied and adequately disclosed.
•	 the	reasonableness	of	significant	accounting	estimates	made	in	the	preparation	of	the	financial	
statements, and
•	 the	overall	presentation	of	the	financial	statements.
I also seek to obtain evidence about the regularity of financial transactions in the course of audit.
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oPINIoN oN ThE fINANCIAL STATEMENTS
In compliance with the directions of the Minister for Health, the Board recognises the costs of 
superannuation entitlements only as they become payable. This basis of accounting does not 
comply with Financial Reporting Standard 17 which requires such costs to be recognised in the year 
the entitlements are earned. 
Except for the non-recognition of the Board’s superannuation costs and liabilities in accordance with 
Financial Reporting Standard 17, the financial statements give a true and fair view, in accordance 
with Generally Accepted Accounting Practice in Ireland, of the state of the Board’s affairs at 31 
December 2011 and of its income and expenditure for the year then ended.
In my opinion, proper books of account have been kept by the Board. The financial statements are in 
agreement with the books of account.
MATTERS oN WhICh I REPoRT By ExCEPTIoN
I report by exception if
•	 I	have	not	received	all	the	information	and	explanations	I	required	for	my	audit,	or
•	 my	audit	noted	any	material	instance	where	moneys	have	not	been	applied	for	the	purposes	
intended or where the transactions did not conform to the authorities governing them, or
•	 the	Statement	on	Internal	Financial	Control	does	not	reflect	the	Board’s	compliance	with	the	
Code of Practice for the Governance of State Bodies, or
•	 I	find	there	are	other	material	matters	relating	to	the	manner	in	which	public	business	has	been	
conducted.
I have nothing to report in regard to those matters upon which reporting is by exception.
Andrew Harkness 
For and on behalf of the 
Comptroller and Auditor General  
12 June 2012
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ACCOuNTING POLICIES
 
hISToRICAL CoST CoNvENTIoN
The Financial Statements are prepared in accordance with generally accepted accounting principles 
under the historical cost convention and comply with the financial reporting standards of the 
Accounting Standards Board, with the exception of superannuation - see note below.
INCoME RECoGNITIoN
Income is recognised in the financial statements on the following basis:
•	 In	the	case	of	applications	for	marketing	authorisations	(new	applications,	variations	to	existing	
authorisations, or transfers) and clinical trial applications, income is recognised in the financial 
statements when a valid application form is received.  
•	 In	the	case	of	wholesale	and	manufacturing	licences	and	maintenance	of	marketing	
authorisations, fees are payable annually and a full year’s income is accrued in each financial 
year.
ExPENdITuRE RECoGNITIoN
Expenditure is recognised in the financial statements on an accruals basis as it is incurred.
REPoRTING CuRRENCy ANd CuRRENCy TRANSLATIoN
The financial statements are prepared in euros.
Transactions in currencies other than euro are recorded at the rates ruling at the date of the 
transactions or at a contracted date.  Monetary assets and liabilities are translated into euro at the 
balance sheet date or at a contracted date.  Exchange differences are dealt with in the income and 
expenditure account.  
TANGIBLE ASSETS
Tangible Assets excluding Premises
Tangible assets excluding premises are stated at cost less accumulated depreciation.  Depreciation is 
calculated in order to write off the cost of tangible assets to their estimated residual values over their 
estimated useful lives by equal annual instalments.
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The estimated useful lives of tangible assets by reference to which depreciation has been calculated 
are as follows:
Fixtures and Fittings :  5 years
Computer Equipment :  3 years
Improvements to Premises : 10 years
Premises
The IMB purchased its premises at Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2 
on 22 December 2004. The value capitalised was equal to the purchase price plus those costs directly 
attributable to bringing the asset into use.
No depreciation has been calculated on the value of premises, as the remaining useful economic life 
is estimated to be greater than 50 years.
TAxATIoN
The IMB is exempt from liability to Corporation Tax under Section 32 of the Finance Act, 1994.
dEBToRS
Known bad debts are written off and specific provision is made for any amount the collection of 
which is considered doubtful. 
SuPERANNuATIoN
The superannuation scheme operated by the IMB is in accordance with the Local Government 
(Superannuation Revision) (Consolidation) Scheme, 1986. It is an unfunded statutory scheme and 
benefits are met from current income as they arise.
The charge to salaries and wages is stated gross of superannuation deductions of € 689,860 (2010 -       
€ 641,249). The surplus for the year on page 94 is then shown both before and after superannuation 
transactions for the year. The income and expenditure reserve on the balance sheet is split between 
retained reserves and superannuation reserves in note 11.
By direction of the Minister for Health, the provisions of FRS 17 are not being complied with.  
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PRovISIoNS
A provision is recognised when the IMB has a present obligation as a result of a past event, it is 
probable that this will be settled at a cost to the IMB and a reliable estimate can be made of the 
amount of the obligation.
LIBRARy
No value has been placed on the books, audio-visual resources and electronic databases in the 
library.  Expenditure on these items is written off in the year in which it is incurred.
LEASES
All leases are treated as operating leases and the rentals thereunder are charged to the Income and 
Expenditure account on a straight line basis over the lease period. 
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  2011 2010
 Notes € €
Fee Income 2  21,399,720  21,901,934 
Other Income 3  3,546,480  2,043,111 
   
  24,946,200  23,945,045 
    
 
     
Salaries and Wages 4 16,433,330  15,652,918 
Other Operating Costs 5  6,679,498  5,532,894 
Depreciation 1  1,272,749  1,446,488 
     
  24,385,577 22,632,300 
    
Surplus for the year before write     
back of Superannuation contributions  560,623  1,312,745 
    
 
Staff Superannuation Contributions   689,860  641,249 
    
 
Surplus for the year   1,250,483  1,953,994 
    
 
Balance brought forward   20,376,418  18,422,424 
    
Balance carried forward  21,626,901  20,376,418 
    
 
All income and the surplus for the year arises from continuing activities. 
The accounting policies on pages 91 to 93 and the notes on pages 97 to 103 form part of the financial 
statements.
Chairman Board Member
Mr. Michael Hayes Ms. Ann Horan 
STATEMENT of INCoME ANd ExPENdITuRE ACCouNT
for the year ended 31 December 2011
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  2011 2010
 Notes € €
Tangible Assets 1 23,019,503  23,753,247 
     
Current Assets     
Debtors and Prepayments 6 1,420,295  1,530,265 
Stock of Stationery  2,469  2,366 
Cash at Bank and in Hand 12  36,890  24,260 
Short Term Deposits   14,669,317  12,518,096 
      
  16,128,971 14,074,987 
    
 
Creditors - Amounts falling     
due within one year    
 
Creditors and Accruals 7  7,208,237  6,345,148 
Mortgage 13 793,332  793,332 
     
  8,001,569  7,138,480 
    
Net Current Assets   8,127,402  6,936,507 
    
Long Term Liabilities     
Mortgage 13  9,520,004  10,313,336 
    
 
TOTAL NET ASSETS   21,626,901  20,376,418 
    
 
Financed by     
Income and Expenditure Reserve 11  21,626,901  20,376,418 
     
  21,626,901  20,376,418 
     
 
The accounting policies on pages 91 to 93 and the notes on pages 97 to 103 form part of the financial 
statements.
Chairman Board Member
Mr. Michael Hayes Ms. Ann Horan 
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  2011 2010
 Notes € €
Reconciliation of surplus to net cash     
inflow from operating activities     
 
Surplus for Year  1,250,483 1,953,994 
Depreciation Charge  1,272,749 1,446,488 
(Increase)/Decrease in Debtors  139,654 579,624*
(Increase)/Decrease in Stocks  (103) 193 
Increase/(Decrease) in Creditors - amounts    
falling due within one year  862,733 (46,435)*
Deposit Interest   (256,205) (149,692) 
Bank Interest and Charges  460,323 492,254 
Loss/(Gain) on Disposal of Fixed Assets  458 198 
    
Net Cash Inflow      
from Operating Activities  3,730,092 4,276,624 
     
Cash Flow Statement     
 
Net Cash Inflow from Operating Activities  3,730,092 4,276,624 
     
Return on Investments and Servicing of Finance 8 (233,446) (370,605)*
Capital Expenditure 8 (539,463) (1,005,389) 
Management of Liquid Resources 8 (2,151,221) (2,391,094) 
Financing 8 (793,332) (793,332)
 
Increase/(Decrease) in Cash   12,630 (283,796)
    
Reconciliation of net cash flow to movement in net debt     
    
Increase/(Decrease) In Cash  12,630 (283,796)
Increase/(Decrease) In Short Term Deposits  2,151,221 2,391,094
(Increase)/Decrease In Long Term Finance  793,332 793,332
    
Change In Net Funds/(Debt)  2,957,183 2,900,630
Net Debt at start of year  1,435,688 (1,464,942)
    
Net Funds/(Debt) at end of year 9 4,392,871 1,435,688
 
* Certain amounts have been reclassified for presentation purposes
The accounting policies on pages 91 to 93 and the notes on pages 97 to 103 form part of the financial 
statements.
Cash flow Statement
for the year ended 31 December 2011
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1. Tangible Assets Fixtures and Computer  Leasehold Improvements Premises Total  
 Fittings Equipment Improvements Premises    
 € € € € € €
 Cost       
Balance as at        
1 January 2011  930,309 8,286,297 502,445 3,541,486 20,383,000 33,643,537
         
Additions for the year  47,926  481,813  - 9,924  - 539,663
 Disposals for the year  - (161,174)  -  -  - (161,174)
    
 As at        
31 December 2011 978,235 8,606,936 502,445  3,551,410 20,383,000 34,022,026
    
 Depreciation       
Balance as at        
1 January 2011  694,160 7,490,736   300,213 1,405,181 -  9,890,290
         
Charge for the year  153,522 713,841 50,245 355,141   - 1,272,749
 Disposals for the year  -  (160,516)  -     -     -  (160,516)
        
 As at        
31 December 2011  847,682 8,044,061 350,458  1,760,322   - 11,002,523
         
   
 Net Book value at        
31 December 2011  130,553 562,875 151,987 1,791,088 20,383,000 23,019,503
        
 Net Book value at        
1 January 2011  236,149 795,561 202,232  2,136,305 20,383,000 23,753,247
2. Income
      2011     2010
      €     €
 Fee Income  
 Clinical Trials 123,617  120,743 
 Human Medicine - National Fees 7,750,395  8,839,533 
 Human Medicine - European Fees 7,056,707  6,166,008 
 Veterinary Medicine - National Fees 1,104,294  1,098,288 
 Veterinary Medicine - European Fees 1,339,833  1,391,667 
 Compliance Department 3,773,733  4,068,806 
 Medical Devices 251,141  216,889 
   21,399,720  21,901,934 
 Other Income ( Note 3 ) 3,546,480  2,043,111 
 Total Income 24,946,200 23,945,045 
    
 Certain fees, totalling €17,740,955, are required by law to be disposed of in accordance with the directions 
of the Minister for Finance.    
    
 
Notes to the financial Statements
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3. Other Income 2011     2010
      €     €
 Dept Of Health Funding 3,230,479  1,750,508 
 IT Income -  5,000 
 Conference Fee Income 60,254  138,109 
 Deposit Interest 256,205  149,692 
 (Loss)/Gain on Disposal of Fixed Assets (458) (198)
     
  3,546,480  2,043,111
4. Salaries and Wages
  2011     2010
      €     €
 Salaries and Wages  15,144,077  14,425,188 
 Social Welfare Costs 1,289,253  1,227,730 
 
  16,433,330  15,652,918 
    
 The average number of staff employed during the year was 289 ( 2010 - 282 ).   
Staff employed at 31 December 2011 can be analysed across the following departments :    
 
  2011 2010 
 
 Chief Executive 10  9 
 Compliance 58  57 
 Finance & Corporate Affairs 16  16 
 Human Products Authorisation & Registration 108  109 
 Human Products Monitoring  36  34 
 Human Resources  7  7 
 IT & Change Management 13  12 
 Scientific Affairs 2  2 
 Veterinary Medicines  19  21 
 Pensioners  21  16 
 
   290  283
 Pension related deductions for Public Servants of €938,674 were deducted from staff during the year and 
paid over to the Department of Health.   
  
Notes to the financial Statements
for the year ended 31 December 2011
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5. Operating Costs 2011     2010
      €     €
 
 Accommodation Costs 1,347,919  1,104,086 
 Travel, Representation and Training  720,158  808,855 
 Bank Charges and Interest 460,323  492,254 
 Legal & Professional Fees  1,780,330  514,964 
 Stationery, Publications and Postage 438,945  536,715 
 Other Operating Costs 1,931,823  2,076,020 
    
   6,679,498  5,532,894 
    
 Operating costs of €6,679,498 includes an amount of €17,819 in relation to canteen consumables  and 
events which include a lunch to acknowledge each of the unremunerated statutory committees and an 
event in the canteen to recognise the contribution of the retiring Board and Chair, who with the exception 
of the Chair are also unremunerated. It also includes an amount of €4,020 related to staff hospitality.  
 
6. Debtors (all due within one year) 2011     2010
      €     €
 
 Trade Debtors 788,523 896,769 
 Prepayments 357,405 375,872 
 Other Debtors 274,367  257,624 
    
   1,420,295  1,530,265
7. Creditors (amounts falling due within one year) 2011     2010
      €     €
 
 Trade Creditors  540,975 629,102 
 Accruals 6,146,590 5,222,976 
 Revenue Commissioners 520,672  493,070 
    
   7,208,237  6,345,148 
Notes to the financial Statements
for the year ended 31 December 2011
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Notes to the financial Statements
for the year ended 31 December 2011
8. Gross Cash Flows 2011     2010
      €     €
 Returns on Investment and Servicing of Finance:  
 Deposit Interest 226,521  122,451 *
 Bank Interest and Charges (459,967) (493,056)*
     
 (233,446) (370,605) 
 
 Capital Expenditure  
 Payments to acquire Tangible Fixed Assets (539,663) (1,006,314) 
 Receipts from sales of Tangible Fixed Assets 200 925  
     
 (539,463) (1,005,389) 
 Management of Liquid Resources  
 (Increase)/Decrease in Short Term Deposits (2,151,221) (2,391,094) 
     
 (2,151,221) (2,391,094) 
 Financing  
 Increase/(Decrease) in Long Term Finance (793,332) (793,332) 
     
 (793,332) (793,332) 
    
* Certain amounts have been reclassified for presentation purposes    
 
9. Analysis of Changes in Net Funds/(Debt) As At  As At
  01/01/2011 Cashflow 31/12/2011
 Cash at Bank and in Hand  24,260  12,630 36,890 
 Short Term Deposits  12,518,096  2,151,221 14,669,317 
 Debt Due Within One Year (793,332) 0 (793,332)
 Debt Due After One Year (10,313,336) 793,332  (9,520,004)
  1,435,688 2,957,183  4,392,871
10. Administration Expenses 2011 2010
 Surplus for the year was calculated having charged :     
 Auditor’s Remuneration 17,390  17,390 
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11. Movement on Income and Expenditure Reserves As At  As At
  01/01/2011 Movement 31/12/2011
 
 Retained Reserves  15,280,032  560,623  15,840,655 
 Staff Superannuation Contributions  5,096,386   689,860  5,786,246 
      
  20,376,418  1,250,483 21,626,901
12. Cash and Bank Balances 2011     2010
      €     €
 Current Account Balances 35,976  23,279 
 Cash on Hand 914  981 
    
  36,890  24,260
13. Long Term Liabilities 
  Mortgage  
 On 22 December 2004 the Board purchased its premises at Kevin O’Malley House, Earlsfort Centre,   
Earlsfort Terrace, Dublin 2. The purchase was financed by way of a mortgage, secured on the premises,  
of  €20,400,000 over 20 years from Bank of Ireland Corporate Lending.   
 
  The Irish Medicines Board is committed to making the following capital repayments on its mortgage :
  2011     2010
      €     €
 - within one year 793,332  793,332 
 - between one and five years 3,173,328  3,173,328 
 - after five years 6,346,676  7,140,008 
    
   10,313,336  11,106,668
14. Interest Rate Exposure 
 The IMB has taken all necessary steps to minimise its interest rate exposure by fixing 2/3s of the borrowings 
for a period of 10 years. The balance of the borrowings are fully offset  by cash reserves.  
For 2012 it is estimated that the net borrowings for which an interest rate exposure may arise is  €0.   
 
    
Notes to the financial Statements
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15.  Financial Commitments  2011     2010
      €     €
 Operating Leases
 Amounts payable during the next twelve   
months in respect of leases which expire
 - within one year  -  -   
 - between one and five years (in respect of Longphort House) 167,056  167,056 
 - after five years ( in respect of Alexandra House ) 285,984  285,984 
    
   453,040  453,040 
    
 Included in Accommodation Costs (Note 5) is expenditure of €453,040 under operating leases. On 22 
December 2004 the IMB signed a leasehold interest in respect of the 5th floor, Alexandra House,  Earlsfort 
Centre, Dublin 2. At 31 December 2011 this lease had 10 years and four months remaining.  
On 1 June 2010 the IMB signed a leasehold interest in respect of the 3rd floor, Longphort House,  Earlsfort 
Centre, Dublin 2. At 31 December 2011 this lease had 3 years and 3 months remaining.
16.  Capital Commitments  2011     2010
      €     €
 Contracted For ( Contract Signed )  145,000  212,000 
 Not Contracted For  5,212,000  4,355,000 
    
   5,357,000  4,567,000
17.  Board Remuneration  2011     2010
      €     €
 Chairman’s Salary  19,596 22,305 
 Board Members’ Travel Expenses 4,723  5,537 
    
   24,319  27,842 
18.  Staff Remuneration  2011     2010
      €     €
 Chief Executive’s Total Remuneration    
         Basic Salary 156,386 174,913
 
   156,386  174,913 
 The Chief Executive’s pension entitlements do not extend beyond the standard entitlements in the model 
public sector defined benefit superannuation scheme.    
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19. Related Party Transactions    
There have been no transactions with related parties which require disclosure under Financial Reporting 
Standard 8.    
 
      
20. Prompt Payment Of Accounts    
The Irish Medicines Board ( IMB ) confirms that it is complying with EU law in relation to prompt payments 
of account.    
 
      
21. Exchange Rates     
The exchange rates used in preparing these financial statements were as follows :     
 
 2011      €1 = STG £0.838     
 2010      €1 = STG £0.8568     
      
22. Provisions    
The Board has been notified of a number of legal proceedings or potential proceedings. The information 
usually required by FRS 12 Provisions, contingent liabilities and contingent assets is not disclosed as the 
Board believes that to do so would be prejudicial to the outcome. In 2009 the Board was the unsuccessful 
defendant in a Supreme Court appeal, the issue of costs and damages have been referred back to the 
High Court. The Board is satisfied that they have made adequate provision against any award.   
  
      
23. Going Concern    
The Board has a reasonable expectation, at the time of appoving the financial statements, that the IMB 
has adequate resources to continue its operations. For this reason, the Board continues to adopt the 
going concern basis in preparing the financial statements.    
 
      
24. Approval of Financial Statements    
The financial statements were approved by the Board on 23 May 2012.
Notes to the financial Statements
for the year ended 31 December 2011
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Prof. Brendan Buckley    
Chairman to September 2011
Prof. Mary Horgan    
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Dr. Paul Browne
Dr. Kevin Connolly
Dr. Desmond Corrigan
Prof. David Kerins
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Prof. Patrick Murray
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Dr. Patrick A. Sullivan
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Prof. Fergal O’Brien
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Ms. Maebh Smith
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Mr. Sean Paul Teeling
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APPENDIX 2      
PRESENTATIONS 2011
ThIRd LEvEL PRESENTATIoNS
College Course Presentation Title
DCU Chemical and Pharmaceutical Sciences  Irish Pharmaceutical Industry Regulation and the Role of  
  the IMB
Limerick IT Pharmaceutical and Forensic Analysis  Pharmaceutical Assessment and Related Activities at the IMB
RCSI Nurse Midwife Prescribing Role of the IMB (2 presentations)
RCSI Nurse Midwife Prescribing Pharmacovigilance (2 presentations)
RCSI Pharmacy Regulation of New and Generic Medicines
TCD Pharmaceutical Medicine Legal provisions - SPCs, Leaflets and Packaging
TCD Pharmaceutical Medicine The Role of the CMDh
TCD Pharmaceutical Medicine Regulation: International Quality Standards and   
  Pharmacopoeias
TCD Pharmaceutical Medicine Advanced Therapy Medicinal Products 
TCD Pharmaceutical Medicine Herbal Medicinal Products
TCD Pharmaceutical Medicine Role of the Pharmacist in Regulatory Affairs
TCD Pharmaceutical Medicine Regulation of Medical Devices
TCD Pharmaceutical Medicine Interaction between EU and WHO on Pharmacovigilance
TCD Pharmaceutical Medicine Communicating Drug Safety Data
TCD Hospital Pharmacy  Pharmacovigilance - A Regulatory Perspective
TCD Biomedical Sciences  Biopharmaceuticals - Introduction to EU Regulation
UCD Nursing - Prescription of Medications Role of the IMB (2 presentations)
UCD Nursing - Prescription of Medications Pharmacovigilance (2 presentations)
UCD Veterinary Medicines Regulation of Veterinary Medicines in Ireland
UCD Clinical and Translational Research  Medical Device Studies
UCD Pharmaceutical Management  Regulatory Environment for the Irish Pharmaceutical Industry
UCD MSc Bioengineering Regulation of Medical Devices
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REGuLAToRy PRESENTATIoNS
Event/organiser Presentation Title
Advanced Therapies Medicinal Products  Regulation of Medical Devices and Combined Advanced 
Training (EMA)  Therapies Medicinal Products (ATMPs)
Advanced Therapies Medicinal Products Environmental risk Assessments for Genetically Modified 
Training (EMA)  Organs
Competent Authorities for Medical Devices Roadmap for the Revision of the Medical Devices Legislation
Competent Authorities for Medical Devices Regulation of Drug Device and Combination Products
Competent Authorities for Medical Devices Funding and Resourcing of Medical Device Authorities
DIA/IFAH Conference Challenges in Maintaining Availability of Veterinary Medicines
Drug Safety Research Unit New Pharmacovigilance Legislation - PSURs
Drug Safety Research Unit New Pharmacovigilance Legislation - Risk Minimisation Plans
EMA ATMP Assessors training Information on the CTD on the Combined ATMP
EU High-level Conference  Optimising Resources and Co-ordination of Medical Device  
 Regulation
Forum Institute Conference Variations Regulation
Good Manufacturing Practice Conference Pharmaceutical Quality Systems
Good Manufacturing Practice Conference Risk-based Validation and Qualification  
HMA - Competent Authorities for Medical Devices Funding and Resourcing of Medical Device Authorities
IBEC Ireland’s Unique Potential for the Commercialisation of Drug,  
 Device and Biologic Combination Products
Industry Event Type II Variations According to the Regulation
Industry Events Advertising Compliance (2 presentations)
Informa Clinical Investigations of Medical Devices and Revision of the  
 Legislation
Informa National Perspectives In Regards To Clinical Data Evaluation
Institute of Validation Technology  Qualification and Validation: Regulatory Inspectional Findings  
 - IMB Perspective
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REGuLAToRy PRESENTATIoNS
Event/organiser Presentation Title
International Society of Pharmacoepidemiology Risk/Benefit Management: The Importance of Risk   
 Minimisation Activities
Irish Cardiovascular and Stroke Research Network  Medical Device Research
ISPE Conference Quality Risk Management
ISPE Conference Issues Driving the European Regulatory Agenda on Drug Risk/ 
 Benefit Management: Importance of Risk Minimisation
IVT Validation Week Qualification and Validation: regulatory inspectional findings -  
 IMB perspective
PAT and Quality by Design Conference Quality by Design for Pharma and BioPharma
Pharmacovigilance for the Veterinary Industry Periodic Safety Update Reports    
Conference
Pharmacovigilance for the Veterinary Industry Signal Detection – A Regulator’s Perspective   
Conference
Regulatory Workshop Risk-Based Validation of Submission Management
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APPENDIX 3
PUBLICATIONS AND ARTICLES 2011
CoNSuMER INfoRMATIoN LEAfLETS
Topic Published
IMB Advice on Automated External Defibrillators December
dRuG SAfETy NEWSLETTERS 
Edition Articles
February 2011 − Multaq (dronedarone) – Association with Severe Liver Injury    
40th Edition  − Thelin (sitaxentan) – Marketing Authorisation withdrawal    
 − Fluoroquinolones - Risk of QT Prolongation      
 − Viewing the Drug Safety Newsletter online or receiving via email   
 − Safe Use of Insulin Pens
April 2011 − Paracetamol - Available evidence does not support a causal relationship with asthma in 
41st Edition   children after exposure in pregnancy or use in early infancy    
 − Provigil (Modafinil) – Restriction of use and recommendations to support safer use 
 − Tygacil (tigecycline) – Recommendations for use     
 − Efient (prasugrel) – Reports of hypersensitivity reactions    
 − Revlimid (lenalidomide) – Risk of venous and arterial thromboembolic events
June 2011 − Cubicin (daptomycin) – Risk of eosinophilic pneumonia    
42nd Edition  − Drospirenone containing combined oral contraceptives (Yasmin, Yasminelle, Yaz and  
  generics) - Risk of venous thromboembolism     
 − Bisphosphonates – Risk of atypical femoral fracture     
 − Revlimid – Investigation of potential risk of second primary malignancies  
 − Intravenous Paracetamol Solutions for Infusion – Risk of medication errors in infants  
  and children (Insert).
August 2011 − Pioglitazone – New contraindications and warnings following European review of  
43rd Edition  bladder cancer risk        
 − Dexrazoxane (Cardioxane) – Restrictions for use     
 − Dronedarone (Multaq) – Update on benefit-risk review    
 − View the Drug Safety Newsletter online or receive via email    
 − Gardasil – Overview of National Monitoring Experience
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dRuG SAfETy NEWSLETTERS 
Edition Articles
October 2011 − Multaq – Restriction of use and new monitoring requirements    
44th Edition − MabThera – Association with fatal infusion related reactions in patients with   
  rheumatoid arthritis        
 − Non-prescription cough and cold medicines for young children – New advice  
 − Revlimid – Risk of second primary malignancies in authorised indication  
 − Vimpat 15mg/ml syrup – Discontinuation of supply
December 2011 − Domperidone – Risk of cardiac disorders      
45th Edition  − Citalopram and Escitalopram – Risk of QT interval prolongation   
 − Strattera (atomoxetine) – Effects on blood pressure and heart rate   
 − Pradaxa (dabigatran etexilate) – Recommendations for assessment of renal function  
  and monitoring in the elderly 
IMB huMAN MEdICINES ARTICLES – ExTERNAL PuBLICATIoNS 
Topic Publication Month
BCG Vaccine SSI and Severe Local Reactions MIMS January
Champix – Psychiatric Adverse Reactions MIMS February
Antipsychotics – Risk of Venous Thromboembolism IMF February
Multaq – Hepatic Adverse Reactions MIMS March
Fluoroquinolones – Risk of QT Prolongation MIMS April
Paracetamol – Evidence does not support causal association with asthma in    
children after exposure in pregnancy or use in early infancy MIMS May
Revlimid – Venous Thromboembolism risk (Oncology Supplement) MIMS May
Bisphosphonates – Risk of atypical femoral fracture MIMS June
Drospirenone containing oral contraceptives (Yasmin, Yasminelle, Yaz and    
generics – risk of venous thromboembolism MIMS July
Bisphosphonates and Osteonecrosis of the Jaw: Current Guidance on Risk    
Minimisation Measures JIDA July
Gardasil – Overview of National Monitoring Experience MIMS August
Bisphosphonates – Risk of Stress Fractures IMF August
Pioglitazone – New contra-indications and warnings following European    
review of bladder cancer risk MIMS September
Non-prescription Cough and Cold Medicines for Young Children – New Advice MIMS October
111IMB ANNUAL REPORT 2011
IMB huMAN MEdICINES ARTICLES – ExTERNAL PuBLICATIoNS 
Topic Publication Month
Multaq – Restriction of use and new monitoring requirements MIMS November
Pioglitazone – New contra-indications and warnings following European review of    
bladder cancer risk (Diabetes Supplement) MIMS November
Pradaxa (dabigatran etexilate) – Recommendations for assessment of renal function    
and monitoring in the elderly MIMS December 
IMB vETERINARy MEdICINES ARTICLES – ExTERNAL PuBLICATIoNS 
Topic Publication Month
Suspected adverse reactions to veterinary medicinal products 2008-2009 Veterinary Ireland January 
 Journal
Vigilance in Prescribing and Using Antibacterials in Dry Cows Veterinary Ireland  August 
 Journal 
The Pending EU Review of the Regulatory Framework for Veterinary Medicines Veterinary Ireland  October 
 Journal 
IMB Update on Flukicides Without MRL for Milk Veterinary Ireland November 
 Journal
Veterinary Pharmacovigilance in Ireland - A Simple Guide to Reporting It’s Your Field Spring 
Adverse Reactions
Understanding Veterinary Product Literature It’s Your Field Summer
Best Practice for Maintaining the Cold Chain It’s Your Field Autumn
The Irish Medicines Board Website It’s Your Field Winter
IMB MEdICAL dEvICES NEWSLETTER – SAfETy ARTICLES 
Edition Topic
April Increased global activity in relation to the production and supply of counterfeit/illegal medical  
 devices
August Medicine feeders, including spoons, droppers, syringes, cups and pacifiers/soothers, which   
 are intended for use for administration of medicines – Advice to pharmacists, hospital personnel,  
 retailers and consumers
August Risk of transmission of blood borne agents associated with the use of blood glucose monitoring  
 systems – Advice to hospital/healthcare professionals and consumers
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INduSTRy GuIdANCE doCuMENTS 
document title New/Revision date
Guide to Fees for Human Products 2011 Revision January
Guide to Withdrawal of Authorisations or Certificates for Human Medicines Revision February
Guide to the Definition of an Animal Remedy and the Classification Process Revision February
Guide to Labels and Leaflets of Human Medicines Revision February
Guide to Electronic Submissions - Human Medicines Revision March
Guide to Submitting a Request for the IMB to Act as RMS In a Decentralised    
Procedure for a Human Medicine Revision March
Guide to Clinical Trial Applications Revision March
Guide to Labels and Leaflets of Human Medicines Revision April
Submission of a Variation Application for a Manufacturing Importation   
Authorisation and a Wholesaler’s Authorisation New April
Guide to Fees for Veterinary Medicines Revision May
Guide to Labels and Leaflets of Human Medicines Revision May
Guide to Notification of Marketing Status of Human Medicines Revision May
Guide to Applications for Certificates of Free Sale for Cosmetics Revision May
Guide to Completion of the Tissue Establishment Annual Report Revision May
Guide to Completion of the Tissue Establishment Annual Report for   
Reproductive Tissues and Cells Revision May
Guide to the Quality System for Grocery Wholesale Distributors New June
Frequently Asked Questions on Export Certificates New June
Submission of Risk Minimisation Plans to the Irish Medicines Board New June
Frequently Asked Questions on Advertising Compliance New July
Guide to Parallel Imports for Human Medicines Revision July
Guide to Labels and Leaflets of Human Medicines Revision August
Guide to the Attainment of Qualified Person Status in Ireland: Educational   
Requirements, Training and Licensing New August
Guide to Renewal of Marketing Authorisations - Human Medicines Revision September
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APPENDIX 4
EUROPEAN AND NATIONAL   
COMMITTEE / WORKING GROUP   
PARTICIPATION
EuRoPEAN ANd NATIoNAL CoMMITTEE/WoRkING GRouP PARTICIPATIoN
Committee/Working Group organisation Meetings Per  
  Annum
Central Management Committee CAMD 2
Competent Authority for Medical Devices CAMD 2
New and Emerging Technologies Working Group CAMD 2
Notified Body Operations Group CAMD 3
Recast Working Group CAMD 5
Compliance and Enforcement Working Party (COEN) Competent Authorities Working Group 3
In-Vitro Diagnostic Technical Working Group Competent Authorities Working Group 1
P-SC-COS (Committee of Experts on Cosmetics) Council of Europe 1
Working Group on Anti-Counterfeiting Council of Europe 2
National TB Advisory Committee Department of Health 
Medication Safety Forum and related groups Department of Health/HSE 10
Notice to Applicants Working Group EC 1
Advisory Group to Official Medicines Control Network EDQM 2
Annual meeting of Official Medicines Control Laboratories Network EDQM 1
Annual planning meeting for sampling and testing of centrally    
authorised medicinal products EDQM 1
Ad Hoc Pharmacovigilance Inspectors Working Group (Ph IWG)  EMA 4
Committee for Advanced Therapies  EMA 11
Committee for Medicinal Products for Human Use (CHMP)  EMA 11
Committee for Medicinal Products for Veterinary Use (CVMP) EMA 11
Committee for Orphan Medicinal Products (COMP) EMA 7
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EuRoPEAN ANd NATIoNAL CoMMITTEE/WoRkING GRouP PARTICIPATIoN
Committee/Working Group organisation Meetings Per  
  Annum
Committee on Herbal Medicinal Products (HMPC)  EMA 6
Efficacy Working Party (of CVMP) EMA 4
EudraCT (Clinical Trials Database) EMA 3
GCP Inspectors Working Group EMA 4
GDP Drafting Group EMA 2
GMDP Inspectors Working Group EMA 4
Immunologicals Working Party (of CVMP) EMA 3
Paediatric Committee (PDCO)  EMA 12
Pharmacovigilance Working Party (PhVWP)  EMA 11
Quality Working Party (CHMP/CVMP) EMA 4
Safety Working Party (of the CHMP) EMA 4
Scientific Advice Working Party EMA 11
Technical Implementation Groups (ICT) EMA 
Telematics Committee - Management Board EMA 4
Veterinary Joint Implementation Group EMA 4
Ad hoc group for the development of implementing guidelines for    
Directive 2001/20/EC  EU Commission 4
Borderline and Classification Medical Device Expert Group (MDEG) EU Commission 1
Clinical Investigation and Evaluation Working Group EU Commission 3
Competent Authorities for Blood EU Commission 2
Competent Authorities for Tissues and Cells EU Commission 2
Cosmetic Borderline Working Group EU Commission 2
Cosmetic Standing Committee and Working Group EU Commission 3
CPNP Working Group (Cosmetics) EU Commission 3
Drug Precursors Working Group EU Commission 4
EUDAMED Working Group EU Commission 3
MDEG Software Working Group EU Commission 4
MDEG Working Group on Vigilance EU Commission  2
Medical Device Expert Group EU Commission 1
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EuRoPEAN ANd NATIoNAL CoMMITTEE/WoRkING GRouP PARTICIPATIoN
Committee/Working Group organisation Meetings Per  
  Annum
Notified Bodies Operational Group (NBOG) EU Commission 3
PEMSAC Analytical Methods and Market Surveillance Working Groups EU Commission 2
Regulatory Committee for Medical Devices EU Commission 1
Unique Device Identifier Group EU Commission  2
Working Group on the Common Approach to reporting of  SAR/E for    
Haemovigilance EU Commission 1
European Directorate for the Quality of Medicines (EDQM) EU Public Health Organisation 3
SoHO V&S EU Public Health Project 1
SoHO V&S Steering Committee  EU Public Health Project 1
Vigilance and Surveillance of Substances of Human Origin    
(SoHO)  - WP5 Assisted Reproduction  EU Public Health Project 2
Clinical Trial Facilitation Group (CTFG) HMA 6
Co-ordination Group for Mutual-recognition and Decentralised    
Procedures (Human) CMD(h) HMA 11
Co-ordination Group for Mutual-recognition and Decentralised    
Procedures (Veterinary) CMD(v) HMA 11
Heads of Medicines Agencies Working Group of Enforcement Officers     
(HMA WGEO) HMA 2
HMA ICT Working Groups HMA 
Homeopathic Medicinal Products Working Group (HMPWG) HMA 2
Permanent Forum on International Pharmaceutical Crime International Enforcement Forum  1
Anti-doping Committee  Irish Sports Council 4
National Haemovigilance Conference NHO 1
Review of  Haemovigilance Monitoring Systems NHO 2
Haemovigilance Monitoring NHO/IMB 4
Committee of Officials PIC/S 2
PIC/S GDP working group PIC/S 2
Heads of Medicines Agency meetings – Human  EU Presidency 4
Heads of Medicines Agency meetings – Veterinary  EU Presidency 4
National Immunisation Advisory Committee RCPI 6
Board of the UMC/WHO Collaborating Centre  WHO 3
WHO National PV Centres Meeting  WHO/Croatian Medicines Agency 1
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APPENDIX 5      
GLOSSARY
AED Automated External Defibrillator 
APHA Animal and Plant Health Association
APMI Association of Pharmaceutical Manufacturers in Ireland 
ASR Annual Safety Report 
ATMP Advanced Therapy Medicinal Product
BEMA Benchmarking of European Medicines Agencies
CAMD Competent Authority for Medical Devices 
CAT Committee for Advanced Therapies 
CD Controlled Drugs 
CESP Common European Submission Portal
CHMP Committee for Medicinal Products for Human Use 
CMC Central Management Committee 
CMD(h) Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human
CMD(v) Co-ordination Group for Mutual Recognition and Decentralised Procedures - Veterinary 
CMS Concerned Member State
COMP  Committee for Orphan Medicinal Products 
CTFG  Clinical Trials Facilitation Group 
CVMP  Committee for Medicinal Products for Veterinary Use 
DCP  Decentralised Procedure 
EDQM European Directorate for Quality of Medicines 
EEA European Economic Area 
EMA European Medicines Agency 
EUDAMED European Database on Medical Devices
FAQ Frequently Asked Questions 
GCP Good Clinical Practice 
GDP Good Distribution Practice 
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GMP Good Manufacturing Practice
GVP Good Vigilance Practice 
H1N1 2009 Flu Pandemic 
HIQA Health Information and Quality Authority 
HMA Heads of Medicines Agency
HMPC Committee on Herbal Medicinal Products 
HPSC Health Protection Surveillance Centre 
HPV Human Papillomavirus 
HSE Health Service Executive
IAHS Irish Association of Health Stores 
IBTS Irish Blood Transfusion Service 
ICH International Conference on Harmonisation 
IHTA Irish Health Trade Association 
IMDA Irish Medical Devices Association 
IMF Irish Medicines Formulary 
IPHA Irish Pharmaceutical Healthcare Association
IVD In-Vitro Diagnostics 
JIDA Journal of the Irish Dental Association 
MAH Marketing Authorisation Holder 
MEDDEV Medical Devices Guidance Document from the European Commission
MIMS Monthly Index of Medical Specialities
MRLs Maximum Residue Limits 
MRP Mutual Recognition Procedure 
NBOG  Notified Body Operations Group 
NCA National Consumer Agency 
NHO National Haemovigilance Office 
NSAI National Standards Authority of Ireland 
OMCL Official Medicines Control Laboratories 
OTC  Over-the-Counter 
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PCI Pharmachemical Ireland 
PDCO  Paediatric Committee 
PDP Performance Development Programme
PIC/S Pharmaceutical Inspection Co-operation Scheme 
PSUR Periodic Safety Update Report
QWP Quality Working Party 
RMP Risk Management Plan 
RMS  Reference Member State 
SoHOV&S Substances of Human Origin Vigilance and Surveillance 
THMP Traditional Herbal Medicinal Product
UMC Uppsala Monitoring Centre 
VMD Veterinary Medicines Directorate 
WHO World Health Organization 
irish Medicines board
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